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Ischaemia and reperfusion in the heart
Background
Coronary artery disease has become a worldwide burden for society. In The Netherlands 
every year over 10.000 persons die due to coronary artery disease, presenting either as an 
acute myocardial infarction (AMI) or ischaemic heart failure.275 Moreover annually 25.000 
patients are hospitalised with AMI and 30.000 due to ischaemic heart failure.275
When initiated through a combination of lifestyle, genetics, and age, atherosclerosis will 
slowly progress and in time cause coronary stenotic plaque formation. These laesions can 
finally limit coronary blood flow resulting in myocardial ischaemia. Ultimately, plaque 
rupture causes acute obstruction of the coronary artery resulting in an acute myocardial 
infarction. 
Ischaemia caused by acute and complete occlusion of a coronary artery induces serious 
injury to the myocardium. The amount of damage after AMI, or myocardial infarct size, was 
classically considered to depend on 1) the area at risk of the occluded artery and 2) the 
duration of the ischaemic insult (or the time to reperfusion). As only the latter could be 
modulated during the occurrence of AMI, researchers developed therapeutic strategies 
aimed to accomplish early reperfusion.
In 1950 the in-hospital mortality of patients presenting with AMI (diagnosed using ECG- 
recording) was approximately 15%, as no treatment was yet available.61 With the introduction 
of effective pharmacologic (thrombolysis) or endovascular (percutaneous coronary 
intervention; PCI) reperfusion therapies combined with thrombocyte aggregation 
inhibitors (aspirin and P2Y12 antagonists) and anticoagulants (e.g. heparin), the mortality 
rate of AMI has decreased significantly.275,292 A recent meta-analysis showed that in patients 
suffering a ST elevated myocardial infarction (STEMI) receiving today’s standard care 
(primary PCI and optimal medicinal treatment) 30-day mortality rate is 5.2%.30 
The detrimental effects of ischaemia are known for a long time. However with the 
introduction of fast and successful reperfusion therapy, a new phenomenon became 
apparent: reperfusion injury. The deleterious effects of reperfusion were first noticed in 
1975 as reperfusion was associated with sudden and explosive cell death in hypoxic rat 
hearts.102 Tissue damage due to both the ischaemic injury and the reperfusion injury is 
termed ischaemia and reperfusion (IR) injury.
This finding sparked the thought that reperfusion is a two-faced process; it is an absolute 
necessity for maximal tissue salvage, but it also triggers processes that limit the benefit of 
reperfusion by further damaging the ischaemically injured tissue.33 Although, the 
beneficial effects of timely reperfusion always outweigh its detrimental effects, the net 
benefit of reperfusion could be enhanced by prevention of reperfusion-associated injury. 
12
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In 1986 Murry et al. provided definitive evidence that infarct size not only depends on area 
at risk and duration of ischaemia but that cardiac tissue can develop tolerance to the 
sequellae of ischaemia and reperfusion. They showed in dogs that four cycles of 5 minutes 
of myocardial ischaemia (achieved by circumflex artery occlusion) and 5 minutes of 
myocardial reperfusion preceding a prolonged ischaemic insult (circumflex artery 
occlusion for 40 minutes), limited myocardial infarct size to 25% compared to the control 
group subjected to only 40 minutes of circumflex occlusion. This protective procedure 
was named ischaemic preconditioning (IP).183
Thus, Murry found a third determinant of myocardial infarct size: the intrinsic ability of 
tissue to develop tolerance to ischaemia and reperfusion and thus defined a new target 
for therapeutic intervention. The recent recognition of ischaemic post-conditioning 
(controlled reperfusion with repetitive short episodes of reperfusion and ischaemia, prior 
to definite reperfusion) as a strategy to successfully reduce infarct size both in animals as 
well as humans252 provided definite evidence for the existence of reperfusion-associated 
injury as an important therapeutic target to reduce (myocardial) infarct size.
Physiological and Pathological Changes during Ischaemia  
and Reperfusion
Ischaemia
Sudden occlusion of a coronary artery results in multiple metabolic changes, appearing 
within seconds of cessation of blood flow. ATP reserves in the myocardium are limited, 
and will be depleted within 4 efficient contractions.123 After consumption of the oxygen 
trapped in the ischaemic tissue as oxyhaemoglobin or oxymyoglobin, metabolism shifts 
from aerobic to anaerobic glycolysis.123 To optimise metabolic performance, cellular 
glucose uptake is increased by translocation of GLUT-receptors to the cellular membrane 
and the rate of glycolysis is enhanced by activation of the enzyme 6-phosphofructoki-
nase. Due to inhibition of the enzyme pyruvatedehydrogenase, pyruvate is metabolised 
to lactate (instead of acetyl Co-A), together with the conversion of NADPH
2
 to NAD.200
At the onset of ischaemia, hydrolysis of residual ATP leads to mild cellular acidosis, which 
appears to be beneficial since it reduces cardiac contractility and subsequent metabolic 
demand. With intracellular hydrolysis of ATP, levels of ADP and subsequent AMP and 
adenosine rise. AMP activates the enzyme AMP-kinase which in part further stimulates 
glucose uptake and glycolysis rate.200 Extracellularly, upregulation of the enzyme ecto-5’-
nucleotidase (CD73) results in increased adenosine formation, through augmented phos-
phohydrolysis of AMP.68
During prolonged ischaemia the end products of the anaerobic glycolysis (lactate and 
NAD) start to inhibit glucose uptake and glycolysis, resulting in further ATP depletion and 
severe acidosis. Gradually serious disturbances in the ion homeostasis develop within the 
13
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ischaemic cells that have important physiological consequences. Because of dysfunction 
of the ATP dependant Na-K exchanger and enhanced function of the Na-H+ exchanger 
(due to cellular acidosis) sodium enters the cell, leading to cellular oedema. Furthermore, 
the increase in intracellular sodium causes the activity of the Na-Ca exchanger to reverse 
and transport calcium into the cell.200 As the ATP dependent uptake of calcium by the 
sarcoplasmatic reticulum is inhibited, intracellular calcium overload develops. 
These cumulative metabolic changes cause damage to cardiomyocytes, resulting in both 
necrosis and apoptosis in the area at risk.269 Experiments in dogs have shown that necrosis 
starts to appear after approximately 15-20 minutes of myocardial ischaemia.124 With 
prolonged duration of ischaemia more tissue becomes necrotic and after 6 hours the 
entire area at risk has become irreversibly damaged.214
Thus, for partial salvage of ischaemically injured myocardial tissue, timely reperfusion is an 
absolute prerequisite. The coronary blood flow can be restored, either spontaneously or 
aided by thrombolytic agents or PCI. However, as stated before, reperfusion has been 
referred to by Braunwald and Kloner as ‘the double edged sword’, because reperfusion 
itself leads to myocardial injury beyond that generated by ischaemia.33,180
Reperfusion
Upon reperfusion the aerobic metabolism is restored instantaneously. Post-ischaemic 
hyperaemia will occur due to the release of potent vasodilatory substances during 
ischaemia (e.g. adenosine, bradykinin, nitric oxide), leading to a 4-6 fold increase in flow.136 
Restoration of blood flow will wash out lactate and H+, leading to a quick recovery of tissue 
pH.305 
Calcium overload
There is an acute increase in intracellular and mitochondrial calcium concentration due to 
ischaemic injury to the sacrolemmal-membrane and dysfunction of the sarcoplasmic 
reticulum. During reperfusion this calcium overload can cause hypercontracture of the 
myocytes and contributes to opening of the mitochondrial permeability transition pore 
(MPTP), both leading to cell death.
Reactive oxygen species (ROS)
Reintroduction of abundant oxygen at the onset of reperfusion evokes a burst of potent 
free radicals.180 The most important sources of ROS in cardiomyocytes are the mitochondrial 
electron transport chain, and as by-products of the enzymes nitric oxide synthase (NOS) 
and NADPH oxidase.178
During reperfusion ROS are produced extracellularly by endothelial cells as well as 
phagocytes.178 Their reactive nature causes ROS to interact directly with cellular lipids, 
proteins and (mitochondrial) DNA, resulting in damage to the cell membrane and the 
membranes of cellular organelles and subsequent organelle or cellular failure.178
14
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Endothelial dysfunction
At reperfusion the enzyme arginase is activated. Arginase competes with NO-synthase for 
its substrate L-arginine and results in a subsequent decrease in endothelial NO-
release.67,105,133 This contributes to IR induced endothelial dysfunction, which can be 
clinically recognised as the no-reflow phenomenon. For example after a successful PCI, 
blood flow in the affected coronary artery remains limited due to endothelial vasocon-
striction and vascular plugging. Occurrence of the no-reflow phenomenon limits the 
benefits of timely reperfusion, as the myocardial blood flow remains deprived. 
Inflammation
During myocardial ischaemia, multiple chemokines (e.g. monocyte chemoattractant 
protein (MCP), macrophage inflammatory protein (MIP), several interleukins and tumour 
necrosis factor (TNF-alpha)) are expressed, which regulate monocyte, lymphocyte and 
macrophage recruitment and evoke an inflammatory reaction that will ultimately 
contribute to myocardial healing and scar formation. In the early phase of IR-injury the 
massive influx of inflammatory cells causes vascular plugging, which diminishes reperfusion.200
Mitochondria and MPTP 
Myocardial mitochondria provide energy in the form of ATP for cellular contraction. 
However mitochondria are very sensitive to alterations in cellular environment and they 
can quickly change from being a supporter of life to a promoter of cell death. IR-injury can 
induce mitochondrial fission, which is linked to increased production of ROS, impaired 
function and initiation of cell death.196 Mitochondrial failure is caused by formation of the 
mitochondrial permeability transition pore (MPTP). Opening of this non-selective, large 
conductance channel initiates a cellular cascade resulting in apoptotic myocardial cell 
death.179 Prevention of MPTP opening (e.g. by cyclosporine treatment) has been shown to 
reduce impact of IR-injury.206 
Clinical consequences
The release of ROS and intracellular calcium overload can both result in mitochondrial 
damage caused by opening of the MPTP, activation of caspases and subsequent cell 
damage and eventually cell death (by either necrosis or apoptosis).120 
As a result, IR-injury has several clinical consequences in a patient suffering from AMI. 
It causes myocardial stunning, arrhythmias, increased impedance of microvascular blood 
flow (no-reflow), myocardial cell death, and endothelial dysfunction, all of which contribute 
to increased mortality and morbidity after AMI.133,305
15
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Prevention of Ischaemia and Reperfusion Injury
Reperfusion
Coronary reperfusion after AMI can be established using various therapies. Today the 
most favourable is the percutaneous coronary intervention (PCI), in which the occlusion is 
opened by a wire-guided balloon, introduced via the femoral or radial artery. To increase 
coronary patency most often a stent is deployed at the location of the stenosis and the 
subsequent occlusion. Prior to the procedure patients receive anticoagulant treatment 
and at least double thrombocyte aggregation inhibition to prevent coronary re-occlusion 
after PCI. If a PCI facility is not timely available, thrombolytic therapy can be administered 
in order to attempt to dissolve the occluding blood clot. However 30-day mortality is 
higher in STEMI patients receiving thrombolytic therapy than in those receiving PCI (9% 
vs. 7% respectively).292 
The Netherlands have a high density of PCI facilities, a well organised and swift ambulance 
service, and a decent infrastructure, which together allow all patients with a STEMI to be 
transported to a PCI centre for a primary PCI. 
Today, a 30-day mortality of 12.5% is observed in STEMI patients, in whom reperfusion 
could not be established. If reperfusion can be achieved by PCI within the first hour after 
the onset of symptoms mortality is reduced to 4.7%.292 As the delay between symptom 
onset and restoration of coronary blood flow increases, mortality rises. If coronary 
perfusion is restored within 3-6 hours, mortality is 5.6%.7 A delay of 6-12 hours to 
reperfusion results in a mortality of 8.5%, indicating that even in case of prolonged 
ischaemia, the myocardium still benefits from reperfusion through PCI.30,292
Over the last 30 years interventions aimed at restoring coronary circulation have been 
improved. Moreover early diagnosis (at home) of STEMI and early preparation of the 
 catheterization laboratories have further reduced patient-to-balloon-time. De Luca et al. 
(figure 1) have clearly shown the importance of early reperfusion as in their cohort the 
1-year mortality triples if coronary reperfusion is just established after 6 hours compared 
to one hour after onset of complaints.51
Conditioning
As stated earlier, in 1986 Murry et al. have shown that ischaemic preconditioning (IP), 
consisting of several brief episodes of non-injuring ischaemia and reperfusion prior to the 
index ischaemia, could reduce IR-injury.183 The results of Murry have been replicated by 
many other scientists in animal experiments. Early mechanistic and descriptive studies 
revealed that IP was associated with 2 phases of cardioprotection. After the precondition-
ing event, a protective phenotype occurs immediately and lasts for maximally 6 hours 
(acute preconditioning).304 Twenty-four hours after the preconditioning trigger, a delayed 
preconditioning or second window of protection (SWOP) starts. However, little is known 
about the duration of delayed preconditioning. A duration of at least 72 hours, though no 
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longer than 96 hours has been reported for both ischaemic and adenosine induced 
delayed preconditioning.16,18 Further experiments showed that the protective effect of IP 
was not limited to the heart, as different organs (e.g. kidney, brain) could become 
preconditioned after exposure to repetitive episodes of non-lethal ischaemia, resulting in 
improved tolerance to subsequent prolonged ischaemia.278 Recent experiments report 
that repetitive hypoxic preconditioning induces long-term tolerance in nervous tissue, 
lasting 4 to 8 weeks.255,309 
Further research to investigate the possibilities offered by IP revealed several other 
interesting protective variations.
Przyklenk et al. showed in 1993 that the protective effect of ischaemic preconditioning 
was not limited to the tissue subjected to IP. In dogs, they applied IP to the circumflex 
coronary artery, followed by a 1 hour of sustained left anterior descending (LAD) coronary 
artery occlusion. They found that the IP in one vascular bed could protect remote virgin 
myocardium from IR-injury. This transfer of protection is termed remote ischaemic precon-
ditioning (RIPC). Further experiments have shown that protection against IR can be 
transferred between various organs and tissues.97 
In 2003 Zhao et al. published their results comparing the myocardial protection provided 
by IP and ischaemic postconditioning (or controlled reperfusion). Again in dogs, they 
showed that a single cycle of 5 minutes LAD ischaemia and 10 minutes of reperfusion 
Figure 1   One-year mortality in patients with STEMI related to time between onset of 
complaints and coronary reperfusion by PCI, calculated using a quadratic 
regression model by De Luca et al. (Circulation 2004;109:2737-43). 
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reduced myocardial infarct size induced by a subsequent 60 minute LAD occlusion. 
Interestingly, when the 60 minutes LAD occlusion was followed by 3 cycles of 1 minute of 
reperfusion and 1 minute of re-occlusion, infarct size was smaller compared to control 
heart, and similar compared to ischaemically preconditioned hearts.308 Apparently even 
after occurrence of the index ischaemia, a protective mechanism can be triggered 
rendering the myocardium less vulnerable to IR-injury. 
The most recently published type of conditioning is remote ischaemic perconditioning.132 
Kerendi et al. showed that concomitant renal ischaemia, during prolonged cardiac 
ischaemia reduces myocardial infarct size in rats. Also concomitant ischaemia and 
reperfusion of the brain88 or the leg151 can induce myocardial tolerance against IR. Andreka 
et al. found a reduced infarct size in pigs, when they applied the remote ischaemic post-
conditioning stimulus (4x5min hind limb ischaemia and reperfusion) at the onset of 
myocardial reperfusion.11
This intervention is very promising because of its clinical applicability, for example in 
patients suffering from AMI.97 Whereas preconditioning is only suited for situations with 
foreseeable IR, and postconditioning requires control over the circulation of the target 
organ, remote ischaemic perconditioning can be initiated during the index ischaemic 
event, and applied to for example the lower limb.238
After the landmark publication of Murry, many scientists aimed their efforts at further 
unravelling and exploiting the protective mechanism of IP. Taken together, these 
experiments have provided the insight that protection after conditioning is induced 
through a complex mechanism; several triggers (e.g. adenosine, bradykinin, opioids, and 
NO) act through accompanying G-protein coupled receptors to initiate different 
intracellular cascades (constituted of a variety of protein kinases e.g. PI3K, Akt, ERK, PKC).107 
Subsequent opening of the mitochondrial K
ATP
-channels is part of a final common 
pathway on which the signalling pathways seem to converge. The end-effector of 
protection is ultimately the prevention of opening of the mitochondrial permeability 
transition pore (MPTP).99  This MPTP, situated through both inner and outer mitochondrial 
membrane, remains closed under physiological circumstances by means of multiple 
pro-survival signal pathways. IR-induced opening of the MPTP triggers a cellular cascade 
ultimately leading to apoptosis.179 
Experiments clarifying the mechanism of delayed preconditioning have shown 
involvement of increased transcription of cardioprotective genes and expression of 
various proteins including iNOS, COX-2, heme oxygenase and antioxidant enzymes.254,304
Elucidation of this mechanism has provided multiple targets for pharmacologic 
modulation of ischaemia and reperfusion injury. Pharmacological interventions mimicking 
the effect of ischaemic preconditioning are called pharmacologic preconditioning. Drugs 
that have been proven to be able to reduce infarct size in animal models include several 
statins, adenosine, NO, dipyridamole, cyclosporine, diazoxide, angiotensin receptor 
antagonists, isoflurane, and nicorandil.222
18
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Methods to Study IR-Injury in Humans In Vivo
In animal experiments the primary endpoint most frequently used to study the impact of 
IR is myocardial infarct size. This is usually assessed histologically and expressed as the 
fraction of the area at risk, which is determined independently. Obviously, in human 
research other outcomes (surrogate endpoints) are studied. This paragraph summarises 
different models used to study simulated IR in healthy volunteers and endpoints used in 
follow-up of patients exposed to IR-injury. 
Surrogate endpoints in translational models of IR-injury
In contrast to clinical trials, translational experimental models are not designed to study 
clinical outcomes. Translational models of IR-injury can be used to study in detail different 
aspects of IR-injury and to study the pathogenesis of IR-injury. Also the mechanism of 
action of interventions and drugs preventing IR-injury can be studied using translational 
models. The use of healthy volunteers instead of patients reduces burden for patients and 
facilitates more easy inclusion of participants. 
IR-induced phosphatidylserine exposition
Introduced by Rongen et al. in 2005, this technique enables visualisation and quantification 
of phosphatidylserine (PS) exposure that occurs after IR in humans in vivo. Ischaemia 
induced phosphatidylserine exposure on cardiomyocytes has been associated with 
reversible cellular damage and apoptosis.189,269 Rongen developed an experimental model 
to study PS exposure after IR in healthy male volunteers. This model uses radiolabeled 
recombinant annexin A5 to visualise PS-exposition occurring after 10 minutes of forearm 
ischaemia combined with isometric exercise.226 Interventions that have been shown in pre- 
clinical and clinical research to modulate myocardial infarct size (ischaemic preconditioning, 
and pharmacologic preconditioning with adenosine and dipyridamole) similarly modulate 
annexin A5 targeting in this forearm model.220,224,226
IR-induced endothelial dysfunction
Flow mediated dilation
Flow mediated dilation (FMD) represents a shear stress induced, largely NO-mediated182 
endothelium-dependent vasodilation. Originally this method was introduced to assess 
endothelial function. Endothelial dysfunction is considered to be the first clinical feature 
of atherosclerosis, and in a large cohort study reduced FMD was an independent predictor 
of cardiovascular death.294
In 2001 Kharbanda et al.133 introduced repeated FMD measurements in the radial artery as 
a model to study IR-injury in humans in vivo. In this non-invasive and well-tolerated model, 
they showed in healthy volunteers that 15 minutes of ischaemia and reperfusion reduced 
FMD from 7.7% at baseline to 3.5%. This endothelial dysfunction proved to be temporary, 
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as after one hour of reperfusion endothelial function had completely recovered. Moreover 
they showed in this model that ischaemic preconditioning (3 episodes of 5 minutes upper 
limb ischaemia and reperfusion) could prevent IR-induced endothelial dysfunction. 
FMD measurement before and after IR has successfully been used to further explore 
(pharmacologic) interventions improving tolerance against IR-induced endothelial 
dysfunction. Therapies that prevent endothelial dysfunction after IR include treatment 
with sildenafil, bradykinin, NO-donors and rosuvastatin, and interventions such as remote 
ischaemic preconditioning and ischaemic postconditioning.80,83,155,156,158,159
Plethysmography
Another widely used technique to measure endothelial function is venous occlusion 
 plethysmography. In this model mercury-in-silastic strain gauges are placed around the 
forearm. A pneumatic cuff is placed at the upper arm and inflated to 40mmHg for 6-10 
heartbeats. This pressure exceeds venous pressure but remains below arterial pressure. Thus 
during the venous occlusion, blood flow into the arm is unhindered, while venous return is 
closed off. The pooling blood will cause the forearm to swell subtly. The increase in forearm 
diameter is registered by the mercury strain gauges. The speed of the increase of the 
diameter, is related to the forearm blood flow.225 Forearm blood flow can be influenced by 
conduit artery vasodilation and vasoconstriction. These functions are locally controlled by 
endothelium in both the arterial and venous vascular bed.277 Endothelium function can be 
assessed by measuring changes in forearm blood flow in response to different dosages of 
vasoactive agents (NO donors like nitroprusside or nitroglycerine, endothelium dependent 
vasoactive agents like acetylcholine and vasoconstrictive agents like L-NMMA).
As stated above, endothelial dysfunction is a distinct feature of IR-injury. Venous occlusion 
plethysmography has been used to test pharmacological interventions aimed at prevention 
of endothelial dysfunction after IR.31,207 
Endpoints in intervention studies in patients with coronary  
artery disease
Observational clinical data and functional measurements
Observation of the clinical course of a patient for example after STEMI, PCI or CABG surgery 
can provide interesting information. The clinical need of inotropic support or vasopressor 
therapy and monitoring heart rhythm provide information on the effect of IR-injury on 
myocardial stunning and arrhythmias. Clinical relevant endpoints used to measure 
outcome after IR-injury include survival rate, duration of hospital stay, and major adverse 
cardiac events (MACE; e.g. myocardial death, myocardial infarction, hospital admission due 
to acute coronary syndrome (ACS) and coronary revascularisation).
The effect of IR on myocardial performance can be analysed using functional outcomes, 
for example left ventricular function121 (assessed using cardiac ultrasound or MRI), or left 
ventricular stroke work index.219 
20
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Myonecrosis markers
Myocardial damage can be assessed biochemically with myocardial necrosis biomarkers 
(e.g. troponin-I, troponin-T, MB fraction of creatine kinase (CK-MB)). The amount of released 
biomarker is related to the extent of myocardial damage and is a predictor of mortality.216,244 
As a small blood sample is sufficient to determine myocardial injury, measuring 
myonecrosis markers represents a rather easy and rapid way to gather clinically relevant 
information on IR-injury. Follow-up of myocardial necrosis biomarkers is performed and 
validated in the course of myocardial infarction, PCI and cardiac surgery.14,280
MRI assessment of IR-injury
Several aspects of myocardial IR-injury can be visualised using cardiac magnetic resonance 
imaging (MRI).2 Infarct-associated myocardial oedema, assessed using T2 imaging, depicts 
the area at risk. Irreversible myocardial injury can be detected with late gadolinium 
enhancement and enables accurate and reproducible assessment of infarct size. The 
no-reflow phenomenon can be visualised using gadolinium enhancement. Finally also 
left ventricular ejection fraction can be measured with MRI reliably.
Clinical Studies on Attenuation of Myocardial IR-injury 
Studies on prevention of IR-injury in the setting of an acute 
myocardial infarction
In a patient presenting with an acute myocardial infarction, the possibilities to prevent 
IR-injury (apart from swift reperfusion) are limited to interventions that are timed during 
and after the index ischaemia, being (remote) ischaemic per and postconditioning and 
pharmacologic per- and postconditioning.
Staat et al. were the first to successfully apply ischaemic postconditioning (or controlled 
reperfusion) in patients undergoing PCI during a STEMI. After opening of the culprit 
laesion, they exposed the patient to 4 cycles of 1 minute of reperfusion and 1 minute of 
coronary occlusion by balloon re-inflation. Postconditioning significantly increased blush 
grade (a measure of patency of the cardiac microcirculation) and reduced release 
myonecrosis markers (CK-MB) compared to unhindered reperfusion.252 These findings 
were confirmed by other research groups142,283, though not all.75,251 
Piot et al. studied the effect of cyclosporine (inhibitor of MTPT opening) in patients with 
STEMI. They assessed infarct size using cardiac MRI, and found that absolute mass of 
infarcted tissue was significantly reduced in patients receiving cyclosporine compared to 
placebo (37 grams vs. 46 grams respectively).206 
Several retrospective studies have shown that in patients with a history of angina pectoris, 
survival after STEMI was significantly better (97%) compared to patient without any 
prodromal symptoms (92%). Also the occurrence of cardiogenic shock after STEMI was 
21
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lower in patients with prodromal symptoms (1% vs. 6%). As the angina resulted from 
transient bouts of myocardial ischaemia, the myocardium became ischaemically 
preconditioned and thus less vulnerable for a future ischaemic insult and subsequent IR-
injury.116,137 Albeit, these retrospective studies could have been confounded, as patients 
with prodromal symptoms were probably more likely to search medical support, and 
thereby facilitate early recognition of e.g. myocardial infarction and possibly reduce time 
to reperfusion.
In a Japanese experiment, the long-term follow-up after a single intravenous bolus of 
nicorandil (a hybrid compound of mitochondrial K
ATP
-channel opener and NO-donor) in 
patients with STEMI, significantly reduced occurrence of MACE (6.5%), compared to 
placebo (16.4%).115 The Italian ARMYDA-ACS trial showed that atorvastatin treatment just 
prior to PCI in statin naïve patients reduces MACE at 30 days from 17% to 5% in patients 
with acute coronary syndrome.203
Large clinical trials on pharmacological improvement of outcome after myocardial 
infarction using adenosine and pexelizumab infusion failed to significantly reduce 
mortality.12,166,228 Also administering erythropoietin at myocardial reperfusion in patients 
with STEMI did not convincingly reduce myonecrosis markers nor did it reduce patient 
mortality.181
Studies on prevention of IR-injury in the setting of elective PCI
In approximately 30% of the patients undergoing elective PCI IR-injury is present (as 
assessed by a periprocedural rise of myonecrosis markers).14,135 MRI studies have shown 
that this rise in myonecrosis factors after PCI represents actual myocardial injury.216,244 
Furthermore a correlation has been found between post-PCI increase of myonecrosis 
markers and increased risk on restenosis185 and even on long-term mortality.208 Explanations 
on the cause of IR-injury after PCI include transient balloon-induced ischaemia, side 
branch occlusion (either by atheroma or by a stent), no-reflow phenomenon, transient 
vessel closure due to dissection or spasm and embolization of platelet fibrin aggregates 
along with atherosclerotic debris.14,135,187
Deutsch et al. were the first to study the effect of standardised repeated balloon inflations 
(2x90 seconds) in patients undergoing elective PCI. They found a significant reduction of 
ST deviation, angina pain score and myocardial lactate production during the second 
balloon inflation.53 
Initially these findings were questioned because in animal experiments an ischaemic 
episode lasting 90 seconds did not induce myocardial protection.144,169 It was proposed 
that during the first episode of ischaemia collateral flow was recruited, and that the 
changes during the second episode could be contributed to the increased coronary flow 
to the ischaemic area of interest.169 However additional experiments have shown that 
repetitive brief episodes of coronary occlusion do not recruit significant collateral flow.48,171 
Tomai et al. confirmed the results of Deutsch, and moreover they found that oral 
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glibenclamide (ATP-dependent potassium channel blocker) treatment prior to ischaemic 
preconditioning completely abrogated the protective effect of IP.271 Furthermore IP also 
reduced periprocedural arrhythmias.3 Hoole et al. showed that remote ischaemic precon-
ditioning (3 cycles of 5 minutes of upper limb ischaemia) can reduce troponin-I release 
and reduce incidence of MACE with 70% in patients undergoing elective PCI.110
Parallel to findings in preclinical research, investigators initiated experiments to study 
pharmacologic preconditioning in patients undergoing elective PCI. Randomised and 
blinded intracoronary administration of dipyridamole256 and adenosine104 increased myocardial 
resistance against IR. However, more recently intracoronary adenosine did not protect the 
heart in a randomised study with MRI-detected injury as endpoint.52 Intravenous 
administration of nitroglycerin 24 hours prior to PCI also provided protection, indicating 
the existence of a pharmacological induced second window of protection in humans.149
A group of drugs extensively studied concerning their ability to induce protection against 
IR-injury during PCI are statins (HMG-reductase CoA inhibitors). In the first trial studying 
the relation between statin pretreatment and IR-injury, statin naïve hypercholesterolae-
mic patients with stable angina pectoris were randomised to receive three months 
treatment with pravastatin or placebo. To show involvement of adenosine in the alleged 
protective effect, participants were randomised to receive aminophylline (a potent 
adenosine receptor antagonist) just prior to PCI. This experiment showed that statin 
pretreatment provided protection against (measured using ST shift on the ECG) and that 
this effect could completely be abrogated by aminophylline.148
Further experiments have shown a reduction in myonecrosis markers after PCI by both a 
7 day treatment with atorvastatin202 and even a single high loading dose of atorvastatin.34 
A double dose of atorvastatin immediately prior to an acute PCI on top of concurrent 
statin therapy was able to significantly reduce MACE after PCI.55
Studies on prevention of IR-injury in the setting of CABG
In cardiac surgery temporary cardiac arrest is applied to enable valve repair, valve 
replacement, or placement of coronary bypass grafts. During cardiac arrest an extracorporal 
circulation (or heart-lung machine) will provide oxygenated blood to the rest of the body, 
only the heart becomes ischaemic during this period. Extensive experiments on 
cardioplegic solutions used during cardiac arrest have greatly improved tolerance of the 
myocardium to this ischaemic phase of the surgical procedure.38 Nonetheless 99% of 
CABG patients show increased values of troponin-I after surgery. Moreover in a 
post-mortem analysis of patients who died shortly after coronary bypass surgery 25% 
showed histological evidence of extensive IR-injury.289 Different features of IR-injury are 
frequently observed in the aftermath of for example coronary artery bypass surgery, 
including increased levels of myonecrosis markers, myocardial stunning and subsequent 
need for inotropic therapy, and occurrence of arrhythmias is common during the first 
postoperative days.305
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Ample experiments have been carried out to investigate and reduce the burden of 
perioperative IR-injury. In 1993 preliminary data were published by Yellon and Alkhulaifi on 
the possible benefit and clinical applicability of ischaemic preconditioning in the setting 
of cardiac surgery.7,303 After initiation of the cardiopulmonary bypass, 14 patients were 
randomised to receive either two 3 minute episodes of generalised cardiac ischaemia 
(induced by aortic cross clamping) and subsequent reperfusion followed by 10 minutes of 
ischaemic ventricular fibrillation (VF), or just 10 minutes of ischaemic VF. In the cardiac 
biopsies taken after ischaemic VF in patients subjected to ischaemic preconditioning 
levels of ATP were higher and levels of lactate were lower than in controls. The authors 
concluded that IP could beneficially influence myocardial metabolism and thus protect 
the myocardium against IR.
Shortly thereafter Alkhulaifi showed that this protocol also significantly reduces troponin-T 
release after CABG, further showing that IP in cardiac surgery could reduce myocardial 
tissue damage.6 Inspired by these results, many researchers have repeated or modified the 
IP protocol in cardiac surgery. Most of them reaching similar conclusions122,152,162,259,298, 
though not all.47,131
More recently the possibility of remote ischaemic preconditioning was successfully 
introduced in the field of cardiac surgery by Cheung.41 In children undergoing correction 
of a congenital cardiac defect postoperative troponin-I release could be reduced by 4 
episodes of 5 minutes ischaemia and reperfusion in a lower limb. This effect was confirmed 
in adult cardiac surgery using CK-MB and cardiac troponins.96,262,279
Surprisingly, by far the largest study on the effect of remote preconditioning during CABG, 
could not show a beneficial effect of preconditioning on troponin release, improved 
haemodynamics or enhanced renal or lung protection. In this experiment over 160 
patients were randomised to a double-blind, dummy controlled experiment with three 
cycles of 5 min upper arm ischaemia prior to CABG.211
Luo et al. have performed two experiments in both children and adults, testing the effect 
of controlled reperfusion (ischaemic postconditioning).164,165 In this protocol patients were 
randomised to direct removal of the aortic clamp and uninterrupted reperfusion or to 3 
episodes of 30 seconds of aortic reclamping, initiated 30 seconds after original clamp 
removal. In both children and adults postconditioning reduced CK-MB release postopera-
tively. Schlensak et al., showed that mortality could be reduced from 11% to 5%, in patients 
undergoing urgency CABG, by controlled reperfusion compared to direct reperfusion.237 
However, as this study was a non-randomized patient-control experiment, several forms 
of bias could have influenced the outcomes. 
Moreover numerous papers have been published studying pharmacologic precondition-
ing in the setting of cardiac surgery. A series of different drugs have been administered to 
patients prior to cardiac surgery, and postoperatively myonecrosis factors were followed 
up. The results published were rather variable. Here we would like to summarise the most 
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important and best studied. For example adenosine delivered intracoronary appeared to 
induce protection146, whereas if it was administered intravenously19 no effect on IR-injury 
could be noted. An A1 adenosine receptor agonist did not reduce injury after CABG.259 
Nitric oxide either delivered in the cardioplegia281 or through the ventilation79 reduced 
postoperative myocardial injury.
Volatile anaesthetics have also been shown to be able to reduce infarct size in animal 
experiments.36  In two experiments in CABG patients isoflurane reduced troponin-I and 
CK-MB release after CABG surgery20,94 and improved haemodynamics.184 However this 
protective effect of isoflurane could not be confirmed by all.167 Continues administration 
of volatile anaesthetics (desflurane or sevoflurane) reduced post CABG troponin-I release 
and shortened postoperative hospital stay compared to propofol or midazolam based 
anaesthesia.50 Finally, in another observational study Jacobsen studied the influence of 
volatile anaesthetics on IR-injury as opposed to propofol as sedative. For 10,535 patients 
undergoing CABG in Denmark, multiple parameters were filed in an obligatory national 
registry. After stratification for case load by the EuroSCORE (a validated scoring system to 
assess operative mortality risk), no differences were found in 30 day mortality, postoperative 
AMI or postoperative arrhythmias.118
Other drugs that have been described reducing myocardial necrosis markers after CABG 
are bradykinin287, levosimendan272, and nicorandil100. In the MEND-CABG trial, the effect of 
pyridoxal 5’-phosphate on inhibiting calcium influx in ischaemic cardiomyocytes via ATP 
(non-selective P2 receptor antagonist212) and subsequent myocardial tolerance for after 
CABG was tested in 900 patients. Only a post-hoc analysis with stringent definitions of 
myocardial infarction showed a significant reduction in the composite of death and AMI.127 
Subsequently 3000 CABG patients were included in the MEND-CABG II study. However in 
this large clinical trial the researchers did not find any difference in postoperative death or 
AMI after treatment with pyridoxal 5’-phosphate.5,258
There are several limitations to studying IR-injury in the setting of CABG. The use of 
extracorporal circulation induces a systemic inflammatory response, which could 
contribute to the occurrence of vascular plugging and endothelial dysfunction, leading to 
no-reflow. Moreover, surgical trauma to the heart may also increase myonecrosis factors 
independent from IR-injury. 
Ex vivo model on myocardial IR-injury
In 1995 Yellon introduced an ex vivo model that measured contractile force recovery after 
IR-injury in human atrial tissue harvested during cardiac surgery.282 In brief, the right atrial 
appendage is collected during cardiac surgery before the initiation of extracorporal 
circulation. An atrial trabecle with sufficient length and diameter is dissected, vertically 
suspended in an organ bath and linked to a force transducer. To recover from preparation 
the trabecle is superfused with a nutritious and well-oxygenated solution. Next the 
trabecle is exposed to 90 minutes of simulated ischaemia, by removing oxygen and 
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nutrients from the superfusate. After 90 minutes reperfusion was simulated by restoring 
oxygen and nutrient delivery to the trabecle by the superfusate. During both simulated 
ischaemia and reperfusion contractile force delivered by the trabecle is continually 
monitored. Contractile force recovery after simulated ischaemia and reperfusion is 
influenced by irreversible damage and stunning of the atrial tissue.
A modified setup can be used with two trabecles measured simultaneously, one trabecle 
can be exposed to experimental interventions (e.g. ischaemic preconditioning, or addition 
of any pharmacologic agent to the superfusate) whilst the other serves as a control.224
Studies on optimisation of prevention of IR-injury 
To further elucidate determinants of susceptibility to prevention of IR-injury several 
translational and clinical experiments have been performed. Two different experiments 
have studied the effect of age on susceptibility to IP induced protection against IR. Wu et 
al. showed in CABG patients, that IP could reduce troponin-I release postoperatively in 
patients younger than 68 years, whereas in patients older than 68 years no effect of IP on 
troponin-I was observed.299 In the experiment of DeVan et al. middle-aged volunteers 
showed larger effect of IR on endothelial dysfunction compared to young volunteers. 
Moreover, sedentary volunteers were more susceptible to endothelial dysfunction after IR 
than endurance-trained participants (in both young and middle aged groups).54 These 
methodological different experiments cover different aspects of the relation between 
age and IP. DeVan shows that age and habitual exercise influence the impact of IR on 
endothelial dysfunction, whereas Wu shows that with ageing efficacy of ischemic precon-
ditioning to reduce IR-injury may decrease.
Riksen et al. have shown that in volunteers with a dysfunctional gene for the enzyme 
adenosine mono-phosphate deaminase-1 (AMPD-1), post-occlusive reactive hyperaemia 
was augmented and annexin A5 targeting after voluntary ischemic exercise was reduced. 
AMPD-1 normally catalyses intracellular conversion of adenosine monophosphate (AMP) 
to inosine monophosphate (IMP), whereas this action is blocked in the 34 C>T variant. It is 
suggested that during ischaemia in humans with the variant allele, increased cellular levels 
of AMP are preferentially degraded to adenosine, which will increase tolerance to IR.221 
These results indicate that humans with the 34 C>T variant of AMPD-1 are endogenously 
protected to ischaemia and reperfusion injury. This observation provides a mechanism for 
the survival benefit that has been reported in cardiac patients with the 34 C>T variant of 
the AMPD-1 gene.9
As stated above, many drugs have been found to be able to either interfere with or to 
induce tolerance against IR. Several experiments have used sulfonylurea derivates 
(K
ATP
-channel blockers, e.g. glibenclamide), to abrogate protection induced by for example 
IP.23,161,271 A randomised trial in patients undergoing CABG, showed protection by isoflurane 
anaesthetics, an opener of K
ATP
-channels. In diabetic patients on glibenclamide, this 
protection was completely prevented. 74 However another retrospective cohort study 
26
Chapter 1
could not confirm this interaction.70 Ishihara et al. have shown that in patients with diabetes 
mellitus the protective effect of prodromal angina prior to STEMI was abrogated, 
compared to non-diabetic patients. This suggests that diabetes mellitus prevents the 
protective effect of IP.114 This conclusion is supported by preclinical evidence.176 In animal 
research synergistic effects of for example dipyridamole and atorvastatin on protection 
against IR have been published.302 Human data on this subject however are still missing.
Aim and Outline of this Thesis
In this thesis, we describe a series of experiments focused on measurement of ischaemia 
reperfusion injury and pharmacologic modulation of IR-injury in humans in vivo. We aim 
to find a model to study in vivo the efficacy and mechanism of various interventions to 
reduce IR-injury. Moreover, we explored whether these models can predict clinical efficacy 
of these strategies in patients who present with cardiac ischaemia. For this purpose we 
investigated atorvastatin and irbesartan, both drugs with a proven benefit on IR-injury in 
several clinical trials.128,202,203
In chapters 2,3 and 4 we focus on the use of annexin A5 to assess phosphatidylserine 
exposition in the course of IR-injury. We studied the effect of several drugs, all known to 
be protective against IR-injury (pharmacologic preconditioning) in previous animal and 
clinical experiments. 
In chapter 2 we tested if short-term treatment with atorvastatin reduces PS exposition after 
forearm ischaemia and subsequent reperfusion. Atorvastatin, a widely used drug in patients 
with cardiovascular disease, has been proven to prevent IR-injury in multiple relevant 
settings (e.g. patients undergoing PCI, either elective202 or in the setting of an ACS203). As 
atorvastatin has previously been shown to prevent myocardial damage, we tested whether 
prevention of PS exposition is a part of the protective mechanism. This experiment used 
a crossover design, including an extra control group randomised to placebo treatment twice. 
This control group allowed us to calculate within-individual correlation, thereby further 
quantifying the reproducibility of annexin scintigraphy after IR-injury.
In chapter 3 we studied the effect of a 7-day treatment with the angiotensin receptor 
blocker (ARB) irbesartan on PS exposition after IR-injury. Despite the preclinical benefits39,73 
angiotensin II type 1 receptor antagonists seem to enhance rather than reduce morbidity 
and mortality after myocardial infarction compared to angiotensin converting enzyme 
inhibitors.57 This may result from unopposed angiotensin II type 2 receptor stimulation, 
which is associated with enhanced apoptotic cell death and increased infarct size. We 
studied whether the clinical efficacy of irbesartan is hampered by enhanced apoptotic 
activity, detected by exposition of phosphatidylserines, during ischaemia and reperfusion 
in humans in vivo.
27
Ischaemia and reperfusion in the heart
Our research group has shown previously that a 7-day treatment with dipyridamole 
reduces annexin A5 targeting after voluntary forearm IR-injury. However, this study was 
neither blinded nor randomised, and therefore the conclusions have to be considered 
carefully.220 To test our hypothesis more rigorously, we decided to readdress the protective 
effects of dipyridamole against IR in chapter 4 using a randomised double-blind placebo- 
controlled design. Moreover we further examined the mechanism of protection. To 
address a possible role of extended nucleoside transport inhibition in the apparent 
long-term action of dipyridamole, we investigated the 4-week post-treatment effect of 
a 7-day oral dipyridamole administration on nucleoside transport ex vivo in human 
erythrocytes.
In chapters 5,6 and 7 we used two techniques for the assessment of endothelial function 
to study the effects of ischaemia and reperfusion injury. Ischaemia and reperfusion 
reduces endothelial function as assessed by flow-mediated dilatation (FMD). 
We have previously shown that one week treatment with rosuvastatin improves formation 
of adenosine in the forearm and increases forearm post-occlusive reactive hyperaemia 
(PORH).172 In chapter 5 we further clarified the mechanism behind this effect of rosuvastatin. 
We have assessed the activity of the enzyme ecto-5’-nucleotidase, which dephosphoryl-
ates extracellular AMP, as a potential source of extracellular adenosine. Moreover we 
investigated the role of adenosine receptor stimulation in rosuvastatin-induced 
augmentation of PORH. We hypothesized that an adenosine dependent reaction should 
be abolished by administering caffeine, a potent adenosine receptor antagonist.
In chapter 6 we used FMD to compare the effect of two different statins (the lipophilic 
atorvastatin vs. the hydrophilic rosuvastatin) on their ability to prevent endothelial 
dysfunction of the human brachial artery induced by IR. Interestingly, hydrophilic and 
lipophilic statins appear to differ in their effects on patients. Lipophilic statins have been 
reported to render endothelial and vascular smooth muscle cells more susceptible to 
apoptosis than hydrophilic statins.130 Moreover hydrophilic statins have been suggested to 
be superior in reducing event rate after a primary acute coronary syndrome in normocho-
lesterolaemic patients.233 Thus, lipophilicity of statins may influence their ability to reduce 
IR-injury.
FMD to assess IR-induced endothelial dysfunction is either measured in the brachial or 
radial artery. To date, little is known about methodological aspects of this technique. For 
example, regional heterogeneity in wall architecture268 and vascular function265, may alter 
the impact of IR-injury on endothelial function between these vascular beds. In chapter 7 
we examined the difference in endothelial tolerance to IR-injury between the radial and 
brachial artery, by measuring the effect of IR simultaneously in both arteries ipsilaterally.
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Abbreviations
ACE Angiotensin II converting enzyme
ACS Acute coronary syndrome
ADP Adenosine diphosphate
AMI  Acute myocardial infarction 
AMP Adenosine monophosphate
AMPD Adenosine monophosphate deaminase
ARA Angiotensin II receptor antagonist
ARB Angiotensin II receptor blocker
AT1 Angiotensin II receptor type 1
AT
2
 Angiotensin II receptor type 2
ATP Adenosine triphosphate
CABG Coronary arterial bypass grafting
CD73 Ecto-5’-nucleotidase
CV Coefficient of variance
CT Computer tomography 
ECG Electrocardiogram
FBF Forearm blood flow
FMD Flow mediated dilation
HDL High-density lipoprotein
IP Ischaemic preconditioning
IR Ischaemia and reperfusion
IRI Ischaemia and reperfusion injury
LAD Left anterior descending coronary artery
LDL Low-density lipoprotein
MACE Major adverse cardiac event
MPTP Mitochondrial permeability transition pore
MRI Magnetic resonance imaging
NO Nitric Oxide
NonSTEMI Non ST elevated myocardial infarction
PCI Percutaneous coronary intervention
PORH Postocclusive reactive hyperaemia
PS Phosphatidylserine 
RNA Ribonucleic acid
RIPC Remote ischaemic preconditioning
ROS Reactive oxygen species
STEMI ST Elevated myocardial infarction
SWOP Second window of protection
UV Ultraviolet
VF Ventricular fibrillation
29
Ischaemia and reperfusion in the heart

Chapter 2
Atorvastatin does not aff ect 
ischaemia-induced phosphatidylserine 
exposition in humans in vivo
Constantijn Wouters
Patrick Meijer
Carola Janssen
Geert Frederix 
Wim Oyen
Otto Boerman
Paul  Smits 
Gerard Rongen
Journal of Atherosclerosis and Thrombosis 2012; 19: 285-291
32
Chapter 2
Abstract
Aim: Statins can induce pharmacologic preconditioning and thereby reduce infarct size. 
Cellular phosphatidylserine (PS) exposition occurs in the course of ischaemia and 
reperfusion and has been associated with IR-injury. In this experiment we studied the 
effect of atorvastatin on PS exposition after a standardised ischaemia and reperfusion 
challenge.
Methods: In a double-blind randomised cross-over trial 30 healthy volunteers were 
allocated to 3 day treatment with atorvastatin (80mg/day) and placebo (n=24), or placebo 
treatment twice (n=6). At the end of each treatment period, volunteers underwent 10 
minutes of forearm ischaemic exercise. At reperfusion radiolabeled annexin A5 was 
administered intravenously and Gamma camera imaging of both hands was performed 1 
and 4 hours after reperfusion. 
Results: Annexin A5 targeting was not different between atorvastatin treatment (26.1 
±9.8% and 24.0 ±9.5% respectively at 1 and 4 hours after reperfusion) and placebo 
treatment (25.6 ±11.0% and 24.5 ±10.7%) (p=0.99). Our time control experiment did not 
reveal a carry-over effect.
Conclusions: Our results show that treatment with atorvastatin 80mg does not reduce 
forearm PS exposition after ischaemic exercise. This suggests that the role of PS exposure 
in the prevention of ischaemia and reperfusion injury by short term treatment with 
atorvastatin is limited.
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Introduction
The cholesterol lowering action of statins (HMG-coenzyme A reductase inhibitors) and its 
associated reduction in cardiovascular events have been well documented in numerous 
clinical trials.150,210,230,231 Traditionally, this beneficial effect of statins has been explained by 
lowering of plasma cholesterol and subsequent reduced progression of atherosclerosis. Apart 
from its cholesterol lowering properties, statins have other (“pleiotropic”) actions, such as 
upregulation of ecto-5’-nucleotidase145,198,234, activation of the phosphatidylinositol 3-kinase-Akt 
pathway274 and up-regulation of NO synthase106,138 which all may increase tolerance against 
ischaemia and reperfusion (IR).22,32,229 Several animal studies have shown reduction of IR-injury 
as a result of statin treatment in both the heart and the kidney.89,101,126,306 This putative protection 
may explain the clinical observation that early initiation of statin treatment in patients with an 
acute cardiovascular event improves long-term prognosis as compared with a delayed start of 
this treatment.49,60,242 Furthermore in two randomised clinical trials one day treatment with 
atorvastatin prior to percutaneous coronary intervention reduced myocardial injury and 
improved clinical outcomes in patients with acute coronary syndromes.55,203
Ischaemia induced phosphatidylserine (PS) exposure on cardiomyocytes has been 
associated with reversible cellular damage and apoptosis.189,269 Treatment to shield exposed 
PS with diannexin, a homodimer of human annexin A5 (with high affinity for exposed 
phosphatidylserines) significantly reduces IR-injury in the liver and kidney.260,290 Likewise, 
diannexin prevents no-reflow in a rabbit cardiac ischaemia-reperfusion model.91 These 
observations suggest a critical role for exposed PS in the development of IR-injury. We have 
developed an experimental model to study PS exposure after IR in healthy volunteers. Our 
model uses radiolabeled recombinant annexin A5 to visualise PS-exposition that occurs 
after 10 minutes of forearm ischaemia combined with isometric exercise.226 Interventions 
that have been shown in preclinical and clinical research to modulate myocardial infarct 
size (ischaemic preconditioning, and administration of adenosine, dipyridamole, and 
caffeine) similarly modulate annexin A5 targeting in our forearm model, further supporting 
a role for PS-exposure in IR-injury.220,224,226
Using annexin A5 scintigraphy after voluntary ischaemic exercise in healthy males, we have 
recently shown that annexin A5 targeting after a short pretreatment with rosuvastatin 20 
mg once daily was significantly reduced (16 ±1% and 18 ±2% respectively at 1 and 4 hours 
after reperfusion) compared to placebo treatment (21 ±3% and 25 ±3%) (p<0.05).172 As 
previously reported for other statins in preclinical research with infarct size as endpoint, this 
effect of rosuvastatin was inhibited by caffeine, an adenosine receptor antagonist.172
There is ample evidence from animal and clinical research that treatment for three days 
with high dose atorvastatin protects against IR-injury.13,27,89,202,203 However, we do not know 
whether PS exposure relates to this clinical benefit of atorvastatin, as differences have been 
observed in the efficacy of various statins to inhibit HMG-CoA-reductase188 and to induce 
pleiotropic effects.213
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Aim
We aim to assess the role of PS-modulation in the beneficial effect of atorvastatin on 
IR-injury. We tested the hypothesis that a short pretreatment with atorvastatin 80 mg 
reduces annexin A5 targeting in our forearm IR-model.
Methods
After approval of the protocol (NCT00441597) by the Institutional Review Board of the 
Radboud University Nijmegen Medical Centre and in accordance with the declaration of 
Helsinki (2008), 30 healthy male volunteers (age 18-54 years) signed informed consent. All 
participants underwent medical screening to exclude cardiovascular disease, hypercho-
lesterolaemia, hypertension, diabetes mellitus, and impaired renal function. Furthermore 
serum values of creatine kinase (CK) and alanine aminotransferase (ALT) were measured to 
exclude participants possibly at risk for adverse events due to atorvastatin use 
(rhabdomyolysis and toxic hepatitis).
In this double blind randomised crossover trial (figure 1) participants were allocated to 
treatment with either atorvastatin and placebo (n=24), or placebo treatment twice (n=6). 
The latter group served as a time-control. Furthermore, it allowed us to verify our 
assumptions on within-subject variability and test-to-test correlation of our annexin A5 
scans. Placebo or atorvastatin (80 mg) was administered for three days, and at least 
4 weeks were allowed between the two treatment periods as a washout. Atorvastatin 
80mg (Pfizer, Capelle a/d IJssel, The Netherlands) was capsulated to match placebo by 
the department of Clinical Pharmacy (Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands according to GMP standards). In both treatment periods the 
first tablet was administered under supervision of the investigator, after venous blood 
sampling to determine fasting lipid profile. The participant was instructed to take the 
second capsule in the morning and to abstain from caffeine during the last 24 hours prior 
to ischaemic exercise. On day 3 after an overnight fast the last tablet was administered 
under supervision, again after assessment of fasting lipid profile and serum caffeine level 
to verify protocol compliance.
Sixty minutes after administration of the study medication in all participants maximal 
voluntary contraction force of the non-dominant forearm was measured with an isometric 
handgrip dynamometer. Subsequently, the circulation of the non-dominant forearm was 
occluded for 10 minutes with an upper arm cuff inflated to 200mmHg. Directly after 
occlusion volunteers were asked to perform isometric contractions of the finger flexors at 
50% of their maximum contraction force. These contractions were performed rhythmically 
with 5 seconds of contraction followed by 5 seconds of relaxation until exhaustion. The 
total duration of ischaemia was 10 minutes, independent of the duration of contractions.
Immediately upon reperfusion 100 microgram recombinant human annexin A5, radio- 
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labeled with 450 MBq Technetium-99m was administered intravenously into the dominant 
arm. One and four hours after this administration both hands were scanned simultaneously 
by use of a gamma camera (Orbiter camera equipped with low-energy high-resolution 
collimators; Siemens, Hoffman Estates, Ill, USA) as previously described.226
Caffeine plasma concentrations were determined using reversed-phase HPLC with UV 
detection set at 273nm.240 Serum lipid profile (total-, HDL- and LDL-cholesterol and 
triglycerides), creatine kinase and alaninine amino transferase were determined with a 
commercially available kit (Aeroset, Abbott, Santa Clara, Cal., USA). 
Data analysis
All the digitised gamma camera images were analysed offline by the same investigator (W. 
J.O.) using Hermes software (Nuclear Diagnostics, Stockholm, Sweden). A predefined 
region of interest was placed over the thenar muscle of both hands. Annexin A5 targeting 
was expressed as the percentage difference in counts/pixel between the experimental 
(non-dominant) hand and the control hand as previously described.226 
Figure 1  Study protocol
From the 30 participants 12 were randomised to 3 days of atorvastatin treatment followed by three 
days of placebo treatment. 12 Participants were randomised to first 3 days of placebo treatment and 
next 3 days atorvastatin treatment, and 6 participants were randomised to placebo treatment twice. 
At day three of treatment participants performed 10 minutes of ischaemic forearm exercise. Upon 
reperfusion Tc-99m labelled annexin A5 was administered and scintigraphy was performed 1 and 4 
hours after reperfusion. Between both treatment periods a 4-week interval was observed.
n=30
n=12
n=12
n=6
Atorvastatin
Atorvastatin
Placebo
Placebo
Placebo
Placebo
IR-injury and Tc-99m annexin A5 scintigraphy
36
Chapter 2
Statistical analysis
Values are expressed as mean ± standard error (SE) unless indicated otherwise. 
This study is the first to use our forearm IR-model in a paired set-up in healthy volunteers. 
Based on previous studies, a between subject SD of 10% was predicted.220,224,226 
Conservatively assuming a correlation coefficient of 0.5 between first and second paired 
observation, we calculated that with an alpha of 0.05 and a power of 90%, using 24 
subjects allows us to find a difference in annexin A5 targeting of 7%. This is well in the 
range of our previous observation after treatment with rosuvastatin.172 Furthermore 6 
additional participants were randomised (in a double-blind fashion) to receive placebo 
treatment twice to serve as time-control experiment. This time-control allows us to verify 
our assumptions regarding this power analysis afterwards.
The effect of atorvastatin treatment on annexin A5 targeting and lipid profile was tested 
using ANOVA for repeated measurements. All statistical analyses were performed using 
SPSS 16.0 for Windows.
Results
Baseline characteristics of all participants are presented in table 1. Caffeine levels were all 
under 0.85 mg/L, indicating satisfactory compliance to the 24 hours caffeine abstinence. 
The annexin A5 targeting was not different between atorvastatin treatment (26.1 ±2.0% 
and 24.0 ±1.9% respectively at 1 and 4 hours after reperfusion) and placebo treatment 
(25.6 ±2.4% and 24.5 ±2.2%) (p=0.999) (figure 2).
Three-day treatment with atorvastatin significantly reduced total cholesterol (from 4.15 
±0.10mmol/L to 3.44 ±0.10mmol/L) and LDL cholesterol (from 2.31 ±0.10mmol/L to 1.84± 
0.10mmol/L as compared to placebo treatment; p<0.001 for both comparisons). HDL 
cholesterol and triglyceride levels were unaffected by atorvastatin (from 1.22 ±0.04 to 1.25 
±0.05 for HDL-C, and from 0.93  ±0.08 to 0.80 ±0.09 for triglycerides).
Workload (50% of the maximal strength * duration of ischaemic exercise) did not 
significantly differ between both study days (4260 ±284kg*sec and 4253 ±219kg*sec after 
atorvastatin and placebo respectively (p=0.96), indicating that potential differences in 
ischaemic challenge did not confound the observed lack of effect on annexin A5 targeting.
In the time control group (n=6) the annexin A5 targeting after the first visit was 23.5 ±5.5% 
and 23.2 ±6.5% (respectively at 1 and 4 hours after reperfusion) and 30.2 ±6.1% and 20.3 
±7.8% after the second visit (figure 3). The between-subject standard deviations in 
annexin A5 targeting were 13.5%, 15.8%, 15.0% and 9.3% at 1 and 4 hours for visit 1 and 2 
respectively. Within subject correlation was 0.93 and 0.79 at 1 and 4 hours respectively. 
This reproducibility should have allowed us to detect a difference in targeting between 
placebo and atorvastatin of at least 7%, closely resembling our initial power calculation.
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Table 1  Baseline characteristics of all participants (n=30)
Mean ±S.D.
Age (years) 23.3 ±6.6
BMI (kg/m2) 22.4 ±2.4
Systolic blood pressure (mmHg) 126 ±8
Diastolic blood pressure (mmHg) 71 ±10
Heart rate (bpm) 62 ±8
Glucose (mmol/l) 4.6 ±0.7
Total cholesterol (mmol/l) 4.0 ±0.6
Triglycerides (mmol/l) 1.19 ±0.94
HDL-C (mmol/l) 1.33 ±0.26
LDL-C (mmol/l) 2.19 ±0.65
Figure 2   Annexin A5 targeting 1 and 4 hours after reperfusion, after placebo 
(open bars) and atorvastatin (closed bars) treatment 
 
Bars represent mean ± SE.
1 1 4 4
0
5
10
15
20
25
30
Hours after reperfusion
A
nn
ex
in
 A
5 
ta
rg
et
in
g 
(%
)
38
Chapter 2
Discussion
The novel finding of this study is the lack of effect of atorvastatin on annexin A5 targeting 
after voluntary ischaemic exercise. This indicates that in our forearm model treatment with 
atorvastatin, in a dose and duration as previously used in clinical trials with patients who 
present with coronary syndromes55,202,203, does not modulate PS exposition after IR, in 
contrast to treatment with rosuvastatin, as reported recently.172 As the protective action of 
atorvastatin in a setting of ischaemia and reperfusion has been convincingly shown in 
multiple animal experiments13,27 and even in several clinical trials42,55,203, we conclude that 
PS modulation is not likely involved in the protective mechanism of atorvastatin.
During reperfusion after an ischaemic event, multiple detrimental processes take place 
simultaneously, including formation of radical oxygen species (ROS), cellular and 
mitochondrial calcium overload, and a rapid increase (restoration) in pH.305 These actions 
result in mitochondrial damage caused by opening of the mitochondrial permeability 
transition pore (MPTP), activation of caspases and subsequent cell damage and possible 
cell death (by either necrosis or apoptosis).120
Figure 3   Annexin A5 targeting 1 and 4 hours after reperfusion in time-control 
group (placebo treatment twice), after visit 1 (open bars) and visit 2 
(closed bars). 
 
Bars represent mean ± SE.
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PS exposition is recognised to be part of the signalling cascade in the course of apoptosis.170 
It attracts phagocytes which remove the dying cell before its remnants evoke an 
inflammatory response.72 The importance of PS exposition in developing tissue damage 
after IR-injury was clearly demonstrated in several experiments where IR-injury could be 
reduced by shielding of PS by diannexin treatment.246,260,290  
The time-control experiment excluded a carry-over effect as a potential reason for the lack 
of observed effect of atorvastatin on annexin A5 targeting. In addition, inter-individual SD 
and within-subject correlation resulted in a power to detect differences between placebo 
and atorvastatin that resembles the results of our initial power calculation. In fact, based 
on these measurements we could calculate a minimal detectable difference of less than 
10%, which is well below the previously observed effect of rosuvastatin on annexin A5 
targeting. Thus, our sample size was sufficient to detect the effect size as expected from 
our hypothesis and previous observation with rosuvastatin.
The (cardio)protective mechanism of statins is well investigated, though its mechanism 
has not been fully elucidated.163 Adenosine appears to play an important role in initiating 
the cascade (adenosine dependent phosphorylation of ERK1/2, Akt and eNOS) leading to 
a protective phenotype after statin therapy.175 Upregulation of ecto-5’-nucleotidase has 
been shown in vitro and in animals in vivo for various statins.197 In humans in vivo however, 
this effect has only been explored for rosuvastatin, which increases ecto-5’-nucleotidase 
activity with 50%.173
In our rosuvastatin trial participants were treated 7 days172, whereas in this atorvastatin trial 
participants were treated for 3 days. However we doubt that treatment duration could 
account for the difference in annexin A5 targeting in these experiments. We have previously 
shown in humans that activation of ecto-5’-nucleotidase mediates prevention of PS 
exposure by rosuvastatin after IR. The effect of statins on ecto-5’-nucleotidase appears to 
occur rapidly.145,234 For example Sanada et al. found a significant increase of ecto-5’-nucle-
otidase activity in dogs for different statins (pravastatin, pitavastatin and cerivastatin) 
already 10 minutes after treatment.234 Thus, our discrepant results between rosuvastatin 
and atorvastatin are not likely explained by differences in treatment duration but rather 
reflect a difference in pharmacodynamics between these two statins. There are significant 
differences between several statins in their efficacy to lower LDL cholesterol.125 Moreover, 
pleiotropic effects have been shown to differ between lipophilic statins (e.g. atorvastatin) 
and hydrophilic statins (e.g. rosuvastatin). Lipophilic statins have been reported to render 
endothelial and vascular smooth muscle cells more susceptible to apoptosis than 
hydrophilic statins.130 In humans rosuvastatin inhibits Rho/Rho kinase activity to a greater 
extent than atorvastatin at a dose that equally reduced LDL cholesterol.213 Moreover 
hydrophilic statins have been suggested to be superior in reducing event rate after a 
primary acute coronary syndrome in normocholesterolaemic patients.233 
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Conclusion
Our results show that treatment with atorvastatin 80mg does not reduce forearm PS 
exposition after ischaemic exercise. This suggests that the role of PS exposure in the 
prevention of ischaemia and reperfusion injury by short-term treatment with atorvastatin 
is limited.
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Abstract
Despite the theoretical benefits angiotensin II type 1 receptor antagonists seem to 
enhance rather than reduce morbidity and mortality after myocardial infarction compared 
with angiotensin converting enzyme inhibitors. This may result from unopposed 
angiotensin II type 2 receptor stimulation, which is associated with enhanced apoptotic 
cell death and increased infarct size. We studied whether the clinical effectiveness of 
irbesartan is hampered by enhanced apoptotic activity, detected by exposition of phos-
phatidylserines, during ischaemia and reperfusion in humans in vivo. Twenty healthy male 
volunteers were randomized to a 1-week treatment with irbesartan (300 mg/d) or placebo 
in a double-blind fashion. After treatment, all participants underwent 10 minutes of 
ischaemic exercise of the non-dominant forearm. Upon reperfusion Tc-99m-labeled 
Annexin A5 was administered and 1 and 4 hours afterward, both hands were scanned 
using a gamma camera. Targeting of annexin A5, expressed as the percentage difference 
in radioactivity in the area of interest (thenar muscle) between experimental and control 
hand, did not differ between participants treated with irbesartan or placebo. Therefore 
irbesartan does not enhance phosphatidylserine exposition in humans in vivo. The results 
of this study do not support enhanced apoptotic activity after treatment with irbesartan 
in a setting of ischaemia and reperfusion.
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Introduction
Angiotensin II functions through 2 receptor subtypes: angiotensin II type 1 (AT
1
) and 
angiotensin II type 2 (AT
2
). Most of the well-known physiological effects of angiotensin II 
are mediated via the AT
1
 receptor, which is widely expressed by most cell types.77 After 
myocardial infarction, the rise of angiotensin II levels results in AT
1
 receptor stimulation, 
subsequent vasoconstriction, increased cardiac contractility and cellular proliferation may 
all worsen the outcome. Indeed, the inhibition of the formation of angiotensin II by angi-
otensin-converting enzyme (ACE) inhibitors improves survival after acute myocardial 
infarction.1 AT
1
 receptor antagonists (ARAs) are suggested to have, at least, similar benefits 
compared with ACE inhibitors as they provide a more intense and sustained inhibition of 
AT
1
 receptor stimulation. Several preclinical studies demonstrated an infarct size limiting 
effect of ARAs after coronary artery occlusion in a variety of species.127,243,247 Unexpectedly 
the optimal trial in myocardial infarction with the ARA losartan (OPTIMAAL) demonstrated 
an increase in cardiovascular mortality of 17% when treated with losartan compared with 
when treated with captopril.57
This impaired clinical effectiveness after acute ischaemic events may result from a 
difference in ancillary properties. ACE inhibitors inhibit the breakdown of bradykinin, 
which has additional benefits during ischaemia and reperfusion.84,241 In contrast ARAs 
facilitate unopposed AT
2 
receptor stimulation. During normal conditions, the expression 
of the AT
2
 receptor is limited and occurs predominantly in foetal tissue where it influences 
development.1 However, in response to pathological conditions, including vascular injury, 
hypertension, myocardial infarction, and congestive heart failure, AT
2
 receptor expression 
is enhanced and may become functionally relevant.45,186,190,193,235,310 Although originally 
believed to form a counter regulatory mechanism against the detrimental effects of AT
1
 
receptor stimulation, it is now apparent that AT
2
 receptor stimulation promotes apoptosis.284,300 
Apoptotic cell death plays an important role in the extent of myocardial infarction as 
shown by the observations that interference in the apoptotic cell death pathway results in 
an infarct size reduction of 48 to 64%.35,40,147 Thus, ARAs may facilitate AT
2
 receptor stimulation, 
which enhances myocardial infarct size and worsen outcome following myocardial 
infarction. Indeed, the inhibition of AT
1
 receptor activity promotes apoptosis and increases 
infarct size whereas AT
2
 receptor antagonists improve functional recovery and reduce 
infarct size after coronary artery occlusion.39,73,141,284 
In summary, clinical data raise concern about the use of ARAs in acute myocardial 
infarction as it seems to have less beneficial effects in comparison with ACE inhibition. This 
may result from a reduced clinical efficacy of ARAs as unopposed AT
2
 receptor stimulation 
may increase apoptotic cell death. Due to the undisputed beneficial properties of ACE 
inhibitors, clinical trials comparing placebo with ARAs in a setting of ischaemia and 
reperfusion are missing. In addition, preclinical studies addressing the effects of ARAs on 
ischaemia reperfusion injury (IRI) are equivocal. This mandates human in vivo experiments 
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for proper translation into clinical practice. We developed a human in vivo ischaemia- 
reperfusion model, which facilitates the comparison between placebo and ARAs in a human in 
vivo setting.226 This model combines annexin A5 scintigraphy and ischaemic forearm 
exercise. Annexin A5 scintigraphy detects the loss of membrane asymmetry, which results 
in phosphatidylserine (PS) exposure on the outer membrane leaflet and occurs shortly 
after an ischaemic insult as an early, reversible, sign of apoptosis.93,139 Radiolabeled 
recombinant annexin A5 binds with high affinity to PS located on the outer leaflet of the 
cell membrane and can be visualized by annexin A5 scintigraphy. This technique has been 
applied in the human heart in which it demonstrated the presence of PS exposition after 
acute myocardial infarction supporting the use of our model as a surrogate end point.109 
The aim of this study is to test the hypothesis that a 1-week treatment with irbesartan 
augments PS exposure in human forearm skeletal muscle after ischaemic exercise. To 
exclude possible confounding coexisting morbidity, including hypertension, this study 
was performed in healthy normotensive volunteers.
Methods
Subjects
The study was performed in accordance with the declaration of Helsinki (2000) of the 
world medical association and approved by the Institutional Review Board of the Radboud 
University Nijmegen Medical Centre. Twenty male volunteers without cardiovascular disease, 
hypertension [Blood pressure (BP) > 140/90 mmHg], hypercholesterolaemia (fasting total 
cholesterol > 6 mmol/L), reduced kidney function, or diabetes mellitus (fasting glucose 
> 7.0 mmol/L) signed informed consent for participation.  
Study protocol
Volunteers were randomly divided in 2 groups (n=10 in each group) to receive double 
blind either a 7-day treatment with placebo (Department of Clinical Pharmacy, Radboud 
University Nijmegen Medical Centre) or irbesartan (300 mg/d, Sanofi-Aventis, Gouda, The 
Netherlands). Before the first and last ingestions of the study drug, blood was drawn to 
determine plasma renin, creatinine, sodium, potassium, and caffeine (only day 7).  On the 
first and sixth study days, the urine produced in 24 hours was collected for analysis of 
sodium and creatinine excretion. On the seventh day, volunteers entered our research 
centre after an overnight fast and 24 hours of caffeine abstinence. Subsequently, the last 
tablet was ingested followed 1 hour later by an ischaemic exercise protocol of the 
non-dominant forearm. Immediately, on reperfusion Tc-99m-labeled (0.1 mg, 400 MBq) 
annexin A5 was injected into an antecubital vein of the dominant arm. Annexin A5 
targeting was recorded by imaging with a gamma camera using the dominant hand as an 
internal control.   
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Ischaemic exercise and annexin A5 imaging
All procedures were performed as described before.226 In brief, maximal voluntary 
contraction was determined in the non-dominant hand with a handgrip dynamometer. 
The circulation of the non-dominant forearm was occluded for 10 minutes by inflation of 
an upper arm cuff to 200mmHg. Immediately after occlusion, the volunteers performed 
rhythmic isometric hand contractions at 50% of their maximal voluntary force for 5 
seconds every 10-second period until exhaustion. After 10 minutes, the upper arm cuff 
was deflated and reperfusion started. Both hands were imaged at 1 and 4 hours of 
reperfusion by using a gamma camera (Siemens Orbiter, Hoffman Estates, IL) connected 
to a Hermes Gold image processing system (Nuclear Diagnostics, Stockholm, Sweden). 
Recombinant human annexin A5 was obtained from Theseus Imaging Corporation and 
conjugated with succininydylhydrazinonicotinamide under good manufacturing practice 
conditions (Department of Clinical Pharmacy, Radboud University Nijmegen Medical 
Centre). Labelling of this conjugated annexin with Tc-99m was performed in the morning 
of the administration (Department of Nuclear Medicine, Radboud University Nijmegen 
Medical Centre) as previously described.224 
Laboratory analysis
Plasma caffeine concentrations were determined by use of reversed-phase high-perfor-
mance liquid chromatography with UV detection set at 273 nm according to Schreiber-
Deturmeny and Bruguerolle.240 Plasma renin concentrations were determined by immu-
noradiometric assay (Cisbio Bioassays, Bagnols-sur-Cèze Cedex, France). 
Statistical analysis
All gamma camera images were analysed by the same blinded investigator (W.O.). 
A predefined region of interest was drawn on each hand representing the thenar muscle. 
Within this region of interest, the annexin A5 targeting was expressed as counts per pixel. 
The effect of ischaemic exercise is presented as the percentage difference in annexin A5 
targeting between the experimental and control hand as previously described.226 The 
effect of irbesartan on annexin A5 targeting was analysed with an analysis of covariance 
for repeated measures with treatment as the between-subject factor and workload as a 
covariate. Workload was defined as the product of 50% of the maximal voluntary force 
and duration of ischaemic exercise. Statistical analysis was performed using the SPSS 
software package (version 16.0). Results are expressed as mean ± SE.
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Results
Our placebo and active treatment group did not significantly differ at baseline with 
respect to age, BP, concentrations of plasma renin nor total and fractional sodium excretion 
(Table 1). Plasma caffeine concentrations at the start of the experiment on day 7 were all 
below 0.8 mg/L indicating adequate compliance to the caffeine-free diet.
In the placebo group, no changes in plasma or urine parameters were observed after 
treatment. In contrast, a 1-week treatment with irbesartan increased circulating renin 
concentrations from 14 ±3 to 86 ±16 mEq/L indicating compliance to the study drug and 
adequate interruption of AT II subtype 1 receptor-mediated feedback inhibition of 
circulating renin. No significant effect was observed on total and fractional sodium 
excretion (Table 2).
Annexin A5 Scintigraphy
There was no significant difference between the workload performed by the volunteers 
between the placebo and irbesartan group (4389 ±304 vs. 4093 ±222, p = 0.4, independent 
t-test). Treatment with Irbesartan did not result in enhanced annexin A5 targeting after 
1 and 4 hours of reperfusion (p = 0.9). This result was unaffected when correcting for 
delivered workload (p = 0.8, Fig. 1). 
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Table 1  Baseline characteristics
Placebo (n=10) Irbesartan (n=10)
Age (yr) 29 ±11 29 ±13
Systolic BP (mmHg) 124 ±10 122 ±9
Diastolic BP (mmHg) 79 ±8 76 ±9
Total cholesterol (mmol/L) 4.7 ±1.2 4.9 ±0.8
Glucose (mmol/L) 4.4 ±0.8 4.8 ±0.6
Plasma creatinine (µmol/L) 80 ±4 84 ±8
Values expressed as mean ±SE
Table 2  Effect of treatment on plasma parameters and sodium excretion
Placebo (n=10) Irbesartan (n=10)
Day 1
   Renin (mmol/L) 10 ±2 14 ±3
   Creatinine (µmol/L) 77 ±2 83 ±3
   Sodium (mmol/L) 140 ±0.4 140 ±0.4
   Potassium (mmol/L) 3.8 ±0.1 3.8 ±0.1
   Total sodium excretion (mmol) 186 ±29 175 ±28
   Fractional sodium excretion (%) 0.65 ±0.07 0.70 ±0.07
Day 2
   Renin (mmol/L) 13 ±3 86 ±16*
   Creatinine (µmol/L) 75 ±2 80 ±2
   Sodium (mmol/L) 141 ±0.4 140 ±0.3
   Potassium (mmol/L) 3.8 ±0.1 3.7 ±0.1
   Total sodium excretion (mmol) 181 ±24 144 ±18
   Fractional sodium excretion (%) 0.64 ±0.10 0.70 ±0.12
Values expressed as mean ±SE
*p=0.001
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Discussion
In this study, irbesartan, in a clinically relevant dose, did not enhance PS exposition on the 
outer leaflet of the plasma membrane in response to an ischaemic stimulus. Therefore, our 
results do not support a reduction in clinical effectiveness of irbesartan as a result of 
increased apoptotic activity during IRI in humans in vivo.
In the last 10 years, it has become apparent that apoptotic cell death plays an important 
role in the extent of myocardial infarction. In this light, we developed a technique that 
detects apoptosis by visualization of PS exposure, an early hallmark of apoptosis. 
 Phosphatidylserines on the outer membrane leaflet provide binding sites for annexin 
A5 thereby enabling the visualization of PS-annexin A5 complexes by detecting 
Tc-99m-labeled recombinant annexin A5 with a gamma camera. Thus, annexin A5 
targeting represents the amount of cells vulnerable to ischaemia and subsequently the 
extent of IRI. Indeed, annexin A5 targeting depends on the intensity of the ischaemic 
stimulus and is limited by ischaemic preconditioning, adenosine, dipyridamole, and 
rosuvastatin confirming the present literature.172,220,226 In addition, shielding of PS exposition 
Figure 1   Annexin A5 targeting after ischemic exercise is presented as the 
percentage difference, in counts per pixel within a predefined region  
of interest (thenar muscle), between the experimental and control hand. 
In all subjects, ischemic exercise was performed after a 24-hour 
abstinence from caffeine-containing beverages. The subjects had been 
randomly allocated to a 1-week treatment with placebo or irbesartan. 
 
p = 0.8, analysis of covariance for repeated measures. Data are expressed as mean ± SE.
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opposes IRI after liver transplantation in an experimental model underlining the clinical 
relevance of PS exposition.246,260 These findings support the use of our model as a 
translational research tool to determine the effects of irbesartan on IRI. 
The results from OPTIMAAL suggest increased cardiovascular mortality after myocardial 
infarction when treated with an ARA compared with ACE inhibition. We therefore studied 
the effect of irbesartan on IRI to determine whether unopposed AT
2
 receptor stimulation 
increases apoptotic activity during ischaemia and reperfusion in a human in vivo setting. 
Based on our results, we conclude that irbesartan does not enhance PS exposition and 
thereby apoptosis. Therefore, increased apoptotic activity does not interfere with the 
clinical effectiveness of ARAs during ischaemia and reperfusion. Several observations 
support these findings. Two trials comparing the long-term effects between ARAs and 
calcium channel blockers revealed no inferiority of ARAs on the reduction of cardiovascular 
mortality and morbidity.129,192,286 In addition, the valsartan in acute myocardial infarction 
trial demonstrated comparable effects on cardiovascular mortality in patients treated 
with valsartan or captopril after myocardial infarction complicated by ventricular 
dysfunction.205 Interestingly, approximately 40% of patients treated with the ARA in the 
valsartan in acute myocardial infarction trial received non-study treatment with ACE 
inhibitors during an average of 5 days after myocardial infarction compared with none in 
OPTIMAAL. This supports the presence of an additional beneficial effect of ACE inhibitors 
over ARAs. Indeed, ACE inhibitors administered during acute myocardial infarction within 
0-36 hours from the onset of symptoms reduces 30-day mortality by 7% compared with 
treatment with placebo.1 More than 80% of this effect was reached within the first week of 
treatment supporting an early effect on myocardial salvage. 
Preclinical studies confirm this direct infarct size limiting effects of ACE inhibitors, which is 
independent of inhibition of the renin-angiotensin system but rather reflects the 
associated reduction of bradykinin degradation.177 Bradykinin increases the cellular 
tolerance against IRI and thereby reduces infarct size after coronary artery occlusion.84,241 
ARAs do not reduce bradykinin degradation but instead facilitate unopposed AT
2
 receptor 
stimulation, which is associated with increased apoptosis and enhanced IRI.284 However, 
preclinical studies addressing the effects of ARAs on IRI have been equivocal as results 
cover the entire range from beneficial to detrimental effects.56,73,127,217,243,247,253 This may 
represent differences in study drug, dosing regimens, ischaemia-reperfusion protocols, 
and species studied. This study in a human in vivo setting does not support a modulating 
effect of ARAs on IRI in humans in vivo. The results obtained in OPTIMAAL therefore do not 
seem to result from a detrimental effect of unopposed AT
2
 receptor stimulation but may 
rather reflect the beneficial ancillary effect of ACE inhibitors. This latter statement will 
need further confirmation in studies addressing the effect of ACE inhibition on IRI in 
humans in vivo.
Potential limitations of our study design need to be addressed. First, we assessed IRI in 
forearm skeletal muscle and not in the myocardium. However, we do know that the 
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skeletal muscle of the human forearm reacts in a similar fashion to ischaemia and 
reperfusion as myocardial tissue. In both organs, the extent of injury depends on the 
intensity of the ischaemic insult and protective strategies applied in human myocardial 
tissue including ischaemic preconditioning122,303, and statin therapy203,239 provides similar 
protection in the human forearm.156,159,172,226 Second, we used healthy volunteers instead of 
patients with an increased cardiovascular risk profile. This method excludes possible 
coexisting morbidity but may hamper the translation of our results to the patient at risk for 
IRI. Indeed, the effects of ARAs on IRI may depend on health status and age as AT
2
 receptor 
up-regulation occurs during pathological conditions and advancing age.15 In contrast, our 
study design is in line with those of the vast majority of experiments performed with ARAs 
in the preclinical setting in which young healthy adult animals were studied and effects 
on IRI were observed albeit equivocally. Nevertheless, we cannot exclude an effect of 
irbesartan on IRI in the patient population. 
Conclusions
A 1-week treatment with irbesartan does not enhance PS exposition in response to an 
ischaemic stimulus in healthy volunteers. Thus, increased apoptotic activity does not 
reduce the clinical effectiveness of irbesartan in a setting of ischaemia and reperfusion.
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Abstract 
Pharmacological protection against ischaemia and reperfusion could benefit patients 
with coronary artery disease. We tested whether dipyridamole, an adenosine uptake 
inhibitor, could provide such protection. 
Ten healthy men were treated in a double-blind randomised crossover design with 2x 
200mg dipyridamole SR and matching placebo for 7 days (minimal wash-out period 
3 weeks). After treatment volunteers performed 10 minutes of forearm ischaemic exercise. 
Subsequently, Tc-99m annexin A5 scintigraphy was used to measure IR-injury 1 and 4 hours 
after reperfusion. 
Dipyridamole reduced annexin A5 targeting in those volunteers who received placebo 
first and dipyridamole next (from 27±14% and 30±16% (1 and 4 hours after reperfusion) to 
15±9% and 16±10%), compared to those receiving dipyridamole first and placebo next 
(from 17±13% and 19±6% to 20±14% and 19±6%; p=0.029).
One week and 4 weeks after cessation of therapy inhibition of nucleoside transport was 
no longer observed (-3.8 ±5.7% and -5.2 ±6.2%; p=0.71 and 0.61 respectively).
Dipyridamole treatment protects against IR in forearm skeletal muscle of healthy 
volunteers. Considering the washout period, this effect appears to persist over 4 weeks. 
A prolonged effect of dipyridamole on nucleoside transport was ruled out as possible 
explanation of this protective action of dipyridamole.
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Introduction
Atherosclerosis and its associated organ perfusion disturbances are a main cause of death 
worldwide. Currently, secondary prevention of cardiovascular disease focuses on prevention 
of new events. However, emerging preclinical and clinical evidence suggests that 
improvement of tissue tolerance to ischaemia and reperfusion (IR) injury should be 
prioritised, in particular in the current era of rapid reperfusion therapy.305 Clinical evidence 
in the setting of both coronary bypass surgery and percutaneous coronary interventions 
indicates that reperfusion injury limits the benefit of early reperfusion and that tolerance 
to ischaemia and reperfusion can be improved pharmacologically.146,203 Ideally, drugs that 
improve tolerance to IR should also prevent events. Dipyridamole has such a beneficial 
profile, as it reduces cerebrovascular events92 and improves tolerance against IR in 
animals.29,257 Presently dipyridamole treatment is part of the standard care of stroke 
patients.76 In patients with coronary artery disease, the FDA still advises to use this drug 
with caution as a coronary steal phenomenon has been observed when dipyridamole 
was administered intravenously in a high dose. However in the ESPS-2 and ESPRIT trials the 
addition of dipyridamole to aspirin did not increase the incidence of cardiac events.58,92 
Further evidence that dipyridamole induces protection against IR in humans in vivo, would 
support the conductance of a phase-2 clinical trial with dipyridamole to reduce cardiac 
IR-injury  in  patients suffering from coronary artery disease.
Dipyridamole has several pharmacological properties including inhibition of the equilibrative 
nucleoside transporter (ENT), cyclic-GMP specific phosphodiesterase inhibition (5, 6), and 
scavenging of free radicals.24,44,71 Of these properties, inhibition of the ENT has been 
characterised in detail in humans in vivo and occurs at clinically applied doses.25,223
The inhibitory effect of dipyridamole on the ENT decreases uptake of endogenous 
adenosine by erythrocytes and endothelial cells, thereby increasing adenosine levels at its 
extracellular formation sites.14,15 A subsequent increase in adenosine receptor (A
1
, A
2A
 and 
A
3
) stimulation can induce several tissue-protective effects, including vasodilation, 
inhibition of inflammation and thrombocyte aggregation and induction of tolerance 
against IR-injury, so called preconditioning.16,17 
Using our forearm model with Tc-99m-annexin A5 scintigraphy, we have addressed the 
protective effect of 7-day oral dipyridamole treatment on IR-injury in humans in vivo.220 In 
this model, annexin A5 targeting results from phosphatidylserine (PS) exposure on cell 
membranes, which has been associated with IR-induced cell stress and apoptosis.72 
However, this study was neither blinded nor randomised, and therefore the conclusions 
have to be considered carefully. To test our hypothesis more rigorously, we decided to 
readdress the protective effects of dipyridamole against IR using a randomised 
double-blind placebo-controlled design. To decrease inter-individual variation and thus 
increase statistical power, the experiment was carried out in a crossover design. As 
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described previously, we used in vivo annexin A5 targeting after forearm ischaemic exercise 
as a measure of IR-injury.172,220,224,226 Since our results showed a surprisingly long-lasting 
effect of dipyridamole on PS-exposition, we also addressed a  possible role of extended 
nucleoside transport inhibition in this long term action of dipyridamole. For this purpose, we 
investigated the 4-week post-treatment effect of a 7-day oral dipyridamole administration 
on nucleoside transport ex vivo in human erythrocytes.
Methods
Subjects
Approval was obtained for both experiments from our institutional medical ethical 
committee (CMO regio Arnhem-Nijmegen, The Netherlands) and all participants gave 
written informed consent prior to inclusion. 
Ten healthy male volunteers were included in the in vivo annexin A5 targeting experiment 
(NCT00457405) and 7 healthy volunteers were included in the additional study to explore 
the long-term effect of dipyridamole on ex vivo nucleoside transport. Medical screening 
was performed to exclude cardiovascular disease, hypercholesterolemia, hypertension, 
diabetes mellitus, asthma and use of concomitant medication. In the 24 hours prior to the 
experiment all volunteers agreed to a caffeine free diet.
Experimental protocols
In vivo annexin A5 targeting after forearm ischaemic exercise (experiment 1)
Volunteers were treated for 7 days with dipyridamole (Persantin® slow release) 200 mg 
(Boehringer-Ingelheim, Alkmaar, The Netherlands) or placebo twice daily. Placebos were 
prepared according to GMP standards by our department of Clinical Pharmacy (Radboud 
University Nijmegen Medical Centre, Nijmegen, The Netherlands). To match placebo, 
dipyridamole was recapsulated. Between both experimental periods a washout period of 
at least three weeks was observed.
On day one the first capsule was taken under supervision of the investigator. On day 7, the 
volunteers returned to the research centre after an overnight fast. A blood sample was 
drawn to determine serum caffeine and steady-state dipyridamole trough concentrations. 
Subsequently the final capsule was taken. One hour thereafter a blood sample was drawn 
to determine serum dipyridamole peak concentrations. Subsequently, volunteers 
underwent ischaemic exercise of the non-dominant forearm and annexin A5 scintigraphy 
was performed as previously described.220,224,226 In brief, the circulation of the non-dominant 
forearm was occluded for 10 minutes with an upper arm cuff inflated to 200 mmHg. 
Directly after occlusion, participants performed rhythmic hand contractions at 50% of 
their maximum contraction force until exhaustion. The total duration of ischaemia was 
10 minutes, independent of the duration of contractions. Immediately upon reperfusion 
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0.1 mg annexin A5 radiolabeled with 450 MBq Technetium-99m was administered 
intravenously into the dominant arm. One and four hours after annexin A5 administration, 
scans were made of both hands with a gamma camera (Siemens Orbiter equipped with 
low-energy high-resolution collimators).226 At least three weeks later this procedure was 
repeated for the second treatment period.
Post treatment effect of dipyridamole on nucleoside transport (experiment 2)
Volunteers were treated for 7 days with dipyridamole (Persantin® slow release) 200 mg 
(Boehringer-Ingelheim, Alkmaar, The Netherlands) twice daily. Prior to the start of 
treatment, blood was sampled for baseline assessment of ENT-mediated nucleoside 
transport and dipyridamole concentration. At day 7 of dipyridamole treatment this 
procedure was repeated, one hour after supervised intake of the last capsule. Furthermore, 
assessment of ENT activity and dipyridamole concentrations were repeated 1 week and 4 
weeks after cessation of treatment. All blood samples were collected after at least 2 hours 
of fasting.
Laboratory analysis
Caffeine plasma concentrations were determined using reversed-phase HPLC with UV 
detection set at 273 nm.240 Dipyridamole plasma concentrations were determined in 
deproteinised plasma using HPLC with fluorescence detection set at 286/470 nm.295 To 
assess ENT activity, nucleoside transport was measured as reported previously.220
Statistical analysis
The baseline characteristics were compared using paired Student T-test. All digitised 
gamma camera images were analysed offline by the same investigator (WO) using Hermes 
software (Nuclear Diagnostics, Stockholm, Sweden). A predefined region of interest was 
placed over the thenar muscle of both hands. Annexin A5 targeting was expressed as the 
percentage difference in counts/pixel between the experimental hand and the control 
hand as previously described.226 The effect of the intervention was analysed using ANOVA 
for repeated measurements. In addition, the treatment order was entered as a between-
subjects factor in the ANOVA for repeated measurements. 
Nucleoside transport inhibition after oral treatment with dipyridamole is calculated as 
percentage change in nucleoside transport compared to baseline and analysed statistically 
with a paired Student T-test.
Results are expressed as mean ± standard error, except when stated otherwise. All statistical 
analyses were performed using SPSS 16.0.2 for Windows.
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Results
In vivo Annexin A5 targeting after forearm ischaemic exercise
Mean age of healthy participants was 23.3 ± 3.8 (SD) years, dipyridamole plasma trough 
concentration was 0.65 ±0.32 (SD) mg/L and peak concentration was 0.77 ±0.44 (SD) mg/L 
after 7 days of treatment (baseline characteristics are presented in table 1). After placebo, 
dipyridamole levels remained below the minimal detection limit. In all participants 
caffeine levels on day 7, of both dipyridamole and placebo treatment, were under 0.75 
mg/L, indicating adequate compliance to the 24 hours caffeine abstinence.
When treatment order was not taken into account, our analysis showed no effect of 
dipyridamole treatment on annexin A5 targeting (17.6 ±3.6% at 1 hour and 17.1 ±2.5% at 4 
hours) compared to placebo treatment (22.1 ±4.3% at 1 hour and 22.8 ±4.8% at 4 hours; 
p=0.236). However a subsequent analysis revealed a statistically significant interaction 
effect of the randomisation order on the effect of dipyridamole on annexin targeting in 
this crossover experiment (p=0.029). In participants (n=5) who were randomised to first 
receive placebo followed by dipyridamole, a strong tendency was demonstrated for a 
reduction in annexin A5 targeting after dipyridamole treatment (14.9 ±4.0% at 1 hour and 
15.5 ±4.4% at 4 hours) compared to placebo treatment (26.7 ±6.2% at 1 hour and 30.3 
±7.1% at 4 hours; p=0.057; see figure 1). In participants (n=5) who received dipyridamole 
first and placebo next, annexin targeting after dipyridamole (20.3 ±6.2% and 18.7 ±2.8% 
after 1 and 4 hours respectively) and was similar to that of the participants with opposite 
randomisation order (see above; p=0.62). However in the participants randomised to 
dipyridamole first, there was no difference between the annexin targeting after 
dipyridamole treatment (see above) and placebo treatment (17.4 ±6.0% and 15.3 ±5.0% 
Table 1   Baseline characteristics of healthy volunteers from the experiment 
with Annexin A5 targeting (experiment 1) and the experiment on the 
post treatment effect of dipyridamole (experiment 2).
Experiment 1 
Mean ±SD (n=10)
Experiment 2 
Mean ±SD (n=7)
Age (yr) 23.3 ±3.8 23.1 ±4.4
BMI (kg/m2) 23.1±2.3 21.9 ±1.5
Syst pressure (mmHg) 129 ±6 127 ±7
Diast pressure (mmHg) 78 ±6 77 ±7
Heart rate (bpm) 63 ±6 68 ±8
Glucose (mmol/L) 4.5 ±0.8 5.9 ±0.8
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after 1 and 4 hours respectively; p=0.431; see figure 1), as opposed to the observed 
tendency in participants with the opposite randomisation order.
Thus, a within subject effect of dipyridamole was only observed in participants who 
received placebo in the first treatment period and dipyridamole in the second (p=0.029 
for the effect of treatment order). 
The actual mean wash out period was 28 days (range 20-48 days). Heart rate did not differ 
between dipyridamole and placebo treatment, respectively 62 ± 2.4 bpm and 60 ± 2.2 
bpm (p=0.23), indicating that the dose of dipyridamole in this experiment was sufficiently 
low to prevent systemic actions due to ENT inhibition.227 The workload achieved during 
ischaemic exercise was comparable between dipyridamole (4023 ± 315 kg*sec) and 
placebo treatment (3988 ± 269 kg*sec; p=0.893).
Post treatment effect of dipyridamole on nucleoside transport
Mean age of participants was 23.1 ± 4.4 (SD) years, more baseline characteristics are 
presented in table 1. On the seventh day of treatment, serum dipyridamole concentration 
Figure 1   Annexin A5 targeting 1 and 4 hours after ischaemic exercise (N=10). 
Participants are grouped according to randomisation order (placebo  
first (n=5) or dipyridamole first (n=5)) after dipyridamole treatment  
(open bars) and placebo treatment (closed bars).
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was 1.29 ± 0.44 (SD) mg/L and nucleoside transport was reduced with 86.6 ± 2.1 % compared 
to baseline (p<0.05). One week and 4 weeks after cessation of therapy, dipyridamole levels 
were below minimal detection limits and inhibition of nucleoside transport was no longer 
observed (-3.8 ± 5.7% and -5.2 ± 6.2%; p=0.71 and 0.61 respectively).
Discussion
In this study we show a protective effect of dipyridamole against IR-injury. In a previous 
study from our group, we observed protection by dipyridamole in a similar forearm model 
using annexin A5 targeting. However, this previous study used an historical control group. 
The current study substantiates this finding in a more rigorous randomised placebo-con-
trolled crossover design.  Interestingly, our present data suggest that this protection lasts 
for at least 4 weeks  (considering the minimal 3 week wash-out period and subsequent 
one week placebo treatment). To explore a prolonged effect of dipyridamole on ENT as a 
potential explanation for this surprising result, we performed a post treatment effect 
study, which demonstrated a complete absence of dipyridamole in the serum and a full 
recovery of nucleoside transport one week after cessation of oral dipyridamole treatment. 
To our knowledge, we are the first to report a protective effect against IR-injury that lasts 
for at least 4 weeks after a pharmacologic intervention. Large similarities in the mechanism 
of preconditioning appear to exist amongst different tissues eligible for protection against 
IR-injury (e.g. myocardial, brain, skeletal muscle, kidney, and liver).8,59,98 Adenosine is 
considered to play a pivotal role in the initiation of ischaemic preconditioning. 17,154 
Furthermore, administration of exogenous adenosine can induce pharmacologic precon-
ditioning.18,270 Adenosine-induced protection (either ischaemic or pharmacologic) against 
IR-injury consists of two different phases. After the preconditioning event, a protective 
phenotype occurs immediately and lasts for maximally 6 hours (acute preconditioning).304 
Twenty-four hours after the preconditioning trigger, the second window of protection (or 
delayed preconditioning) starts. This SWOP is dependent on increased transcription of 
cardioprotective genes and expression of various proteins including iNOS, COX-2, heme 
oxygenase and antioxidant enzymes.254,304 However, little is known about the time course 
of delayed preconditioning. Baxter et al. reported the delayed protective effect of 
adenosine receptor stimulation in rabbit myocardium to last at least 72 hours, though no 
longer than 96 hours.18 Harralson et al. found similar results after ischaemic precondition-
ing skeletal muscles (m. latissimus dorsi) in rats.95 However in mice, repetitive hypoxic pre-
conditioning is reported to induce long-term tolerance against IR in nervous tissue, lasting 
four to eight weeks.255,309 Still, there are very few experiments allowing a delay between 
the preconditioning stimulus and index ischaemia of more than 48 hours.
In the post treatment effect study we did not find a prolonged effect of dipyridamole on 
ENT-mediated nucleoside transport. Thus, potential accumulation of dipyridamole in the 
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cellular membrane did not influence ENT activity after dipyridamole was completely 
cleared from plasma. This indicates that the prolonged benefit of dipyridamole cannot be 
explained by on-going nucleoside transport inhibition.
Since  the serum dipyridamole concentration was under the detection limit and nucleoside 
transport was no longer inhibited one week after therapy cessation, our results suggest 
that a 7-day treatment with dipyridamole initiates a chain of events that results in a 
protective phenotype that lasts for at least 4 weeks. As reported previously by our group, 
we observed a significant inhibition of the ENT after 7 days of oral treatment with 
dipyridamole that should be sufficient to enhance the action of endogenous 
adenosine.220,227 Normal physical activity of the forearm results in repetitive bouts of 
extracellular adenosine formation.46,140 By inhibiting the ENT, dipyridamole intensifies the 
subsequent activation of adenosine receptors, which may have initiated a long-lasting 
increased expression of various cytoprotective proteins such as heme oxygenase, iNOS, 
and COX-2.17,21 This resembles the repetitive preconditioning stimuli as described in 
nervous tissue, also resulting in prolonged protection.255,309
Conclusion
We conclude that treatment with dipyridamole provides protection against IR-injury in 
forearm skeletal muscle of healthy volunteers as detected with annexin A5 scintigraphy. 
Moreover, in our forearm model of ischaemia and reperfusion, this protective effect of 
dipyridamole appears to persist even when nucleoside transport has returned to baseline. 
These results support the conduct of a phase 2 clinical trial to study the effect of 
dipyridamole on cardiac IR-injury in patients with coronary artery disease. Confirmation of 
the long-term protection and exploration of its mechanism warrants further  research. 
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Abstract
3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are effective in the 
primary and secondary prevention of cardiovascular events. Although originally 
developed to improve lipid profile, statins have demonstrated a surplus of beneficial 
pleiotropic effects, including improved endothelial function, reduced inflammation, and 
increased tolerance to ischaemia-reperfusion injury. In preclinical studies, increased 
 ecto-5’-nucleotidase activity, the key enzyme in extracellular adenosine formation, plays 
an important role in these effects. Because human data are absent, we explored the 
effects of rosuvastatin on ecto-5’-nucleotidase activity and the clinical relevance of 
increased extracellular adenosine during ischaemia in humans in vivo.   
The forearm vasodilator responses to 3 increasing periods of forearm ischaemia (2, 5, and 
13 minutes) were determined during placebo and caffeine (an adenosine receptor 
antagonist) infusion into the brachial artery. At the end of an 8-day treatment period with 
rosuvastatin (20 mg per day), this whole procedure was repeated. During both experiments 
ecto-5’-nucleotidase activity was determined. Vasodilator responses are expressed as the 
percentage increase in forearm blood flow ratio from baseline. 
Rosuvastatin increased ecto-5’-nucleotidase activity by 49±17% and enhanced the 
vasodilator response after 2, 5, and 13 minutes of ischaemia in the absence (146±19, 
330±26, and 987±133 to 312±77, 566±107 and 1533±267) but not in the presence of 
caffeine (98±25, 264±54, 727±111 vs. 95±19, 205±34 and 530±62). 
Rosuvastatin increases extracellular formation of adenosine in humans in vivo probably by 
enhancing ecto-5’-nucleotidase activity. This action results in the improvement of reactive 
hyperaemia and may further enhance the clinical benefit of statins, in particular in 
conditions of ischaemia.
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Introduction
3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are effective in the 
primary and secondary prevention of cardiovascular events.63,204 Although originally 
developed to improve lipid profile, statins have demonstrated a surplus of beneficial 
pleiotropic effects, including improved endothelial function, reduced inflammation, and 
increased tolerance to ischaemia-reperfusion injury.4,143,172,195,218 These effects are 
independent of plasma cholesterol lowering and improve outcome after cardiovascular 
events.203,242 
Increased extracellular adenosine formation has been implicated as one of the underlying 
mechanisms. This is supported by several preclinical studies demonstrating the activation 
of ecto-5’-nucleotidase (CD73) activity, increased stimulation of adenosine receptors, and 
adenosine-mediated protection against ischaemia-reperfusion injury by statins.145,234,301 
The enzyme CD73 dephosphorylates extracellular AMP, which forms the rate-limiting step 
in the formation of extracellular adenosine.215 We recently demonstrated increased 
extracellular adenosine formation in healthy human volunteers after a 1-week treatment 
with rosuvastatin using a pharmacological approach. In addition, we demonstrated rosu-
vastatin-induced augmentation of postocclusive reactive hyperaemia (PORH).172 However, 
we did not assess CD73 activity as a potential source of extracellular adenosine, nor did we 
investigate the role of adenosine in rosuvastatin-induced augmentation of PORH. CD73 
activity plays a pivotal role in the formation of atherosclerosis and increased cellular 
resilience against ischaemia-reperfusion injury observed after ischaemic precondition-
ing.37,68,307 An increase in CD73 activity may therefore reduce atherosclerosis formation and 
improve cellular tolerance against ischaemia. The extent of PORH in the human forearm 
correlates well with the vasodilator impairment in the coronary circulation.236 Indeed, it 
reflects vascular health status, because increased forearm PORH is associated with a reduced 
incidence of stroke and cardiovascular disease in patients with essential hypertension.261 
Compared with normotensive subjects patients with essential hypertension have a reduced 
vasodilator response to reactive hyperaemia and may therefore benefit from therapies 
aimed at or associated with an improvement of PORH.108 Insight into the underlying 
mechanism of rosuvastatin-induced augmentation of reactive hyperaemia may help us in 
optimizing the beneficial effects of statins and improve treatment of patients at risk for 
cardiovascular events.
We, therefore, assessed the involvement of adenosine in rosuvastatin-induced augmentation 
of PORH by testing the following hypotheses: a 1-week treatment with rosuvastatin 
enhances CD73 activity of circulating mononuclear blood cells, and caffeine, an adenosine 
receptor antagonist, inhibits the effect of rosuvastatin on forearm PORH. 
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Methods
Subjects
The study was performed in accordance with the Declaration of Helsinki of the World 
Medical Association and approved by the Institutional Review Board of the Radboud 
University Nijmegen Medical Centre. Ten healthy volunteers (5 women; aged 19-24 years) 
with a normal medical history, physical examination, blood pressure, body mass index, 
fasting plasma lipid profile, and glucose concentration gave written informed consent 
before entering the study. Experiments were performed in a temperature-controlled 
room (23 ±1°C) in the morning after an overnight fast and ≥24 hours of caffeine abstinence. 
All of the experiments were performed according to institutional guidelines.
Procedures
At the start of each experiment, a 27-gauge needle (B. Braun Medical B.V.) was inserted 
into the brachial artery of the non-dominant arm for intra-arterial drug administration. In 
both arms, forearm blood flow (FBF) was measured simultaneously with venous occlusion 
plethysmography using mercury-in-silastic-strain gauges and occluded hand circulation 
as described previously.174 
Experimental design
Figure 1 shows the design of the study. All volunteers received an 8-day treatment with 
rosuvastatin (20 mg per day) and entered our research facility twice, the first time before 
the start of treatment with rosuvastatin and the second time on the final day of treatment 
with rosuvastatin. On both visits forearm vasodilator responses to 3 increasing periods of 
forearm ischaemia (2, 5, and 13 minutes) were determined, once during the infusion of 
placebo (saline 0.9%, 50 µL/min per 100 mL forearm volume) and once during the 
administration of caffeine (90 µg/min per 100 mL forearm volume) into the brachial artery.
Ecto-5’-nucleotidase activity
We determined the activity of CD73 exposed on the surface of intact mononuclear cells 
by quantifying the conversion of 1,N6-ethenoadenosine 5’-monophosphate to 1,N6-etheno-
adenosine119 in the presence and absence of the CD73 specific inhibitor α,ß-methylene-
adenosine 5’-diphosphate. The difference in these 2 activities reflects CD73 activity. To 
eliminate the influence of non-specific dephosphorylation of 1,N6-etheno adenosine 5’-
monophosphate to 1,N6-ethenoadenosine and 1,N6-ethenoadenosine transport, CD73 
activity was measured in the presence of ß-glycerophosphate and dipyridamole. ß-Glyc-
erophosphate forms a competitive substrate for non-specific phosphatases eliminating 
the contribution of nonspecific dephosphorylation of AMP. Dipyridamole is an equilibrative 
nucleoside transport inhibitor that, in this concentration, prevents adenosine transport 
across the cell membrane. 
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At the start of each experiment 8 mL of venous blood was sampled and collected in cell 
preparation tubes (BD Vacutainer CPT), which were centrifuged at 1600g for 20 minutes to 
isolate mononuclear cells. After harvesting they were washed twice in PBS (5.39 mmol/L 
of Na
2
HPO
4
, 1.29 mmol/L of KH
2
PO
4
, and 0.15 mol/L of NaCl [pH 7.4]), followed by 
centrifugation for 15 minutes at 319g. The obtained pellets were resuspended in 1 mL of 
Hanks’ balanced salt solution (Invitrogen). 
Pilot experiments were performed to confirm optimal (V
max
; maximum CD73 velocity) 
substrate concentrations (data not shown). For analysis 30 µL of homogenate was buffered 
in Hanks’ balanced salt solution containing 10.0 mmol/L of MgCl
2
, 10.8 mmol/L of ß-glyc-
erophosphate, 20 µmol/L of dipyridamole, 0.2 mmol/L of 1,N6-ethenoadenosine 5’-
monophosphate with or without 400 µmol/L α,ß-methyleneadenosine 5’-diphosphate. 
All of the assays were performed for 5 minutes at 37ºC in a total volume of 100 µL. The 
reaction was terminated by adding 50 µL of perchloric acid 70% and the obtained lysate 
centrifuged for 3 minutes. The supernatant was used for measurement of 1,N6-etheno-
adenosine concentration by ion-paired reverse-phase high-performance liquid 
chromatography with fluorescence detection set at 280/420 nm. For separation, an Altima 
HP C18 AQ column was used with a mobile phase containing 50 mmol/L of NH
4
H
2
PO
4, 
5 
mmol/L of hexane sulfonic acid (pH 3.0), and acetonitrile as the organic modifier. 
Other analytical procedures
In all of the volunteers, blood was collected before and at the end of oral treatment to 
determine fasting serum lipid profile with a commercially available kit (Aeroset, Abbott). 
Compliance to caffeine abstinence was monitored by determination of plasma caffeine 
Figure 1   Schematic overview of the experimental protocol, indicating arterial 
occlusion, placebo and caffeine infusion, and FBF measurements.  
In addition, the graph above the protocol represents the absolute FBFs,  
at baseline and reperfusion, in the experimental (white) and control 
(orange) arms (n=8).
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concentration before each experiment. Plasma caffeine concentrations were determined 
by use of reversed-phase high-performance liquid chromatography with UV detection set 
at 273 nm according to Schreiber-Deturmeny and Bruguerolle.240 
Solutions
The caffeine (Genfarma) solution was freshly prepared to reach a final syringe concentration 
of 90 µg per 50 µL. Rosuvastatin tablets contained 20 mg per tablet and were obtained 
from Astra Zeneca SA.  
Statistical analysis
All of the CD73 activity measurements were performed in duplicate, averaged for each 
subject and visit, and differences between the 2 visits were analysed by paired t tests. To 
correct for random changes in FBF unrelated to the intervention, the ratio of simultaneously 
measured FBF in intervention and control arms was calculated (FBF ratio). The FBF ratios of 
the last 4 minutes of reference measurements (during intra-arterial saline or caffeine, as 
appropriate) and first 3 minutes of each reperfusion period were averaged to 1 value. To 
reduce the influence of intra-individual changes between visits and inter-individual 
variations in the baseline FBF ratio, results are expressed as the percentage increase in FBF 
ratio from baseline measurements. An ANOVA for repeated measures was performed on 
FBF ratio with rosuvastatin, caffeine, and arterial occlusion time as within-subject factors 
to determine the effect of caffeine on rosuvastatin-enhanced PORH. Results are expressed 
as mean ± SE. 
Results
The experiments were successful in 8 volunteers. Baseline serum caffeine concentrations 
were <1.5 mg/L during both experimental days, indicating adequate compliance to the 
caffeine-free diet. Treatment with rosuvastatin significantly reduced fasting total cholesterol 
and low-density lipoprotein cholesterol (Table).
Ecto-5’-nucleotidase activity
Rosuvastatin significantly increased CD73 activity with 49 ± 17% compared with baseline 
(Figure 2).
Forearm circulation 
The absolute changes in FBF are presented in Figure 1. FBF ratio returned to baseline 
before the start of the second set of ischaemic challenges on each study day. Rosuvastatin 
treatment did not influence baseline FBF ratios nor the course of FBF in the control arm 
between study days. Rosuvastatin treatment significantly increased the vasodilator response 
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to reactive hyperaemia (Figure 3). In the presence of caffeine, this augmentation of the 
vasodilator response was abolished. When analysing both experimental days separately, 
caffeine significantly altered the vasodilator response to reactive hyperaemia while on 
rosuvastatin (p=0.03) but not during baseline conditions (before rosuvastatin treatment, 
p=0.2).
Table  Effect of treatment with rosuvastatin on lipid profile
Biochemistry Day 1 Day 8
Fasting total cholesterol (mmol/L) 4.2 ±0.1 3.3 ±0.1*
Fasting low-density lipoprotein cholesterol (mmol/L) 2.3 ±0.1 1.5 ±0.1*
Fasting triglycerides (mmol/L) 1.0 ±0.1 0.8 ±0.1
Fasting high-density lipoprotein cholesterol (mmol/L) 1.4 ±0.1 1.4 ±0.1
Data are expressed as mean ±SE
*p<0.05 day 1 vs. day 8, paired t test (n=8)
Figure 2   Ecto-5’-nucleotidase (CD73) activity of intact mononuclear cells. 
Experiments were performed in the presence and absence of the 
specific CD73 inhibitor α,ß-methyleneadenosine 5’-diphosphate 
(AMP-CP). The difference between these two measurements reflects 
CD73 activity (bars). 
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Discussion
We recently demonstrated by using a pharmacological approach that rosuvastatin 
increases extracellular adenosine formation. We now demonstrate that this is, at least 
partly, mediated by increased CD73 activity. In addition, we underline the clinical relevance 
of the increased adenosine formation as it augments PORH after rosuvastatin treatment. 
Rosuvastatin increases ecto-5’-nucleotidase
Previous studies already reported on the stimulatory effect of statins on CD73 activity. This 
was demonstrated for lovastatin in rat endothelial cells145, pitavastatin in canine in vivo234, 
and atorvastatin in human vascular endothelial cells.198 Our results support these previous 
findings and are the first to demonstrate this effect in a human in vivo setting. The 
underlying mechanism still has to be unravelled. Inhibition of mevalonate is one of the 
potential mechanisms, because it not only reduces the synthesis of cholesterol but also 
isoprenoids, which are implicated in isoprenylation of small GTPases, including members 
Figure 3   Percentage increase in FBF ratio after arterial occlusion compared with 
baseline. P values indicate the level of significance for the effect of 
rosuvastatin on FBF ratio after arterial occlusion in the absence (left) 
and presence of caffeine (right) and the interaction between 
rosuvastatin and caffeine (left vs. right, ANOVA for repeated measures). 
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of the Rho family. Inhibition of Rho may result in reduced endocytosis of CD73 and 
subsequently increased expression of CD73 on the cell membrane.145 It has also been 
demonstrated that phosphatidylinositol-3-kinase and protein kinase C may influence 
CD73 activity by influencing its phosphorylation state and may thereby form an alternative 
route for statin-induced enhancement of CD73 activity.191,234 Regardless of the underlying 
mechanism, activation of CD73 by statins is likely to contribute to the clinical efficacy of 
statins in a setting of cardiac infarction, because inhibition of CD73 attenuates the limiting 
effect of statins on infarct size in animals.234 Furthermore, we have shown previously in a 
human forearm model of ischaemia-reperfusion injury that endogenous adenosine is 
likely to contribute in rosuvastatin-induced protection against ischaemia-reperfusion 
injury.172 
Rosuvastatin enhances PORH in the absence but not in the presence  
of caffeine
The additional increase in PORH provided by rosuvastatin was abolished by the adenosine 
receptor antagonist caffeine indicating the involvement of enhanced adenosine receptor 
stimulation. Previous observations already showed that rosuvastatin did not affect the 
vasodilator response to adenosine which excludes an effect of rosuvastatin on adenosine 
clearance, adenosine receptors, or post receptor signalling.172 Thus, the increased 
adenosine receptor stimulation observed during this study results from increased 
availability of extracellular adenosine. This conclusion is supported by data from the 
current study indicating activation of CD73 on mononuclear cells as a result of treatment 
with rosuvastatin.
Potential limitations to our study design need to be addressed. First, because this study 
was neither randomized nor placebo controlled, a nonspecific time effect could have 
interfered. However, we have shown previously that repeated ischaemia on a single day26 
or with a 1-week interval264 results in similar reactive hyperaemia. This observation makes 
it superfluous to explore potential carryover effects in this study. We opted for a limited 
study design to reduce the experimental load for our volunteers as much as possible. 
Second, we did not test the effect of caffeine on an adenosine-independent vasodilator, 
and, therefore, our findings may potentially be the result of adenosine-independent 
effects. A previous study from our institute demonstrated that intra-arterial caffeine (90 
µg/min per 100 mL of forearm volume) did not influence the vasodilator response to the 
endothelium-independent vasodilator sodium nitroprusside, which rules out a nonspecific 
effect of caffeine on PORH.248
Implications of our observations
Atherosclerosis is an inflammatory disease of large- and medium-sized arteries and the 
most important precursor of cardiovascular disease. Studies in atherosclerosis-susceptible 
mice, including CD73-deficient mice, demonstrate the correlation between reduced CD73 
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activity and enhanced vascular inflammation and subsequent atherosclerosis formation.37,307 
Therefore, increased CD73 activity may aid in the prevention of atherosclerosis. In addition, 
inhibition of CD73 or targeted gene deletion of CD73 intervenes with the infarct 
size-limiting effect of ischaemic preconditioning.68,87 This effect can be restored by 
administration of soluble CD73. Adenosine forms the likely mediator of CD73-dependent 
effects, because its activity is functionally associated with increased adenosine receptor 
stimulation.69 This is also in line with the observation that administration of an adenosine 
receptor agonist restored the proinflammatory state of CD73-deficient mice to baseline 
wild-type values.307 However, because we did not measure other adenosine forming 
enzymes, for example, alkaline phosphatase, we cannot rule out a significant contribution 
of this enzyme in rosuvasatin-induced augmentation of adenosine formation.
Reactive hyperaemia in the human forearm depends on postocclusive dilation of arteriolar 
resistance vessels and correlates well with the degree of vasodilator impairment in the 
coronary circulation.236 Indeed, PORH correlates with the incidence of cardiovascular 
events in patients with essential hypertension and decreases with an increase in 
cardiovascular risk factors.113,261 In addition, the extent of PORH after coronary angioplasty 
reflects the clinical effectiveness of revascularization.232 These findings support the use of 
PORH as a marker for cardiovascular disease and effectiveness of treatment. The 
improvement of reactive hyperaemia by rosuvastatin, therefore, at least in part, represents 
its therapeutic effect. This effect is attenuated by caffeine, which supports the involvement 
of adenosine in rosuvastatin-induced effects on cardiovascular disease. 
Intake of 2 cups of coffee results in a plasma caffeine concentration of ~9 mg/L.249 In our 
current design we aimed at optimal adenosine receptor blockade, which is obtained with 
90 µg/min per 100 mL of forearm volume.248 During intra-arterial infusion of caffeine, the 
plasma concentration in the venous effluent depends on FBF and decreases with higher 
flows. Unfortunately, we did not collect blood during caffeine infusion and are, therefore, 
not able to provide caffeine concentrations in the venous effluent in the present study. 
However, in a previous trial with comparable design,174 we measured plasma caffeine 
concentrations after 2 and 13 minutes of arterial occlusion and ~6 minutes of reperfusion 
which were, respectively 15±2 and 8±1 mg/L (mean ±SE, unpublished data). This indicates 
that local caffeine concentrations in the present study approach values that occur during 
regular caffeine consumption. We studied the effects of acute caffeine administration. 
Previous studies have indicated the development of (partial) tolerance to the effects of 
caffeine on blood pressure. However, in chronic caffeine consumers the blood pressure 
response to adenosine continuously increased during a 2-week period of caffeine 
abstinence, suggesting that the interaction between caffeine and adenosine may be less 
prone to tolerance development. Therefore, we believe that our observations strongly 
support the advice that patients who are treated with statins should abstain from caffeine 
consumption to fully utilize its clinical benefit. Additional evidence for this advice would 
need a large clinical trial in patients treated with statins randomized to long-term regular 
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caffeine consumption or caffeine abstinence with mortality and morbidity as clinical 
endpoints. Such a trial is very expensive and, in our opinion, hardly feasible.
Perspectives
In the last 20 years statins have been shown to improve outcome observed during acute 
coronary syndromes203,242, cardiac bypass surgery43,199, and percutaneous coronary 
interventions.202 The underlying mechanism is extensively studied but nonetheless not 
fully understood, which may hamper the full potential of this class of drugs. Our results 
demonstrate for the first time the effect of rosuvastatin on CD73 in a human in vivo setting 
and confirm the clinical relevance of increased adenosine receptor stimulation in the 
beneficial effects exerted by statins. These findings are of particular interest because phar-
macological modulation, both beneficial and detrimental, of the transport and actions of 
adenosine is already in widespread use, for example, dipyridamole and caffeine. Indeed 
the combination of a statin with an inhibitor of adenosine uptake into the cell, dipyridamole 
and cilostazol, and subsequent increased extracellular adenosine concentrations 
potentiate the infarct size-limiting effect of statins in animals.168,302 Our observations 
support caffeine abstinence in patients treated with a statin to fully utilize its clinical 
benefit. 
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Abstract
Statins are known to have cholesterol-independent pleiotropic effects, such as 
upregulation of the enzyme ecto-5’-nucleotidase. These effects may contribute to the 
protective effect of statins against ischaemia and reperfusion (IR). Interestingly, pleiotropic 
effects have been shown to differ between hydrophilic and lipophilic statins. 
Flow mediated dilation (FMD) represents a largely nitric oxide-mediated, endothelium-
dependent dilation and has been shown to decrease after exposure to IR in humans. FMD 
has been validated to study (pharmacological) interventions in IR-injury. We examined the 
effect of a short-term (3-7 days) statin pretreatment on brachial artery endothelial function 
before and after IR, and whether the effect on brachial artery endothelial function differs 
between rosuvastatin (hydrophilic statin) and atorvastatin (lipophilic statin).
Our results show that IR significantly decreases FMD, however statin pretreatment did not 
alter the effect of IR on FMD (irrespective of treatment duration or type of statin used). 
This experiment suggests that the cardioprotective effects of statins (both lipophilic and 
hydrophilic) against IR are not mediated through preservation of endothelial function. 
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Introduction
Cardiovascular disease represents the greatest burden in terms of morbidity and death 
in the Western world. Previous studies demonstrated that statins (3-hydroxy-3-methyl-
glutarylcoenzyme
A reductase inhibitors) reduce serum low-density lipoprotein (LDL) cholesterol, which is 
associated with a significant reduction in cardiovascular events.63,150,210,230 Statins also have 
cholesterol-independent pleiotropic effects, such as upregulation of ecto-5’-nucleoti-
dase145,173,198,234, activation of the phosphatidylinositol 3-kinase-Akt pathway274, activation of 
the ERK 1/2 pathway175 and upregulation of nitric oxide (NO) synthase.106,138 These 
pleiotropic actions may contribute to the cardioprotective effects of statins, such as an 
improved tolerance against ischaemia and reperfusion injury (IR-injury).22,32,163,229 Indeed, 
we have recently demonstrated that rosuvastatin reduces IR induced phosphatidylserine 
exposition in the thenar muscle in humans in vivo, involving activation of adenosine 
receptors.172 In addition, we have reported that rosuvastatin improves formation of 
adenosine in the forearm and increases forearm postocclusive hyperaemia via an adeno-
sine-dependent mechanism. Finally we have shown in humans a 50% increase in ecto-5’-
nucleotidase activity on peripheral blood mononuclear cells after rosuvastatin treatment 
as compared with placebo.173 Whether this increase is a result of a change in enzyme 
production, presence or activity remains unclear. Because the vasodilator response to 
adenosine involves endothelial release of NO, prevention of IR-induced endothelial 
dysfunction could be involved in these actions of rosuvastatin.250 Currently, little is known 
about the potential of statins to prevent IR-injury of the vasculature.
Severe endothelial dysfunction is one of the consequences of IR-injury.133 Ischaemia 
activates arginase, which competes with NO synthase for its substrate L-arginine and 
results in subsequent decrease in endothelial NO-release.67,105 Flow mediated dilation 
(FMD) represents a largely NO-mediated 182, endothelium-dependent dilation and has 
been shown to decrease after exposure to IR-injury in humans.133,161 Recently, it was 
demonstrated that a single dose of rosuvastatin could prevent the decrease in FMD after 
IR-injury, indicating a possible protective effect of the pleiotropic effects of statins on 
endothelial function.156 Interestingly, pleiotropic effects have been shown to differ 
between hydrophilic and lipophilic statins. Lipophilic statins have been reported to render 
endothelial and vascular smooth muscle cells more susceptible to apoptosis than 
hydrophilic statins.130 Moreover hydrophilic statins have been suggested to be superior in 
reducing event rate after a primary acute coronary syndrome in normocholesterolaemic 
patients.233 Thus, lipophilicity of statins may influence their ability to reduce IR-injury.
We hypothesize that short-term statin treatment prevents endothelial dysfunction after 
IR-injury. Therefore, the primary aim of our study is to examine the effect of a short-term 
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statin pretreatment on brachial artery endothelial function before and after IR-injury, and 
second to examine whether the effect on brachial artery endothelial function differs 
between a hydrophilic statin (i.e. rosuvastatin) and a lipophilic statin (i.e. atorvastatin). Finally, 
we assess RNA expression of ecto-5’-nucleotidase before and after statin therapy to elucidate 
more about the mechanism of increased ecto-5’-nucleotidase activity after statin therapy. 
Methods
After approval of the protocol by our local ethics committee, 48 healthy non-smoking 
volunteers (age 18-48 years) were included after signing informed consent. All participants 
underwent medical screening to exclude cardiovascular disease, hypertension, hypercho-
lesterolemia, impaired renal function, and diabetes mellitus. Serum values of creatine 
kinase and alanine aminotransferase were measured to exclude participants with an 
increased risk of adverse events during statin treatment. Subjects with concomitant use of 
medication or participation to other drug experiments during the past 60 days were 
excluded. Oral contraceptive use by female participants was permitted, but measurement 
was planned during the drug-free interval of the oral contraceptive to minimise the 
influence of the menstrual cycle on the endothelial function measurements.293
Experimental design
In this double-blind randomised controlled trial (NCT00987974), participants were 
allocated to daily treatment with either rosuvastatin (20 mg, AstraZeneca, Zoetermeer, 
The Netherlands), atorvastatin (80 mg, Pfizer, Capelle a/d IJssel, The Netherlands) or 
placebo (Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands). Both rosuvastatin and atorvastatin were capsuled by the 
Department of Clinical Pharmacy (Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands according to good manufacturing practice standards) to 
match placebo. Participants were equally divided across a 3- or 7-day pretreatment, 
because the duration of pretreatment may influence the impact of statins on IR-injury. On 
the first day, drug intake was performed under medical supervision. On subsequent days, 
capsules were taken individually before breakfast. At the end of the treatment, subjects 
returned to our laboratory to examine right brachial artery endothelial function before 
and after IR-injury. The latter was induced using 15 minutes of ischaemia, followed by 15 
minutes of reperfusion of the right arm.
Measurements
In the 24 hours before the test, participants were instructed to refrain from caffeine. 
Participants were instructed to take the last capsule 3 hours before the test and to fast 4 
hours before the test. Before the test, venous blood was taken from the antecubital vein 
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to assess lipid profile, caffeine level and RNA-expression of ecto-5’-ectonucleotidase in 
mononuclear cells. 
Flow mediated dilation
Endothelium-dependent, largely NO-mediated, vasodilator function was assessed using 
FMD.62,182 Participants rested in the supine position in a temperature-controlled room 
(22oC) for at least 15-minutes to facilitate baseline assessment of heart rate and blood flow. 
To examine brachial artery FMD, the right arm was extended and positioned at an angle 
of ~80o from the torso. A rapid inflation and deflation pneumatic cuff (D.E. Hokanson, 
Bellevue, WA) was positioned on the forearm immediately distal to the olecranon process 
to enable induction of forearm ischaemia.263 A 10-MHz multifrequency linear array probe 
attached to a high-resolution ultrasound machine (T3000; Terason, Burlington, MA) was 
used to image the brachial arteries in the distal one-third of the upper arm. When an 
optimal image was obtained, the probe was held stable and the ultrasound parameters 
were set to optimize the longitudinal, B-mode images of lumen-arterial wall interface. 
Continuous Doppler velocity assessment was simultaneously obtained using the 
ultrasound machine, and was collected using the lowest possible insonation angle (always 
<60o), which did not vary during each study. Baseline images were recorded for 1 minute. 
The forearm cuff was then inflated (>200 mmHg) for 5-minutes. Diameter and blood flow 
recordings resumed 30 seconds before cuff deflation and continued for 3 minutes 
thereafter.  
The baseline FMD measurement was followed by the experimental IR-injury. The 
pneumatic cuff was placed proximally around the upper arm and inflated to 200mmHg to 
apply 15 minutes of ischaemia followed by cuff deflation. After 15 minutes of reperfusion, 
the procedures for FMD assessment as described above were repeated by the same 
experienced sonographer.  
FMD analysis
Analysis of brachial artery diameters and shear rate were performed using edge-detection 
and wall-tracking software which is largely independent of investigator bias.296 Recent 
articles contain detailed descriptions of our analysis approach.28 From synchronised 
diameter and velocity data, blood flow (the product of lumen cross-sectional area and 
Doppler velocity (ν) was calculated at 30 Hz. Shear rate (an estimate of shear stress without 
viscosity) was calculated as 4 times mean blood velocity/vessel diameter.201 Reproducibility of 
the FMD using this semiautomated software possesses a within subject coefficient of 
variance of 6.7%-10.5%.266  
Baseline diameter, blood flow, and shear rate were calculated as the mean of data acquired 
across the 1 minute preceding the cuff inflation period. Peak diameter after cuff deflation 
was automatically detected using an algorithm that identified the maximum bracket of 
data subsequent to performance of a moving window smoothing function. FMD was 
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calculated as the percentage rise of this peak diameter from the preceding baseline 
diameter and was calculated based on standardised algorithms applied to data which had 
undergone automated edge-detection and wall-tracking, and were therefore observer-
independent.28 In accordance with recent findings 28,209, we calculated the shear rate 
stimulus responsible for endothelium-dependent FMD after cuff deflation.
Blood analysis
In all volunteers, blood was collected to determine fasting serum lipid profile (high-density 
lipoprotein, LDL and total cholesterol and triglycerides) with a commercially available kit 
(Aeroset, Abbott). Plasma caffeine concentrations were determined by use of reversed- 
phase HPLC with UV detection set at 273nm.240
Real-time quantitative-polymerase chain reaction procedures
All procedures were carried out according to the manufacturers’ instructions. Whole 
blood was collected in PAXgene blood RNA tubes and stored at -80oC., after which RNA 
was isolated using the PAXgene Blood RNA Kit (both from Qiagen, Venlo, The Netherlands). 
Total intact RNA was reverse transcribed using pd(N)6 random hexamer primers and 
Moloney murine leukaemia virus reverse transcriptase (Invitrogen). Real-time quantitative-
polymerase chain reaction was performed using the ABI/PRISM 7900HT Gene Expression 
Micro Fluidic Card (Applied Biosystems). Complementary DNA amplification was 
performed in Taqman® Universal polymerase chain reaction Master Mix, supplemented 
with 20x solution of primer probe sets for ecto-5’-nucleotidase (Hs01573922_m1), and 
b-actin (Hs; all from Applied Biosystems). Polymerase chain reactions were analysed using 
700 System Sequence Detection Software (version 1.2.3; Applied Biosystems).
Sample size  and statistical analysis
 Using the observed difference in FMD after IR between treatment and control, SD and 
group size reported by Liuni et al.,156 we calculated that the SD of the observed difference 
in FMD before and after IR was 3.85%. Thus, with 48 volunteers in the present study, and 
based on the predicted SD of 3.85%, and 80% power and a significance level of 5% we 
expected to detect  a treatment effect of 4% in FMD response after IR.
All data are presented as mean ± standard error, unless stated otherwise. To avoid multiple 
testing, we used analysis of variance (ANOVA) for repeated measures with interaction 
terms to analyse the effect of different treatments on cholesterol and FMD. Paired t-test 
was used to test the effect of ischaemia on FMD within the placebo group. Statistical 
analyses were performed using SPSS 16.0. For ecto-5'-nucleotidase expression data, 3 
measurements were found to have a deviation from the group average of >4 times the 
SD. This was related to very high b-actin cycle threshold values of these measurements: >5 
cycle thresholds above average. Because this suggests that the quality of these RNA 
samples was compromised, these measurements were excluded from the analysis.  
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Results
Before deblinding, 1 volunteer (placebo) was excluded because of caffeine intake (caffeine 
level of 1.5mg/L). Baseline characteristics and cholesterol data of all groups are presented 
in Table 1.
LDL and total cholesterol were not affected by placebo treatment. Statin treatment 
significantly reduced LDL and total cholesterol in all groups (ANOVA p<0.05). We found no 
differences in the effect of treatment on LDL and total cholesterol between rosuvastatin 
and atorvastatin (ANOVA p=0.98 and 0.86 respectively).
Statin pretreatment had no effect on the RNA expression of ecto-5’-nucleotidase in 
peripheral blood mononuclear cells (figure 1) (ANOVA p=0.38).
Table 1   Baseline characteristics and cholesterol values after treatment with 
placebo, rosuvastatin or atorvastatin 
Placebo
(n=15)
Rosuvastatin
 (n=16)
Atorvastatin
 (n=16)
At baseline
Age (years) 21.8 (1.5) 24.4 (7.1) 22.2 (1.3)
Female (%) 60 75 62.5
BMI (kg/m2) 22.1 (1.7) 22.7 (2.2) 22.3 (2.2)
Systolic blood pressure (mmHg) 119 (9) 122 (10) 122 (7) 
Diastolic blood pressure (mmHg) 73 (8) 75 (7) 76 (7)
Heart rate (bpm) 68 (10) 63 (10) 66 (11)
Glucose (mmol/l) 4.7 (0.5) 5.0 (0.8) 5.0 (0.6)
Total cholesterol (mmol/l) 4.6 (0.7) 4.3 (0.7) 4.7 (0.8)
LDL (mmol/l) 2.8 (0.6) 2.5 (0.6) 2.7 (0.8)
After treatment
Total cholesterol (mmol/l) 4.6 (0.7) 3.4 (0.7) 3.8 (1.2)
LDL (mmol/l) 2.7 (0.6) 1.7 (0.6) 1.9 (0.9)
Data represent mean (SD)
84
Chapter 6
Figure 1   Ecto-5’-nucleotidase mRNA expression (percentage change from baseline 
measurement before treatment) before treatment (closed bars) and after 
treatment (open bars). 
 
Error bars represent standard errors.
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Table 2   Results FMD measurement before and after ischaemia and reperfusion 
Placebo (n=15) Rosuvastatin (n=16) Atorvastatin (n=16)
Before IR-injury
Baseline diameter (mm) 0.34 (0.07) 0.36 (0.07) 0.35 (0.06)
FMD (mm) 0.37 (0.07) 0.39 (0.07) 0.38 (0.06)
FMD (%) 7.7 (3.9) 6.9 (3.4) 8.3 (4.7)
Shear rate(s-1) 27211 (14614) 28609 (11349) 27693 (8409)
Time to peak (s) 63 (24) 56 (23) 50 (16)
After IR-injury
Baseline diameter (mm) 0.34 (0.07) 0.37 (0.06) 0.34 (0.06)
FMD (mm) 0.36 (0.07) 0.39 (0.06) 0.36 (0.05)
FMD (%) 5.1 (2.4) 5.8 (3.0) 5.7 (3.4)
Shear rate (s-1) 26817 (11661) 27150 (10755) 27553 (9676)
Time to peak (s) 44 (25) 48 (24) 46 (20)
Reduction FMD (%) 34 16 31
Data represent mean (SD)
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Endothelial function and IR
An overview of the FMD measurements is presented in table 2. No differences were 
observed in baseline diameter or in the shear rate stimulus between the FMD-response 
before and after IR-injury. 
In the placebo group, IR significantly decreased FMD (paired t-test p<0.05). Treatment 
duration (3 vs. 7 days) did not affect the results. Therefore, for each statin, data of 3 and 
7-day treatment are pooled. Statin pre-treatment did not alter the effect of IR on FMD, 
irrespective of  the type of statin used (see figure 2). Figure 3 shows the reduction in FMD 
(FMD before IR minus FMD after IR) for all individual participants in all treatment groups.
Figure 2   Brachial artery flow mediated dilation (presented as percentage change 
from baseline) in all pooled treatment groups before IR (open bars) and 
after IR (closed bars). 
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Discussion
Using a double blind, randomised design we examined the effect of a short-term 
pretreatment (3 to 7-days) of a lipophilic (i.e. atorvastatin) and a hydrophilic (i.e. rosuvastatin) 
statin to prevent the IR-induced attenuation in endothelial function in humans. First, we 
confirmed previous observations of a brachial artery endothelial dysfunction after IR-injury 
in healthy volunteers. However, in this relatively large sample size, the observed effect of 
IR on brachial FMD was smaller (34%) than reported previously  (40-80%).54,134,158-161,194 In 
contrast to Liuni et al., we observed a persistent reduction in FMD by IR in statin-treated 
individuals, irrespective of the type of statin used. This suggests that the protective effects 
of statins against IR-injury are not mediated through preservation of NO-mediated 
endothelial function.
We found that IR resulted in endothelial dysfunction in the control group, which confirms 
observations in previous studies.80,83,133,134,156 However, the 34% decrease in endothelial 
function seen in the current study is less than typically observed in most studies.80,83,133,156 
A potential explanation for this finding is that our ischaemic stimulus was relatively mild 
compared with previous studies. Indeed, using an ischaemic stimulus of 20 minutes, 
MacAllister’s group repeatedly demonstrated a reduction of the brachial artery endothelial 
function of 50% to 70%.158,160,161 Because we adopted a methodological design comparable 
to MacAllister’s group, our findings suggest that the duration of ischaemia to induce 
IR-injury importantly determines the magnitude of decrease in FMD after IR-injury. In 
Figure 3   Individual results of reduction in FMD after IR (FMD before IR minus FMD 
after IR) for all treatment groups. 
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addition, the site of FMD assessment may play a role in the magnitude of endothelial 
dysfunction after artificial IR-injury. Liuni et al. found a remarkable reduction of 83% in 
radial artery FMD after a 15-minute ischaemic stimulus.156 Recent reports have 
demonstrated heterogeneity in response to physiological stimuli between the brachial 
and radial artery, which may contribute to variation in FMD decrease after a 15-minute 
ischaemic stimulus between studies. For example, a 6% constriction in radial artery was 
found when exposed to 5-minutes ‘low flow’82, whereas a similar stimulus in the brachial 
artery has no impact on resting diameter 267,288 or even leads to a slight dilation267. Also, the 
degree of dilation to a 5-minute ischaemic stimulus differs between both arteries when 
examined simultaneously within subjects.265 Taken together, these observations suggest 
that methodological aspects (e.g. site of measurement, ischaemia-stimulus for IR-injury) 
must be considered when comparing studies that examine the impact of IR on endothelial 
function. 
The site of measurement of endothelial (dys)function in relation to IR is of special interest 
to ultimately extrapolate the results to more clinically relevant vascular beds, such as the 
coronary arteries. In the brachial artery a diminished FMD can predict future cardiovascular 
events86,111, whereas such prognostic value is less clear for the radial artery. In addition, a 
correlation was found between coronary artery endothelial function and brachial and 
radial artery endothelial function.10,276 Combining the correlation of the coronary circulation 
with the strong predictive value of the FMD for clinically relevant end-points (future 
cardiovascular events), the brachial artery seems a logical measurement site for human 
in vivo models studying IR-injury.
It is important to realise that experiments on endothelial dysfunction after IR-injury are 
almost exclusively carried out in healthy volunteers. At present it is not known to what 
extent these findings can be extrapolated to patients with ischaemic heart disease. 
Furthermore, given the current discrepancies between studies adopting a different 
methodological design, we strongly recommend harmonization of the methodological 
approach for future studies of the effects of IR on endothelial dysfunction. To further 
support this process we are currently performing a study to directly compare brachial and 
radial artery with respect to the effect of 15 minutes of IR on FMD.
An important finding of our study is the persistent reduction in FMD after short statin 
pretreatment on brachial artery endothelial function after IR-injury in a relatively large 
study population. The effect of statins was independent of the duration of the pretreatment 
(3 vs. 7 days), also compound lipophilicity did not alter the ability to protect the endothelium 
against IR-injury. Our findings suggest that statins do not protect the brachial artery 
against IR induced endothelial dysfunction, which is in contrast to a previous study that 
demonstrated that a single dose of 40 mg of rosuvastatin completely prevents IR-induced 
endothelial dysfunction in the radial artery.156 As discussed above, methodological 
differences between studies relating to the site of measurement (brachial vs. radial) may 
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contribute to these conflicting findings. In addition, differences in the dose (40 vs. 20 mg) 
and duration of pretreatment (3-7 days vs. single dose) between our study and that of 
Liuni et al.156 may contribute to the distinct findings of these studies. However, based on 
the pharmacokinetics of rosuvastatin, the estimated serum levels of rosuvastatin at the 
time of FMD measurement in the experiment by Liuni et al. should be comparable with 
those in the present study before IR, because of some accumulation of rosuvastatin after 
repeated dosing. Therefore, the protective effect of statins against endothelial dysfunction 
after IR may occur in the radial artery but not in the brachial artery. However, future studies 
should further examine this potentially clinically important topic.
Recently, we found that short-term treatment with rosuvastatin reduces ischaemia-in-
duced  phosphatidylserine exposition in the thenar muscle as quantified with annexin A5 
targeting.172 This finding indicates that rosuvastatin pretreatment increases tissue tolerance 
against ischaemia-induced cellular apoptosis and subsequent injury. The results of our 
present experiment add the novel knowledge that the attenuating effect of rosuvastatin 
on ischaemia induced phosphatidylserine exposition is not related to endothelial 
dysfunction after IR-injury.
 
We have previously observed a 50% increase in ecto-5’-nucleotidase activity on peripheral 
blood mononuclear cells of volunteers who received an 8 day rosuvastatin pretreatment 
(20 mg daily).173 In this study we show that RNA-expression of ecto-5’-nucleotidase on 
peripheral blood mononuclear cells was not increased after short-term statin treatment. 
Although we did not measure ecto-5’-nucleotidase activity, combining our findings with 
previous observations suggests the presence of a nongenomic effect of rosuvastatin on 
ecto-5’-nucleotidase activity, such as changes in posttranslational modification or 
localization of the enzyme. In accordance with this interpretation, others have 
demonstrated in endothelial cell culture that lovastatin increases ecto-5’-nucleotidase 
activity by reducing enzyme endocytosis.145 In the dog heart, the phosphatidylinositol 
3-kinase/Akt pathway has been involved in the upregulation of ecto-5’-nucleotidase by 
statins.234 The exact mechanism of up-regulation in humans needs further exploration.
Conclusion
In the present study, we show a moderate effect of IR on brachial artery endothelial 
function, which persisted after adequate short-term hydrophilic or lipophilic statin 
treatment. Because brachial FMD predicts cardiac events, this suggests that the cardiopro-
tective effects of statins are not mediated through preservation of endothelial function 
after IR. 
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Abstract
Aim: Flow mediated dilation as a read-out of endothelial function is often used to explore 
the efficacy of interventions to reduce endothelial ischaemia-reperfusion injury in humans. 
These proof-of-concept studies translate preclinical findings in animals to humans and 
facilitate optimal design of future clinical trials. Differences in methodology, such as the 
used artery, limits comparison of results between various research groups. Between-study 
comparisons suggest a difference in susceptibility of IR-injury between the brachial and 
radial artery. Therefore, we directly compared the effect of IR on endothelial function 
between the radial and the brachial artery.
Methods: We simultaneously examined FMD responses in the brachial artery and ipsilateral 
radial artery before and after IR of brachial and radial artery. We applied 15 minutes of 
ischaemia and 15 minutes of reperfusion which represents a frequently used and validated 
method to induce forearm IR-injury. To determine the FMD, we measured brachial and 
radial artery diameter and blood flow using duplex ultrasound before and after a 5-minute 
ischaemic stimulus applied distal from the measurement sites.
Results: FMD was significantly attenuated after IR in the radial artery from 7.8±3.8% to 
6.3±2.7% and in the brachial artery from 5.1±2.4% to 3.6±1.6% (p=0.03 and p=0.01, 
respectively). We found no difference in the absolute or relative decrease in FMD between 
the brachial and radial artery (p=0.68 and p=0.97, respectively).
Conclusions: We have shown that the radial artery and the brachial artery demonstrate an 
equal and  significant decrease in FMD in response to IR in healthy volunteers.
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Introduction
Ischaemia and reperfusion injury (IR-injury) is an important determinant of mortality and 
morbidity in patients after an ischaemic insult, such as a myocardial infarction or stroke.305 
Interventions such as ischaemic preconditioning, aimed at improving tolerance to IR-injury 
can reduce infarct size up to 75%, which emphasises the importance to modulate 
tolerance to IR-injury in the clinical management of ischaemic insults.183 A distinct feature 
of IR-injury relates to the presence of endothelial dysfunction.103 It is believed that 
IR-induced endothelial dysfunction is caused by the activation of arginase during 
ischaemia, which competes with NO-synthase for its substrate L-arginine and subsequently 
impairs NO-release.105 In a clinical setting, endothelial dysfunction after IR-injury may 
contribute to the ‘no-reflow’ phenomenon during reperfusion and thereby increase 
infarct size.117
The assessment of the flow-mediated dilation (FMD) before and after artificial ischaemia 
and reperfusion provides a popular, non-invasive and well tolerated model to study 
endothelial tolerance to IR in humans in vivo.133 This model has successfully been used to 
translate preclinical findings in animals to humans in vivo. These proof-of-concept studies 
are important to facilitate effective design of clinical trials aimed to reduce IR-injury and 
subsequent prognosis. The validity of this model is supported by the ability to prevent the 
decrease in FMD after IR by well established (non)pharmacological interventions that 
improve IR tolerance.156,158,161 Both radial and brachial artery can be used for FMD 
assessment. Regional heterogeneity in wall architecture268 and vascular function265, has 
been demonstrated to alter the magnitude of FMD. Accordingly, the significant difference 
in baseline diameter between the brachial and radial artery may have an influence on the 
impact of IR-injury on endothelial function between both arteries. Indeed, a between-study 
comparison of non-interventional experiments (placebo or control) reveals an apparent 
larger decrease in FMD after IR-injury in the radial artery, compared to the brachial artery 
(Table 1). Moreover, such differences between arteries may also explain apparent conflicting 
results from recent studies. For example, recent reports showed a preserved endothelial 
function of the radial artery after single dose rosuvastatin treatment prior to forearm 
IR156,157, whilst another study found no protective effect of rosuvastatin when examining 
the brachial artery.297
These observations highlight the importance to directly compare the change in FMD in 
response to IR-injury between different artery sites in humans. Therefore, we simultaneously 
studied the radial and ipsilateral brachial artery FMD before and after IR-injury in healthy 
subjects. Based on available literature, we hypothesised a larger IR-induced decrease in 
radial artery FMD compared to the brachial artery.
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Methods
Subjects
A total of 20 healthy young volunteers (8 men, 12 women) without a history of cardio-
vascular disease, diabetes or family history of cardiovascular death (<50 years) were 
recruited from the community (Table 2). All subjects were non-smokers and normotensive 
(<140/90mmHg). None of the subjects used any medication known to interfere with the 
cardiovascular system. The local Ethics Board of the Liverpool John Moores University 
approved the protocol and written informed consent from all participants was obtained 
Table 1   Relative decrease in radial (left panel) and brachial (right panel) artery 
flow-mediated dilation after ischaemia reperfusion (I/R) injury in non-
interventional groups (placebo or controls), presented per individual 
study (with first author, sample size and duration for the ischaemia 
and reperfusion (I/R) in minutes) and all studies averaged (last row).
Radial artery Brachial artery
Reference n I/R %Decrease Reference n I/R %Decrease
Kharbanda 2001 133 31 20/15 55% Kilian 2005 134 9 10/30 34%
Gori 2005 83 10 15/15 85% Kilian 2005 134 9 20/30 80%
 Dragoni 2005 65 10 15/15 78% Loukogeorgakis 2005 158 13 20/20 44%
Liuba 2005 155 8 20/15 63% Loukogeorgakis 2006 159 11 20/20 60%
Gori 2006 81 10 15/15 61% Loukogeorgakis 2007 161 11 20/20 65%
Dragoni 2006 64 10 15/15 68% Loukogeorgakis 2010 160 11 20/20 65%
Liuni 2010 156 10 15/15 83% Okorie 2011 194 9 20/20 61%
Dragoni 2007 66 10 15/15 76% Devan 2011 54 10 20/15 37%
Gori 2007 80 10 15/15 84% Wouters 2011 297 15 15/15 34%
Liuni 2010 156 9 15/15 74% Webb 2008 285 10 20/20 60%
Liuni 2010 156 10 15/15 56%
Liuni 2012 157 9 15/15 56%
Liuni 2012 157 10 15/15 75%
Lisi 2012 153 8 15/15 86%
Ha 2012 90 20 15/15 62%
Average 71±11% Average 54±16%
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prior to participation. All experiments were carried out in accordance with the declaration 
of Helsinki (2000). 
Experimental design and measurements
Testing was performed between 8.30 AM and 4 PM. Previous studies found that the FMD 
does not change significantly across this time frame, assuming that testing is performed 
under well-controlled conditions263. All measurements were performed under standardised 
conditions in a temperature-controlled room and after at least 6 h of fast and at least 8 h 
of abstinence from caffeine and alcohol. No subject performed strenuous physical activity 
for at least 24 h before testing. 
 
Flow mediated dilation. Subjects rested in a supine position with the experimental arm 
extended and immobilised, supported at an angle of ~80° abduction from the torso. 
Heart rate and mean arterial pressure were determined from an automated sphygmo-
manometer (GE Pro 300V2, Dinamap, Tampa, FL). For the assessment of FMD, a rapid 
inflation/deflation pneumatic cuff was placed distal to the olecranon process to provide 
an ischaemic stimulus to provoke vasodilation and subsequent shear stress. A 10-MHz 
(T3000, Terason, Aloka, UK) multi-frequency linear array probe attached to a high-resolu-
tion ultrasound machine was used to perform imaging. The brachial artery was imaged in 
the distal third of the upper arm. The radial artery was imaged in the upper part of the 
forearm, proximal to the occluding cuff. Ultrasound parameters were set to optimise 
longitudinal B-mode images of the lumen/arterial wall interface. A continuous Doppler 
velocity assessment was obtained simultaneously, and data were collected using the 
lowest possible insonation angle (always <60°), which did not vary during each study.296 
After a resting period of at least 15 minutes, 1 minute of baseline recording of the arterial 
Table 2   Subject characteristics for all participants (n=20) presented as mean  
± SD
Characteristic Mean ± SD
Age (years) 24 ± 3
Height (cm) 172 ± 8
Body weight (kg) 65.5 ± 1.1
Body mass index (kg/m²) 19.0 ± 2.6
Systolic blood pressure (mmHg) 119 ± 19
Diastolic blood pressure (mmHg) 69 ± 7
Heart rate (beats/min) 63 ± 12
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diameter and velocity was performed (in brachial and ipsilateral radial artery). Subsequently, 
the occlusion cuff was inflated to 220 mmHg for 5 minutes. The arterial diameter and 
velocity recordings were restarted at least 30 seconds before cuff deflation and continued 
for at least 3 minutes after deflation. Peak arterial diameter and flow, and the time to reach 
this peak after cuff deflation, were recorded.
 
IR-injury. The rapid inflation/deflation pneumatic cuff was positioned proximally around 
the upper arm to provide an occlusion for 15 minutes, so that the brachial artery was 
within the ischaemic zone and was exposed to IR-injury. The cuff was inflated for 15 
minutes to 220 mmHg, which was followed by 15 minutes of reperfusion. This method is 
safe and represents a valid and reproducible method to induce transient endothelial 
dysfunction in vivo in humans.83,133 This procedure has no effect on blood pressure, heart 
rate or basal blood flow.296 After simulated ischaemia and reperfusion, we repeated 
simultaneous assessment of the FMD in brachial and ipsilateral radial artery, as described 
above.
Arterial diameter and blood flow analysis
Analysis of the brachial and radial artery diameter was performed using custom-designed 
edge-detection and wall-tracking software, which is independent of investigator bias.296 
Briefly, the echo-Doppler signal was real-time encoded and stored as a digital file. 
Subsequent software analysis of the data was performed at 30 Hz using an icon-bases 
graphical programming language and toolkit (LabView 6.02, National instruments, Austin, 
TX). Furthermore, our method of blood flow assessment is closely correlated with actual 
flow through a “phantom” arterial flow system.85 
Data analysis
Baseline diameter and shear rate were calculated as the mean of data acquired across the 
1 minute preceding the cuff inflation period. Following cuff deflation, peak diameter 
following cuff deflation was automatically detected according to an algorithm which 
identified the maximum bracket of data subsequent to performance of a moving window 
smoothing function. This smoothing routine calculates the median value from 100 
consecutive samples, before the window shifts to the next bracket of data which shares 
20% overlap with the preceding bracket. The maximum value of all the calculated median 
values is then automatically detected and chosen to represent the peak of the diameter 
curve.  FMD was calculated as the percentage rise of this peak diameter from the preceding 
baseline diameter. Calculation of FMD was therefore observer-independent and based on 
standardised algorithms applied to data which had undergone automated edge-detection 
and wall-tracking.296 Reproducibility of the FMD using this semi-automated software 
possesses a CV of 6.7-10.5%.266 The post-deflation shear rate data, derived from 
simultaneously acquired velocity and diameter measures at 30 Hz, was used to calculate 
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the area under the shear rate curve for data up to the point of maximal post-deflation 
diameter (FMD) for each individual.209
Statistics
The statistical analyses were performed using SPSS version 16.0 software. All data are 
reported as means ± SD (unless stated differently), and statistical significance was assumed 
at p≤0.05. We used paired T-test to compare baseline ultrasound measurements between 
radial and brachial artery. A 2-way ANOVA was used to examine the effect of IR-injury on 
FMD (pre versus post IR) and whether this effect was different between the radial and 
brachial artery. A Shapiro-Wilk’s test was used to control for normality.
Results
Subject characteristics are presented in Table 2. At baseline, brachial artery FMD was 
significantly lower compared to the radial artery FMD (Table 3). Brachial artery demonstrated 
a larger diameter, smaller shear rate and similar time-to-peak diameter compared to the 
radial artery (Table 3).
Table 3   Characteristics of flow mediated dilation of the brachial and  
radial artery before (‘Baseline’) and after (‘Post-IR’) ischaemia- 
reperfusion-injury in healthy young subjects (n=20).  
Data is presented as mean ± SD
Radial artery Brachial artery
Parameter Baseline Post-IR Baseline Post-IR
Baseline diameter (mm) 2.4 ± 0.8 2.3 ± 0.8 3.6 ± 0.6# 3.7 ± 0.7*
Peak diameter (mm) 2.6 ± 0.8 2.5 ± 0.8 3.8 ± 0.6# 3.8 ± 0.7
Change from baseline (mm) 0.17 ± 0.07 0.14 ± 0.06* 0.18 ± 0.07 0.13± 0.07
Flow-mediated dilatation (%) 7.8 ± 3.8 6.3 ± 2.7* 5.1 ± 2.4# 3.6 ± 1.6*
Shear rate (s-1x103) 25.4 ± 12.3 25.7 ± 16.3 17.0 ± 9.0# 14.5 ± 6.0
Time to peak (s) 40.0 ±20.0 25.3 ± 8.7* 37.6 ± 15.4 35.8 ± 18.3
* Significant p<0.05 different from baseline
# Significant p<0.05 from baseline of the radial artery
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We found that IR resulted in a significantly attenuated FMD in both the radial and brachial 
artery (2-way ANOVA: p<0.01 for IR-injury, Figure 1). However, we found no difference in 
Figure 1   Results of FMD (%) measurement before and after IR-injury. Individual 
results for the brachial (A) and radial artery (B) and group results (C) in 
healthy young subjects (n=20). 
 
Error bars represent SE.
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the magnitude of decrease in FMD between the brachial and radial artery (2-way ANOVA 
interaction; p=0.97). Also in relative terms, we found no difference between the decrease 
in radial and brachial artery FMD (19% versus 29%, t-test; p=0.68). A significantly shorter 
time to peak after IR compared to baseline was found in the radial, but not in the brachial 
artery (Table 3). We have added gender and baseline diameter as a covariate, but this 
procedure did not alter our results.
Discussion
The main purpose of this experiment was to examine the difference in endothelial 
tolerance to IR injury between the radial and brachial artery; i.e. two frequently used sites 
to study IR injury in humans. First, we confirmed the presence of an immediate decrease 
in endothelial function after IR in healthy humans in vivo. More importantly, the absolute 
and relative decrease in endothelial function caused by IR was comparable between the 
brachial and radial artery in response to the same IR stimulus. This novel finding suggest 
that, in contrast to our hypothesis and suggestions from available literature, IR-injury leads 
to an immediate decrease in endothelial function in healthy subjects that is independent 
of the artery studied (either brachial or radial artery).
In agreement with various previous studies, we found that IR injury in healthy volunteers 
leads to a decrease in brachial and/or radial artery endothelial function. The effect of IR on 
brachial and radial artery endothelial function (29% and 19%, respectively) was similar to 
that observed in a previous study from our laboratory297, but somewhat smaller compared 
to others (Table 1). Methodological differences in FMD assessment other than forearm 
artery (e.g. wrist or forearm cuff placement and (dis)continuous ultrasound recording) 
could partially account for this difference.83,133 A potential methodological issue that 
contributes to the relatively small decrease in FMD in our study relates to the intensity of 
the ischaemic challenge. Indeed, the decrease in FMD observed in our study was 
comparable to previous studies that used similar297 (i.e. 15 minutes) or shorter134 (i.e. 10 
minutes) episode of ischaemia, whilst a larger decrease in FMD was observed when 
adopting a 20 minutes IR stimulus (Table 1). Also subject characteristics may contribute to 
differences in change in FMD between studies. Recently, Devan et al. demonstrated that 
the magnitude of decrease in FMD after IR is strongly and positively related with age.54 In 
their experiment, young participants showed a 37% decrease in brachial artery FMD, 
which was significantly lower than the 68% attenuation in middle-aged subjects.54 The 
decrease in FMD as well as the age of our participants is well matched with that observed 
by Devan et al.. Finally, female sex may alter the impact of IR, as the menstrual cycle alters 
brachial artery FMD.293 However, we found no difference in the impact of IR on brachial or 
radial artery FMD between men and women.
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Regional differences within and between arterial beds in wall architecture and vascular 
function have been described before.268 In accordance with previous observations, we 
found a larger FMD and smaller baseline diameter in the radial artery compared to the 
brachial artery. We hypothesised that these differences may contribute to a different 
susceptibility between arteries for IR-injury. However, we found a similar decrease in 
endothelial function between the radial and brachial artery when exposed to the same IR 
challenge.
Limitations. A strength of this experiment was the simultaneous measurement of the FMD 
in the radial artery and brachial artery, which effectively excludes possible bias by local 
and systemic factors that influence vascular function or the impact of IR-injury. A potential 
limitation of our study relates to the higher baseline diameter of the brachial artery after 
IR-injury, which is a finding that contrasts with previous experiments159, including those 
from our laboratory.297 Since we found no difference in baseline diameter in the ipsilateral 
radial artery, which was measured simultaneously with the brachial artery before and after 
IR, we believe it unlikely that systemic factors contribute to this finding. Moreover, 
statistically controlling for these changes in diameter did not alter the outcomes of our 
study. In clinical experiments, measurement of FMD predicts future cardiovascular events 
in patients with established cardiovascular disease.111 The prognostic value of IR-induced 
endothelial dysfunction, however, remains to be elucidated. Nonetheless, the use of FMD 
before and after an ischaemic event as model to study IR-injury is valid In conclusion, we 
have shown that the radial artery and the brachial artery demonstrate a significant and 
comparable decrease in FMD in response to IR in humans in vivo.
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As stated previously, ischaemia and reperfusion injury contributes significantly to mortality 
and morbidity in patients suffering from an ischaemic event (e.g. cerebrovascular event, 
myocardial infarction). Fortunately, Murry et al. in 1986 reported their novel procedure of 
ischaemic preconditioning, which could spectacularly reduce myocardial infarct size up to 
75%.183 Comparable results have been produced by other researchers in different organs, 
in different species and with several variations to the preconditioning protocol (as 
reviewed in chapter 1). Thereupon, extensive research has been devoted to elucidation of 
this phenomenon. Today much of the protective mechanism of preconditioning has 
been unravelled.
However, translation of the spectacular effect of preconditioning on infarct size in animal 
experiments to clinically relevant settings in cardiovascular patients has rather been 
disappointing. Even though some experiments in patients have found (moderate) clinical 
benefits (e.g. improved MACE after PCI or reduced myonecrosis markers after CABG)202,279, 
these results did not have the impact that could have been expected from a 75% reduction 
in infarct size. As results in clinical experiments fail to live up to the expectations, it is clear 
more research is needed to clarify this apparent discrepancy between preclinical findings 
and clinical effects. Future research has to be performed in humans in vivo to further 
evaluate the possibilities of preconditioning. This calls for validated and well-tolerated 
models to study IR-injury in humans. 
In this thesis we have explored three different methods to study different aspects of 
IR-injury in humans in vivo. Firstly, we used annexin A5 scintigraphy to quantify IR-injury. 
This technique, developed at the departments of Pharmacology-Toxicology, General 
Internal Medicine and Nuclear Medicine of the Radboud University Nijmegen Medical 
Centre226, uses binding of radiolabeled annexin A5 to phosphatidylserines which get 
exposed on the outer leaflet of the cellular membrane upon cell stress. 
In chapter 2 annexin A5 scintigraphy was used to quantify the effect of a short-term 
treatment with atorvastatin on voluntary forearm ischaemia and subsequent reperfusion. 
We found no difference in annexin A5 targeting between atorvastatin and placebo 
treatment. As atorvastatin has previously been shown to prevent myocardial damage202,203, 
we conclude that prevention of PS exposition is not part of atorvastatin’s protective 
mechanism. This experiment included an extra control group that was randomised to 
receive placebo treatment twice. In this control group we calculated a within-individual 
correlation of annexin A5 targeting of 0.93 and 0.79 at 1 and 4 hours after reperfusion 
respectively. These results show an adequate reproducibility of annexin scintigraphy after 
IR-injury, especially for the measurement at 1 hour after reperfusion.
In chapter 3 we studied whether the clinical effectiveness of irbesartan is hampered by 
increased apoptotic activity, detected by exposition of phosphatidylserines, during 
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ischaemia and reperfusion in humans in vivo. Annexin A5 targeting was not influenced by 
a 7-day treatment with irbesartan 300mg, compared to placebo. The results of this study 
do not support enhanced apoptotic activity after treatment with irbesartan in a setting of 
ischaemia and reperfusion.
In chapter 4 we further studied the alleged protective effect of dipyridamole against IR-
injury.92,220 Healthy male volunteers were randomised to dipyridamole and placebo 
treatment in a crossover design. Using annexin A5 scintigraphy we found a carry-over 
effect between the experimental and placebo treatment. Dipyridamole reduced annexin 
A5 targeting in those volunteers who received placebo first and dipyridamole next, 
compared to those receiving dipyridamole first and placebo next. As we implemented a 
washout period of 3 weeks, this carry-over effect existed for at least 4 weeks. Next, we 
further examined the observed prolonged protective effect of dipyridamole. To address a 
possible role of extended nucleoside transport inhibition in the apparent long-term 
action of dipyridamole, we investigated the 4-week post-treatment effect of a 7-day oral 
dipyridamole administration on nucleoside transport ex vivo in human erythrocytes. 
Nucleoside transport was inhibited directly after dipyridamole treatment, however within 
1 week of treatment cessation this inhibitive effect had disappeared completely. A 
prolonged effect of dipyridamole on nucleoside transport is not involved in the apparent 
prolonged protective effect of dipyridamole on PS-exposition. 
Even though annexin A5 scintigraphy appears to be a reproducible and suitable method 
to quantify PS exposure as one of the sequellae of IR-injury, its validity as a tool to translate 
preclinical observations of strategies to prevent IR-injury to humans in vivo is hampered by 
the limited role that PS exposure plays in the mechanism of IR-induced cell death. This 
conclusion is based on our finding that atorvastatin did not prevent annexin A5 targeting, 
despite its proven efficacy in patients who present with an acute myocardial infarction 
(chapter 3) and the limited role of PS exposure in renal IR-injury as reported recently by 
Wever et al.290,291
Finally, further development of this method is seriously hampered, as human grade 
annexin A5 is presently no longer available. Clearly, there is a need to explore alternative 
approaches to study IR-injury in humans in vivo. Therefore, we studied endothelial 
dysfunction as feature of IR-injury and used two models to quantify the impact of IR on 
endothelial function. First, we used post-occlusive reactive hyperaemia (PORH) in the 
forearm of healthy volunteers as a model of post-ischaemic vascular function. As we have 
previously shown that rosuvastatin increases vasodilation after ischaemia in the human 
forearm173, in chapter 5 we further clarified the mechanism behind this effect of 
rosuvastatin. We have shown that rosuvastatin increases the activity of the enzyme  ecto-5’- 
nucleotidase (which dephosphorylates extracellular AMP to adenosine) with almost 50%. 
Moreover we have shown the role of adenosine receptor stimulation in rosuvastatin- 
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induced augmentation of PORH, as rosuvastatin enhanced the vasodilatory response after 
2, 5, and 13 minutes of ischaemia in the absence, but not in the presence of caffeine (a 
potent adenosine receptor antagonist).
Finally, we adapted flow mediated dilation (FMD) measurements performed at the 
Department of Physiology of the Radboud University Nijmegen Medical Centre to be 
used for quantification of IR-injury, according to scientific literature.133
This relatively new and non-invasive technique to study IR-induced endothelial 
dysfunction, appears to be a promising method to study the mechanism of IR-induced 
endothelial dysfunction and the effect of (pharmacological) interventions.161 In chapter 6 
we used FMD to compare the effect of two different statins (the lipophilic atorvastatin vs. 
the hydrophilic rosuvastatin) on their ability to prevent endothelial dysfunction of the 
human brachial artery induced by IR. Our results show that IR significantly decreases FMD, 
however statin pre-treatment did not alter the effect of IR on FMD, in contrast to a similar 
experiment conducted recently by Liuni et al.156 Our results suggest that the cardioprotec-
tive effects of short–term treatment with statins as observed in clinical trials with patients 
presenting with an acute myocardial infarction are not mediated through preservation of 
endothelial function after ischaemia and reperfusion.
The conflicting findings between chapter 6 and those of Liuni et al156, led to the design of 
chapter 7. Presently, FMD measurements to assess IR-induced endothelial dysfunction are 
performed in either the brachial or radial artery. In chapter 7 we showed equal susceptibility 
of the radial and brachial artery to endothelial dysfunction after IR-injury, when we 
measured the effect of IR simultaneously in both arteries ipsilaterally. With this result we 
can compare and extrapolate results from previous experiments using FMD to assess 
endothelial dysfunction after IR.
As stated before, measurement of FMD to assess IR induced endothelial dysfunction 
appears a promising method to investigate IR-injury in humans in vivo. However there are 
several methodological issues to this model that have not yet been addressed scientifically. 
To optimally apply this experimental method, knowledge on the exact impact of the total 
area of ischaemia, duration of ischaemia, or duration of reperfusion on FMD measurement 
is needed. Subtle differences in methodology may be responsible for the discrepant 
results as obtained in our study on the effect of statins on IR-induced endothelial 
dysfunction (chapter 6) and those obtained by others.156. According to our results 
differences in site of measurement (brachial or radial artery) do not seem to be of 
methodological relevance.
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Future perspectives
As reviewed by Yellon et al. myocardial IR-injury has several clinically important aspects: 
cellular death, arrhythmias, myocardial stunning and endothelial dysfunction.305 Models 
used to study IR-injury (as reviewed in chapter 1) rarely cover all these different aspects 
together. For example all the models used in this thesis, study a single aspect of IR-injury: 
annexin A5 scintigraphy visualises cellular PS exposure as a marker of apoptosis, and FMD 
and PORH assess endothelial dysfunction.
However the clinical consequences of IR-injury to patients are the result of all four aspects 
(cellular death, arrhythmias, stunning and endothelial dysfunction) together. If human 
models on IR-injury should be able to study a combination of aspects of IR, and ideally all 
four aspects (as stated above) together, this should enhance translation of study results to 
clinical outcomes. Therefore, the search for appropriate (and more complex) models to 
study IR-injury in humans in vivo should continue. 
As stated before, unfortunately, much of the protective effect of ischaemic precondition-
ing is lost in translation from animal experiments to clinical trials in cardiovascular 
patients.245 This loss has partially been explained by previous experiments showing that 
susceptibility to IP is reduced by e.g. increasing age54, hypercholesterolaemia273 and 
diabetes mellitus114. Moreover susceptibility to IR-injury is influenced by many drugs that 
are frequently prescribed to patients with cardiovascular disease (e.g. statins, dipyridamole, 
ARA’s, ACE-I, sulphonylurea derivatives).78,222 Altogether the ability to prevent IR-injury 
depends on many different factors. In numerous experiments (including those presented 
in this thesis) healthy young volunteers are used as study objects. The use of medication 
was an exclusion criterion in all experiments reported here. Can we really translate the 
results from these young healthy subjects to the aged population of cardiovascular 
patients with co-morbidity and co-medication? To study clinical benefits and applicability 
of strategies to prevent IR-injury, we need to include more relevant study populations. 
Therefore, future research should focus more on patients with relevant co-morbidity, as 
opposed to the healthy volunteers.
Potentially, the use of elective PCI or CABG as models of controlled ischaemia and 
reperfusion could prove to be a more adequate translational model to study the effects of 
IR-injury. Using either troponin release as marker of myocardial tissue damage, or MRI or 
CT-scan to assess both area at risk and the amount of myocardial damage. In this model 
duration of ischaemia can easily be recorded and different aspects of IR-injury can 
contribute to the tissue injury. Moreover this model can (only) be applied in patients 
suffering from cardiovascular disease, with relevant co-morbidity and medication.
Another important reason to continue the search for adequate translational models to 
study IR-injury is the enormous costs of clinical trials. In the end, doctors are not truly 
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interested in ECG changes or raised biomarkers, they really care about the wellbeing and 
survival of their patient. To test hard clinical endpoints (such as survival) in a relevant 
population (i.e. patients suffering from actual IR-injury), large randomised clinical trials are 
needed. These trials often include up to several thousand patients and are often organised 
in an international multicentre setting. Organising such large experiments, compliant to 
standard of Good Clinical Practice is a rather expensive business as costs can reach over a 
billion euro.112 To minimise expenses, study designs have to be optimised prior to initiation 
of the large phase 3 trials. The use of translational experiments can be very helpful. When 
issues as optimal drug dosing, duration of treatment, timing of treatment, and identification 
of  possible confounders (e.g. co-medication) can be tested using small and relatively 
inexpensive translational experiments using intermediate endpoints, this facilitates smart 
and efficient designing of large clinical trials.
In conclusion, ischaemia and reperfusion injury causes significant mortality and morbidity 
in patients suffering from an ischaemic event. In animal experiments successful prevention 
of IR-injury has shown spectacular reductions in (myocardial) infarct size. In a clinical 
setting prevention of IR-injury has been proven, however the effect appears to be 
moderate. To further examine the possibilities and benefits of prevention of IR-injury 
more research is needed. Translational models on IR-injury can be very helpful to further 
unravel the mechanism and optimal setting of successful prevention of IR-injury. The 
models presently available are well suited to perform mechanistic experiments, though 
do not predict clinical outcomes in cardiovascular patients. Development of new 
translational models on IR-injury is warranted as these could further improve research on 
clinical benefits of IR-injury prevention, and aid in clinical trial design.
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Tijdens een hartinfarct is er sprake van een acute afsluiting van de bloedvoorziening 
(ischemie) van de hartspier. Wanneer de doorbloeding niet tijdig hersteld wordt, leidt dit 
onvermijdelijk tot schade aan de hartspier. Bij een patiënt met een acuut hartinfarct is 
medische behandeling er in eerste instantie op gericht om de doorbloeding van de 
hartspier zo snel mogelijk weer te herstellen en zo de schade zoveel mogelijk te beperken. 
Zo kunnen complicaties van hartspierschade, zoals hartfalen of overlijden worden beperkt 
of voorkomen. Echter, er is gebleken dat ook tijdens het herstellen van de doorbloeding 
(reperfusie) de hartspiercellen beschadigd raken. Ischemie en reperfusie (IR) schade is 
derhalve de som van de schade die een orgaan (bijvoorbeeld het hart, de hersenen of de 
nieren) oploopt ten gevolge van een acute onderbreking van de doorbloeding en het 
herstel van de doorbloeding.
In 1986 ontdekten Murry et al. dat IR-schade kan worden beperkt. Zij toonden dier-
experimenteel (bij honden) aan dat wanneer een hartinfarct werd voorafgegaan door 
enkele kortdurende episodes van ischemie van het hart, de schade van het hartinfarct 
met maar liefst 75% kon worden verminderd.183  Het proces van deze voorbereidende 
kortdurende onderbreking van de doorbloeding noemden Murry et al. ischemische pre-
conditionering (IP). Aanvullend onderzoek liet zien dat ischemische preconditionering 
ook in andere organen een beschermend effect heeft (bijvoorbeeld de nieren, de lever en 
de hersenen). Bovendien is aangetoond dat ischemische preconditionering ook werkt bij 
andere dieren, zoals konijnen, muizen, ratten en varkens.
Na de ontdekking van dit beschermende effect van kortdurende ischemie werden 
onderzoekers nieuwsgierig naar het precieze werkingsmechanisme. Na veel wetenschap-
pelijk onderzoek is dit fenomeen inmiddels grotendeels ontrafeld. Op basis van dit werk-
ingsmechanisme zijn diverse interventies bedacht die IR-schade zouden moeten kunnen 
verminderen.
Hoewel bij dieren deze interventies spectaculaire resultaten toonden (tot 75% afname van de 
schade), waren de resultaten bij patiënten vooralsnog teleurstellend. Enkele onderzoeken, 
waarbij statines of ischemische postconditionering als interventie werden toegepast, 
laten wel enige gunstige effecten zien, zoals minder complicaties bij patiënten die een 
dotteringreep ondergingen, of lagere bloedwaarden die de mate van hartspierschade 
weergeven bij patiënten na een bypassoperatie van het hart.202,279 Andere interventies, 
zoals met adenosine, lieten zeer teleurstellende resultaten zien. Om de problemen die 
ontstaan bij de vertaalslag van dier naar mens op te lossen is dringend aanvullend 
onderzoek nodig. Hiervoor hebben we behoefte aan toegankelijke en gevalideerde 
onderzoeksmodellen, waarmee we IR-schade in de mens kunnen bestuderen.
 
In dit proefschrift hebben we drie onderzoeksmodellen gebruikt om verschillende 
aspecten van ischemie en reperfusie-schade in mensen te bestuderen.
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Allereerst hebben we met behulp van annexin A5-scintigrafie het effect van IR op cel - 
schade gemeten. Deze techniek is ontwikkeld door de afdelingen Farmacologie-Toxicologie, 
Algemene Interne Geneeskunde en Nucleaire Geneeskunde van het Universitair Medisch 
Centrum Nijmegen.226 Wanneer cellen door IR beschadigd raken, verschijnen aan de 
buitenkant van deze cellen zogenaamde fosfatidylserines. Deze moleculen spelen een 
belangrijke rol in het afsterven en netjes opruimen van dode cellen. Het eiwit annexine 
A5 bindt specifiek aan deze fosfatidylserines. Door het annexine A5 te labelen met 
radioactief 99mTechnetium kan een gammacamera de ophoping van annexine A5 aan de 
uitgestoken fosfatidylserines in beeld brengen en op deze wijze de intensiteit van de 
celschade meten.
 
In hoofdstuk 2 is met behulp van annexine A5-scintigrafie het effect van een korte 
behandeling met atorvastatine op IR-schade onderzocht bij gezonde vrijwilligers. Er was 
echter geen verschil in annexine A5 binding tussen de groep die werd behandeld met 
atorvastatine en de groep behandeld met een placebo. In eerder klinisch onderzoek is 
meermaals bij de mens een duidelijk gunstig effect van atorvastatine op IR-schade is 
gevonden.202,203 Op basis van deze gegevens concluderen we dat bij dit beschermende 
effect van atorvastatine fosfatidylserines geen rol spelen. 
Om de reproduceerbaarheid van annexine scintigrafie te bepalen hebben we in dit onder- 
zoek een extra controle groep opgenomen, waarin de deelnemers tweemaal een placebo 
kregen toegediend. De resultaten van deze groep laten een goede reproduceerbaarheid 
zien van annexine A5-scintigrafie, met name de meting één uur na reperfusie.
 
In hoofdstuk 3 hebben we onderzocht of de ogenschijnlijk gunstige klinische werking 
een van angiotensine II-receptor (type 1) blokkade negatief wordt beïnvloed door een 
toename van celdood (apoptose) tijdens IR-schade, dat zou kunnen ontstaan door 
stimulatie van de type 2 angiotensine II-receptor. De apoptose-activiteit werd hier 
gemeten met behulp van annexine A5-binding. Proefpersonen die gedurende zeven 
dagen werden behandeld met irbesartan 300mg lieten geen toename van annexine 
A5-binding zien in vergelijking met de groep aan wie het placebo was toegediend. Hieruit 
concluderen wij dat angiotensine II-receptor (type 1) blokkade met irbesartan niet leidt tot 
toename van apoptose-activiteit bij IR-schade.
 
In hoofdstuk 4 hebben we aanvullend onderzoek verricht naar het veronderstelde 
beschermende effect van dipyridamol tegen IR-schade ten gevolge van ischemische 
inspanning van de onderarm.92,220 Gezonde proefpersonen werden gerandomiseerd naar 
een behandeling met dipyridamol en placebo, in een cross-over design. De uitkomsten 
van annexine A5-scintigrafie lieten een carry-over effect zien tussen de experimentele en 
placebo behandeling. De annexine A5-binding was verminderd bij de proefpersonen die 
eerst het placebo kregen toegediend en daarna de dipyridamol, vergeleken met de 
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proefpersonen die in de omgekeerde volgorde werden behandeld. Dit carry-over-effect 
lijkt op basis van onze bevindingen tenminste vier weken aan te houden.
Vervolgens hebben we geprobeerd dit beschermende effect van dipyridamol nader te 
verklaren. Een mogelijk werkingsmechanisme was een langdurig effect van dipyridamol 
op het nucleoside transport. Dit hebben we onderzocht door het effect van een 
behandeling met zeven dagen dipyridamol op nucleoside transport van erythrocyten te 
meten, tot vier weken na het staken van de therapie.
Hierbij namen we waar dat het nucleoside transport direct na de behandeling met dipyridamol 
sterk was verminderd, maar al een week na het beëindigen van de behandeling was het 
remmende effect weer geheel verdwenen. Hieruit concluderen we dat het langdurige 
effect van dipyridamol op fosfatidylserine-expositie niet kan worden verklaard door een 
verlengd remmend effect op het nucleosidetransport.
 
Er is veel preklinisch onderzoek verricht naar interventies en medicijnen die IR-schade 
kunnen voorkomen. De vertaling van deze bevindingen bij dieren naar de werkzaamheid 
op het voorkomen van IR-schade bij mensen behoeft aanvullend onderzoek. Annexine 
A5-scintigrafie lijkt hiervoor echter geen geschikte methode, daar de rol van fosfatidyl-
serine-expositie in het ontstaan van celschade beperkt lijkt. Uit onderzoek van Wever 
et al290,291 blijkt dit bij het ontstaan van IR-schade in de nieren van muizen. Voorts toont ons 
onderzoek met atorvastatine (hoofdstuk 3), een geneesmiddel dat in meerdere humane 
studies heeft bewezen IR-schade te kunnen beperken, dat atorvastatine geen effect heeft 
op annexine A5-binding na ischemie en reperfusie bij gezonde proefpersonen.
Bovendien wordt de verdere ontwikkeling van deze onderzoeksmethode gehinderd, 
doordat annexine A5 dat geschikt is om toe te dienen aan gezonde proefpersonen op dit 
moment nergens wordt geproduceerd en eigen productie te kostbaar is.
Er is veel behoefte aan alternatieve onderzoeksmethoden om de gevolgen van ischemie 
en reperfusie in mensen te onderzoeken. Behalve directe celschade veroorzaakt IR onder 
meer hartritmestoornissen en verstoort het de functie van het endotheel in het aangedane 
weefsel.
Wij hebben vervolgens onze aandacht gericht op onderzoeksmethoden die het optreden 
van endotheeldysfunctie na IR-schade kunnen kwantificeren. Allereerst hebben we in de 
onderarm van gezonde vrijwilligers post-occlusieve reactieve hyperemie (PORH) gemeten 
om de impact van ischemie en reperfusie op endotheel afhankelijke vaatfunctie te 
bepalen. Zoals we in een eerdere studie hebben aangetoond, versterkt rosuvastatine de 
vasodilatatie die optreedt na kortdurende ischemie in de onderarm.173 In hoofdstuk 5 
hebben we het mechanisme van dit effect van rosuvastatine opgehelderd. De activiteit 
van het enzym ecto-5’-nucleotidase (dat zorgt voor defosforylering van extracellulair AMP 
tot adenosine) neemt onder invloed van rosuvastatine met 50% toe. Bovendien hebben 
we aangetoond dat adenosine-receptoren betrokken zijn bij dit effect, aangezien cafeïne 
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(een adenosinereceptor-antagonist) de toename van vasodilatatie na 2, 5 en 13 minuten 
ischemie geheel ongedaan maakt.
 
Tot slot hebben we de metingen aangepast van flow gemedieerde vasodilatatie (FMD) 
zoals die veelvuldig worden verricht op de afdeling Fysiologie van het UMCN, om te 
gebruiken voor metingen van IR-schade conform de inzichten in de literatuur.133
Deze niet-invasieve techniek lijkt een veelbelovende methode om het effect van ischemie 
en reperfusie op endotheelfunctie te bestuderen. Hierbij kan zowel het onderliggende 
mechanisme verder worden opgehelderd als het effect van (farmacologische) interventies 
op IR geïnduceerde endotheeldysfunctie.161
In hoofdstuk 6 hebben we met behulp van de FMD het beschermende effect van twee 
verschillende statines (het lipofiele atorvastatine en hydrofiele rosuvastatine) tegen het 
optreden van endotheeldysfunctie na ischemie en reperfusie in de onderarm bij gezonde 
vrijwilligers bestudeerd. Hierbij zien wij een significante daling van de FMD na ischemie, 
maar er is geen effect van statine voorbehandeling op het effect van IR op de FMD. Deze 
resultaten suggereren dat het beschermende effect van statine-voorbehandeling in 
klinisch onderzoek bij patiënten met een hartinfarct, niet kan worden verklaard door een 
effect van de statines op de endotheelfunctie na ischemie en reperfusie.
De resultaten van hoofdstuk 6 zijn echter in tegenspraak met een recent artikel van Liuni 
et al.156 Deze onderzoekers bepaalden echter de FMD op een iets andere plaats in de arm 
(arteria radialis in plaats van de arteria brachialis). Om te onderzoeken of dit verschil in 
methode een verklaring is voor het verschil in studieresultaten hebben we een experiment 
opgezet zoals beschreven in hoofdstuk 7. In dit onderzoek tonen wij aan dat het 
endotheel van deze beide slagaders even gevoelig is voor IR-schade. Deze bevinding stelt 
ons in staat om eerdere onderzoeksgegevens met elkaar te vergelijken en te extrapoleren.
Zoals reeds gemeld, lijkt het meten van de FMD rondom ischemie en reperfusie een 
veelbelovende methode om IR-schade bij mensen te bestuderen. Echter, voordat dit 
model betrouwbaar gebruikt kan gaan worden, moet er nog wel een aantal methodolo-
gische kwesties worden onderzocht. Zo moet er nog verder worden uitgezocht wat de 
invloed is van de omvang  van het ischemische weefsel op de FMD. Ook is er nog geen 
onderzoek gedaan naar de invloed van de timing van de ischemie en de reperfusie. Kleine 
verschillen in de uitvoering van experimenten kunnen leiden tot ‘onverklaarbare’ 
verschillen tussen de resultaten van verschillende experimenten, zoals het geval is bij onze 
resultaten van het effect van statines op IR geïnduceerde endotheeldysfunctie (hoofdstuk 
6) en de resultaten van anderen.156
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Toekomst perspectief
Ischemie en reperfusie van het hart kan leiden tot de volgende belangrijke klinische 
effecten: celschade en celdood, hartritmestoornissen, tijdelijke dysfunctie van hartspier-
cellen en endotheeldysfunctie.305
De onderzoeksmodellen die gebruikt worden om IR-schade te bestuderen (zoals 
beschouwd in hoofdstuk 1) focussen echter op een van de hiervoor genoemde aspecten. 
Zo wordt met de modellen in dit promotieonderzoek steeds maar een van deze gevolgen 
bestudeerd: annexine-scintigrafie kwantificeert celschade, terwijl de FMD- en PORH- 
metingen focussen op endotheeldysfunctie.
De gevolgen van IR-schade bij een patiënt zijn echter de resultante van alle effecten van 
ischemie en reperfusie. Een nieuw humaan onderzoeksmodel dat alle aspecten van IR 
(celschade en celdood, hartritmestoornissen, tijdelijke dysfunctie van hartspiercellen en 
endotheeldysfunctie) meeneemt in zijn metingen, zou de translatie van de onderzoeks-
uitkomsten naar klinische uitkomsten sterk kunnen verbeteren. Daarom moeten we 
vooral doorgaan met het zoeken naar het ideale (en wellicht meer complexe) model om 
de effecten van ischemie en reperfusie in de mens te bestuderen.
 
Zoals eerder gemeld lijkt het beschermende effect van preconditionering bij patiënten 
met hart- en vaatziekten veel minder krachtig dan bij proefdieren.245 Uit onderzoek is 
gebleken dat het beschermende effect van preconditionering afneemt bij ouderen54, 
patiënten met diabetes mellitus114 en hypercholesterolemie273. Bovendien wordt de 
gevoeligheid voor IR-schade beïnvloed door verschillende geneesmiddelen, die regel - 
matig worden voorgeschreven aan patiënten met hart- en vaatziekten: zoals statines, 
dipyridamole, angiotensine-2 antagonisten, ACE-remmers of sulfonylureumderivaten.78,222 
Derhalve is het voorkomen of reduceren van IR-schade afhankelijk van veel verschillende 
factoren.
In veel wetenschappelijk onderzoek (ook in dit proefschrift) worden de experimenten 
verricht bij jonge gezonde vrijwilligers bij wie medicatiegebruik doorgaans een exclusie-
criterium is. Is het daarom wel betrouwbaar om de uitkomsten van dit onderzoek bij deze 
jonge, gezonde deelnemers te extrapoleren naar patiënten die lijden aan hart- en 
vaatziekten, met co-morbiditeit en het gebruik van verschillende medicamenten? Om op 
zinvolle wijze onderzoek te kunnen doen naar het klinische effect van preventie van 
IR-schade, moet dit onderzoek worden verricht in een relevante onderzoekspopulatie. 
Daarom moet toekomstig onderzoek zich meer richten op patiënten met hart- en 
vaatziekten, in plaats van op gezonde proefpersoenen.
Mogelijk kunnen electieve PCI of CABG als meer geschikt model kunnen dienen voor 
translationeel onderzoek naar het beperken van ischemie-reperfusie-schade. Door het meten 
van vrijgekomen troponines als maat van hartspiercelschade, of door met  beeldvormende 
technieken zoals MRI206 de ernst van de myocardschade na de procedure (en eventuele 
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interventie) als fractie van het totale gebied waarvan de doorbloeding verminderd is 
geweest te meten, kan de invloed van ischemie en reperfusie schade worden onderzocht. 
In een dergelijk model kan de ischemie duur (de totale duur van balloninflatie(s) of de 
duur van het afklemmen van de aorta) worden geregistreerd als potentiële confounder 
(verstoorder van onderzoeksresultaat). Bovendien is de mate van hartschade gerelateerd 
aan prognose van de patiënt waardoor de relevantie van dit eindpunt groter is dan het 
meten van intermediaire gevolgen van IR-schade, zoals phosphatidylserine-expositie of 
endotheelfunctie. Tot slot is dit model alleen toegankelijk voor patiënten die lijden aan 
hart- en vaatziekten, met de bijbehorende co-morbiditeit en medicatie, de relevante 
patiëntencategorie voor dit onderzoek.
 
Een andere belangrijke reden om de zoektocht naar goede methoden om ischemie- 
reperfusie schade bij de mens te meten zijn de enorme kosten van klinisch geneesmiddelen 
onderzoek met harde klinische eindpunten (zoals sterfte en ziekenhuisopnames). Uiteindelijk 
zijn artsen minder geïnteresseerd in ECG-veranderingen of verhoogde schademarkers; 
hun belangstelling gaat uit naar het overleven en welbevinden van hun patiënten. Om 
onderzoek naar harde klinische eindpunten (zoals overleven) te doen in een klinische 
relevante populatie (zoals hartpatiënten), zijn grote gerandomiseerde studies nodig. Voor 
dergelijke studies zijn doorgaans duizenden patiënten nodig. Om zoveel patiënten bijeen 
te krijgen moeten deze onderzoeken worden uitgevoerd in meerdere ziekenhuizen, en 
meestal ook nog in verschillende landen. De kosten van de organisatie van dergelijke 
onderzoeken, uitgevoerd volgens de kwaliteitseisen van Good Clinical Practice, kunnen 
oplopen tot meer dan een miljard euro per studie.112
Het gebruik van translationele experimenten kan een waardevolle bijdrage leveren aan 
het opzetten van dergelijke grote klinische studies. Wanneer vraagstukken als optimale 
dosering van het te onderzoeken geneesmiddel, de timing van de behandeling en het 
opsporen van mogelijke confounders, kunnen worden onderzocht in kleine en relatief 
goedkope onderzoeken die gebruik maken van een adequaat translationeel onder-
zoeksmodel, kan deze kennis worden gebruikt om het design van een grote klinische 
studie te optimaliseren en op deze wijze kosten te reduceren.
 
Zoals hierboven beschreven zal een acute onderbreking van de doorbloeding van het 
hart leiden tot ischemie en reperfusie-schade, waarbij celdood, hartritmestoornissen, 
dysfunctie van hartspiercellen en endotheeldysfunctie bij de patiënt kunnen leiden tot 
beschadiging van het hart of zelfs tot het overlijden. In dierwetenschappelijk onderzoek 
zijn spectaculaire resultaten geboekt bij het reduceren van de omvang van de schade van 
een infarct. Bij  patiënten met hart- en vaatziekten is inmiddels ook aangetoond dat 
IR-schade kan worden voorkomen. In tegenstelling tot de resultaten bij dieren lijkt bij 
mensen het effect echter maar gering. Er is meer onderzoek nodig naar de mogelijkheden 
en potentiële gezondheidswinst van de preventie van IR-schade. Goede translationele 
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modellen kunnen een belangrijke rol spelen in het verder ophelderen van de beschermende 
mechanismen en de optimale omstandigheden voor preconditionering. De huidige 
modellen zijn geschikt voor experimenten naar het mechanisme van preconditionering, 
maar ze zijn niet in staat om uitkomsten te voorspellen bij cardiovasculaire patiënten. Het 
is van groot belang om nieuwe modellen te ontwikkelen voor onderzoek naar IR-schade. 
Deze modellen kunnen dan gebruikt worden voor verder onderzoek naar de preventie 
van IR-schade, en kunnen helpen bij het efficiënt opzetten van grote klinische studies.
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Om te beginnen spreek ik graag al mijn waardering uit voor de proefpersonen die met 
hun deelname ons onderzoek mogelijk hebben gemaakt. De experimenten waar jullie 
vrijwillig aan meewerkten waren behoorlijk belastend: ischemie is erg pijnlijk, medicijnen 
kunnen allerlei bijwerkingen hebben en bij een aantal experimenten werd ook nog radio-
activiteit toegediend. Gedreven door nieuwsgierigheid naar medisch onderzoek, de 
behoefte iets bij te dragen aan de medische ontwikkeling en soms verleid door de 
onkostenvergoeding, meldden jullie je aan voor deelname. Mijn voornemen om al jullie 
namen hier af te drukken werd (terecht) verhinderd door good clinical practice: ik bezit 
alleen nog maar geanonimiseerde onderzoeksgegevens, jullie namen liggen veilig achter 
slot en grendel. Derhalve in een keer: dank jullie wel!
Professor G.A. Rongen, beste Gerard, jouw wetenschappelijke creativiteit en tomeloos 
optimisme waren onmisbaar bij het laten slagen van dit project. Ongehinderd door 
zorgen over de praktische uitvoerbaarheid, heb je in mijn aanwezigheid voldoende 
mooie studies bedacht om wel tien proefschriften mee te vullen. Hartelijk dank voor deze 
promotieplaats en je jarenlange betrokkenheid en toewijding. Om in jouw stijl af te sluiten: 
high five!
Professor W.J.G. Oyen, beste Wim, met de snelheid van het licht (of meer toepasselijk 
gammastraling, ook fotonen) was je er wanneer we je hulp nodig hadden. Het instellen 
van de gammacamera, de analyse van de scans of het beoordelen van de manuscripten, 
binnen no-time kreeg ik de resultaten van je terug. Hartelijk dank voor de prettige en 
uiterst voortvarende samenwerking.
Professor P. Smits, beste Paul, met heel veel plezier heb ik vier jaar lang op jouw afdeling 
Farmacologie en Toxicologie gewerkt. Als afdelingshoofd was je voor alles in: borrelen, 
wekelijks soep scheppen, afdelingsuitjes en afterparties. Jouw integere stijl van 
leidinggeven is inspirerend. En als we er wetenschappelijk even niet uitkwamen, was een 
half uurtje discussiëren op jouw kamer voldoende om met nieuwe inzichten en frisse 
moed weer verder te gaan.
De manuscript commissie bestaande uit professor M.J. de Boer, professor J. de Graaf en 
professor W. van Gilst, wil ik graag danken voor hun kritische beschouwing en enthousiaste 
goedkeuring van het manuscript.
Professor F.W.A. Verheugt, beste Freek, al tijdens mijn introductiecoschap wist je me te 
strikken voor de cardiologie. Tot mijn grote spijt hebben onze klinische wegen zich 
nauwelijks gekruist door jouw overstap naar Amsterdam. Ik ben je zeer dankbaar voor je 
vertrouwen in deze coassistent en de geboden mogelijkheden om me te specialiseren in 
de cardiologie.
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Dr. L. Noyez, beste Luc, als derdejaarsstudent klopte ik bij je aan voor een korte onder-
zoeksstage epidemiologie. Dit heeft geleid tot een lange en vruchtbare samenwerking, 
waarin we een aantal artikelen schreven en samen congressen bezochten. Na mijn 
artsexamen kon ik bij jou op de afdeling (toen nog) Thorax-Hartchirurgie meteen aan de 
slag. Ons gezamenlijke werk vormde van een belangrijke basis voor de toegewezen 
agiko-subsidie die leidde tot dit proefschrift. Met veel plezier denk ik terug aan de vele 
malen dat we het reilen en zeilen van patiënten voor en na hartchirurgie bespraken op het 
kleinste kantoortje van het UMCN.
Geert, Inge, Carola en Maarten: alle vier hebben jullie een wetenschappelijke stage gelopen 
op de afdeling Farmacologie en Toxicologie en tijdens deze stages hebben jullie een 
wezenlijke bijdrage geleverd aan ons onderzoek. Jullie wetenschappelijk talent was toen al 
duidelijk en inmiddels zijn jullie allemaal bezig zijn met een eigen promotieonderzoek, 
heel veel succes!
Researchverpleegkundigen Mariëlle Verstegen, Karin Saini en Aarnout Jansen van Rosendaal, 
jullie gezelschap en ondersteuning maakte de vele meetdagen en de bijbehorende 
 administratieve afwikkeling uiterst aangenaam. Dank voor jullie hulp.
Researchverpleegkundige Anja Rasing, lieve Anja, het was een feest om met je samen te 
werken. De opzet en uitvoering van een klinische trial (die tot verdriet van Gerard dit 
proefschrift niet heeft gehaald) kent vele facetten. Met wellicht als hoogtepunt de dagen 
die we samen doorbrachten in de diepvries (-20oC), terwijl buiten de mussen van het dak 
vielen (35oC). Ik heb nooit zoveel vreemde blikken getroffen als toen wij in deze hittegolf 
in onze skikleding (met muts, sjaal en handschoenen) door het ziekenhuis banjerden.
Hoofdanalist, maar vooral toegewijd kamergenoot Petra van de Broek, lieve Petra, hoewel 
ik al die jaren met mijn rug naar je toe heb gezeten, hebben we veel plezier gehad in de 
Farmacologie-Toxicologielounge. Je verdroeg mijn urenlange Pink Floyd-sessies uitermate 
goed en je was er altijd om mijn promotiefrustraties geduldig aan te horen en van 
constructief commentaar te voorzien. Ik mis je!
Professor D. Thijssen, beste Dick, in het laatste jaar van mijn onderzoek (waarom niet 
eerder?) hebben we onze krachten gebundeld en jouw expertise van de FMD metingen 
gebruikt bij het meten van ischemie en reperfusie-schade. Het tempo waarin jij nieuw 
onderzoek bedenkt, organiseert, uitvoert, analyseert en publiceert is indrukwekkend. 
Je recente benoeming tot hoogleraar in Liverpool is een welverdiende positie voor een 
getalenteerd wetenschapper als jij.
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Michael van Riel, beste Michael, op dagen van annexinemetingen was jij al voor dag en 
dauw bezig met het voorbereiden van het radiofarmacon. Ongevoelig voor mijn 
ongeduld en met kwaliteit hoog in het vaandel, bereidde je het 99mTechnetium-HYNIC-
annexine A5 en kreeg ik het pas mee als alles tiptop in orde was. Dank voor je toewijding 
en de altijd vrolijke samenwerking (ook in de hele vroege ochtend).
Sylvie Kok, lieve Sylvie, zonder jou had mijn promotieonderzoek aanzienlijk langer 
geduurd. Farmacologisch onderzoek vereist een goede samenwerking met de apotheek. 
Onderzoekers willen graag alle gewenste preparaten op stel en sprong geleverd hebben 
en zonder al teveel administratieve rompslomp. Jij maakt dit, en ook nog binnen de 
huidige wet- en regelgeving, mogelijk. Dergelijke flexibiliteit en betrokkenheid is zeldzaam, 
dank je wel voor je hulp.
Collega-(arts-)onderzoekers, onder meer: Annemarie, Alexander, Bart, Bas, Douwe, Fleur, 
Joris, Madeleine, Marc, Marlies, Noortje, Saloua, Suzanne en Thijs, in de hoogtijdagen van 
de wekelijkse agiko-bespreking was het inspirerend om met elkaar onze onderzoeken te 
bespreken en uitkomsten te interpreteren en bediscussiëren. Een aantal van jullie heeft 
reeds de felbegeerde doctorsbul mogen ontvangen en voor de rest komt dit moment 
steeds dichter bij. Het was mij een waar genoegen om samen met jullie in dit schuitje te 
zitten.
Dr. P. Meijer, beste Patrick, veel werk hebben we samen gedaan. Jouw fraaie proefschrift 
heeft mij geïnspireerd tot het afmaken van mijn deel. Dank voor deze vruchtbare samen -
werking.
Waarde collega’s van de afdelingen cardiologie van het UMCN en het CWZ. Graag wil ik 
jullie bedanken voor de betrokkenheid en toewijding bij mijn opleiding tot cardioloog. 
Bovendien ben ik zeer erkentelijk voor het feit dat ik mijn opleiding grotendeels parttime 
kan volgen, waardoor ik mijn specialisatie en promotie op prettige wijze kan combineren 
met de zorg voor mijn gezin. 
Dr. E. Bollen, beste Ewald, uiteindelijk waren het jouw spannende, mooie en (soms 
misschien) sterke verhalen over dokters, patiënten en hun ziektes die mij de geneeskunde 
in geleid hebben. Inmiddels vertel ik zelf ook enthousiast dergelijke verhalen, dank voor je 
inspiratie.
Mijn paranimfen dr. Kim Wever en mr. Reyer Baas. Lieve Kim, de afgelopen jaren hebben 
we samen gewerkt aan ons promotieonderzoek en in het laatste stadium (veel te laat) 
hebben we samengewerkt aan ons promotieonderzoek. Maar veel meer nog dan dat 
koester ik onze vriendschap die ontstond uit de vele werkbesprekingen, lunches, borrels, 
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ijsjes (ook in de sneeuw), cursussen en congressen. Door jouw prachtige voorbeeld op 
30 november 2012 om 10.30 uur precies, weet ik een beetje wat me staat te wachten. 
Waarde Reyer, van bevlogen studenten in de universitaire politiek tot ploeterende 
promovendi. Ik mis de tijd dat we wekelijks tot diep in de nacht doorhaalden (vooral met 
vergaderen weliswaar) of het glas uit de squashbaan sloegen. Ik zie je de laatste jaren veel 
te weinig, daar ga ik verandering in brengen!
Lieve Peter en Will, dankzij jullie ben ik wie ik ben. Ik wil jullie dan ook vanuit de grond van 
mijn hart bedanken voor het door jullie geboden warme nest, vol liefde en vertrouwen, 
met veel aandacht voor zelfontplooiing. Jullie moedigden mij aan om (ver weg) te 
studeren, te reizen, te lezen en musea, kerken (en velerlei andere oude gebouwen) en 
theaters te bezoeken, en leerden mij zo genieten van kunst, cultuur en historie.
Zonder jullie had het ook zeker langer geduurd voordat dit proefschrift klaar was. Jullie 
altijd beschikbare hulp bij het reilen en zeilen van mijn gezin is van onschatbare waarde 
voor ons allemaal en inmiddels even inspirerend als onmisbaar. De toewijding en 
liefdevolle aandacht, waarmee jullie voor ons en onze kindjes zorgen, ontroert mij en 
biedt ons veel geborgenheid. 
Lieve Klaartje, zoals het broer en zus betaamt, hebben we van jongs af aan in verschillende 
toonaarden over de meest uiteenlopende onderwerpen ‘gediscussieerd’. Inmiddels 
bespreken onder het genot van thee, wijn of cola vooral de echt belangrijke zaken van het 
leven. Je bent aandachtig als geen ander en het voelt heel vertrouwd als je bij ons bent.
Allerliefste Hugo en Tijl, kleine boefjes van me. “Ieder nadeel heeft zijn voordeel”, zei een 
voetballer ooit; in de periode dat ik bezig was met het afronden van mijn proefschrift lag 
mijn laptop ook binnen jullie handbereik. Dit opende voor jullie een wereld van youtube-
filmpjes over Knabbel en Babbel, Sjakie Schildpad, angry birds en ‘werken’ op pipapanda.
nl. Zo hebben jullie meegenoten van de laatste loodjes. Mannen, met jullie erbij is alles 
een feest!
Lieve Malaika, mijn engel! Waar zou ik zonder jou zijn? … Eigenlijk sta ik hier nooit bij stil, 
want ik heb het veel te druk met genieten van waar ik samen met jou gekomen ben. Je 
bent mijn steun en toeverlaat, altijd. Ik ben dol op jou en op onze prachtige jongetjes. 
Samen met jullie zijn (en bij voorkeur ergens ver weg) is wat ik het liefste wil. Ik ben 
apetrots en dolblij dat je in Stellenbosch “JA” gezegd hebt en nu kan ik me gaan verheugen 
op ons grote feest.
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Op 2 oktober 1976 werd Stijn Wouters geboren in 
het Radboud Ziekenhuis te Nijmegen. Zijn tienerjaren 
besteedde hij, naast veel hockey, met name aan het 
behalen van zijn gymnasiumdiploma aan het Stedelijk 
Gymnasium te Nijmegen. 
Na uitgeloot te zijn voor de studie Geneeskunde startte 
Stijn in 1995 met de opleiding Biomedische Gezond-
heidswetenschappen aan de Radboud Universiteit 
Nijmegen (toen nog de Katholieke Universiteit Nijmegen). 
Door de jaarlijkse uitlotingsberichten van IB-Groep 
(in totaal zeven) werd hij in de gelegenheid gesteld 
deze studie helemaal af te maken. Met als hoofdvak 
Epidemiologie en stages aan het Department of 
Community Health van de University of Auckland te 
Nieuw Zeeland en het Julius Centrum van het Universitair Medisch Centrum Utrecht, behaalde 
hij zijn doctoraal in 1999. 
Dankzij de welwillendheid van het College van Bestuur van de Radboud Universiteit Nijmegen, 
werd hij in 1999 toegelaten tot de studie geneeskunde. Om meteen een heel studiejaar 
geen enkel college te volgen, maar hij hield zich intensief bezig met facultair, universitair en 
landelijk (medisch) onderwijs en studentenbeleid. Dit deed hij onder meer als studentasses-
sor in het faculteitsbestuur Medische Wetenschappen en de Raad van Bestuur van het 
Universitair Medisch Centrum Nijmegen (UMCN), als lid van de Universitaire Studentenraad 
van de Radboud Universiteit Nijmegen en als student-lid van het Discipline Overleg Orgaan 
Medische Wetenschappen van de VSNU. In 2000 begon hij met een versneld doctoraal 
geneeskunde en in 2002 met de klinische coassistentschappen, om eindelijk in 2004 de 
artsenbelofte af te mogen leggen. 
Stijns eerste baan was als arts-assistent op de afdeling Thorax-Hartchirurgie van het UMCN en 
naast zijn werkzaamheden aldaar, diende hij samen met dr. G.A. Rongen en professor dr. F.W.A. 
Verheugt een aanvraag voor een AGIKO-beurs in bij ZONMW. Met de toekenning van deze 
onderzoeksubsidie was ook toelating tot de opleiding Cardiologie beklonken (opleider 
professor dr. F.W.A. Verheugt en later professor dr. J.L.R.M. Smeets). Tussen 2005 en 2009 werkte 
hij afwisselend aan dit promotieonderzoek en aan zijn vooropleiding Algemene Interne 
Geneeskunde in het UMCN (opleider professor dr. J.W.M. van der Meer). Eind 2009 zette hij zijn 
eerste stappen in zijn toekomstige vakgebied op de afdeling Cardiologie van het UMCN. Tussen 
2011 en 2012 werkte hij op de afdeling Cardiologie van het Canisius Wilhelmina Ziekenhuis 
onder de bezielende opleiding van dr. A.J.M Oude Ophuis en dr. E.J.P. Lamfers.
Op dit moment is Stijn weer werkzaam op de afdeling Cardiologie van het UMCN, voor 
het laatste deel van zijn opleiding.
Stijn woont samen met zijn verloofde Malaika Fuchs en samen hebben zij twee waanzinnig 
leuke, lieve en ondeugende zoontjes: Hugo (2008) en Tijl (2009).
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